User login
Atopic Dermatitis: New Insights and Expanded Treatment Options
Atopic Dermatitis: New Insights and Expanded Treatment Options
Atopic dermatitis (AD) is a chronic skin condition generally characterized by pruritic and erythematous papules and plaques.1 While AD commonly manifests in childhood, 1 in 4 patients living with AD report adult onset of the disease.2 The clinical presentation and prevalence of AD vary across age groups, skin tones, and racial and ethnic groups. Globally, AD is estimated to have a prevalence of 2.6%; however, rates vary widely by region.1 Morphology and distribution of AD lesions also vary by population; therefore, defining one classic presentation of AD is not sufficient in diverse patient populations.3
Epidemiology
The prevalence of AD ranges from 0.2% to 24.6% worldwide, with higher rates in Africa and Oceania and lower rates in India and Northern and Eastern Europe.1 In the United States, AD affects all racial and ethnic groups; however, prevalence and severity are increased in Black children compared with White children.4 In one prospective cohort study, Hispanic children and non-Hispanic Black children aged 3 years and younger had greater odds of AD persisting into mid childhood (approximately age 7 years) compared with non-Hispanic White children.5,6
Key Clinical Features
Clinical features of AD are heterogeneous and may include differences in color, morphology, and distribution. Brown, hyperpigmented, gray, and/or violaceous plaques may predominate in patients with skin of color (SOC) compared with the erythematous plaques commonly described in lighter skin tones.1,3 Established scoring systems for AD rely on erythema as a key diagnostic feature, but because erythema can be difficult to detect in darker skin tones, disease severity may be underestimated and diagnosis may be delayed in this population.4
Atopic dermatitis in SOC may manifest as lichenoid plaques,7 prurigo nodules,7,8 lichenification,1 and follicular accentuation.9 Lichen planus–like AD is a distinct variant characterized by lichenoid plaques with a predilection for the extensor surfaces and face in patients with darker skin tones1,8 occurring in approximately 9% of patients in one study.10
Other key clinical features of AD in patients with SOC include pityriasis alba,10 increased risk for postinflammatory pigment alteration (including hyperpigmentation and/or hypopigmentation),1 and greater trunk and extensor involvement.1,11
Worth Noting
The scientific landscape for AD has grown rapidly, increasing our understanding of its pathophysiology, treatment, and social impact. Nonsteroidal treatments available for pediatric and adult patients with AD have increased in recent years, including crisaborole (approved for use in those ages ≥ 3 months), tacrolimus (≥ 2 years), and pimecrolimus (≥ 2 years). Injectable options include dupilumab (≥ 6 months), lebrikizumab (≥ 12 years), nemolizumab (≥ 12 years), and tralokinumab (≥ 12 years). Oral options include abrocitinib (≥ 12 years) and upadacitinib (≥ 12 years).12 Topical options include roflumilast 0.15% cream (≥ 6 years)12 and 0.05% cream (≥ 2-5 years),13 ruxolitinib 1.5% cream (≥ 2 years),14 and tapinarof 1% cream (≥ 2 years).12
For some patients, postinflammatory pigment alteration associated with AD has a higher impact on quality of life than the AD itself.7 In a study of 260 US adults with AD, the emotional impact of pigmentary changes was greatest in Black patients, with 53.3% reporting that pigment changes bothered them “a lot” or “very much.”15
Genome-wide association studies have not identified a single determinant that explains racial and ethnic differences in susceptibility to AD.4 Instead, social determinants of health are thought to play a role in the difference in AD prevalence and severity across groups in the United States.16
Health Disparity Highlight
In an analysis of 20 US metropolitan cities, urban and inner-city residence was associated with approximately 1.7-fold increased odds of AD.4 Among pediatric patients with moderate to severe AD, Black children were more likely to be exposed to tobacco smoke17 and traffic-related air pollution.18 Low socioeconomic status and low income also have been associated with moderate16 and severe19 AD. At the same education level, Black individuals in the United States receive less income than their White counterparts and have markedly less wealth at equivalent incomes.20
In utero exposure to maternal stress is associated with AD.4 Increased IgE levels have been recorded in children who develop AD, with Black children having the highest IgE levels overall compared to other children.18
An analysis of medical records from an urban medical center in Baltimore, Maryland, from 2013 through 2018 showed that Black patients with AD were less likely to receive topical corticosteroids, topical calcineurin inhibitors, a topical phosphodiesterase 4 inhibitor, and a biologic compared to White patients with AD.21
Since the disproportionate burden experienced by patients with AD is not physiologic, it is imperative to address these systemic complexities and address the barriers impacting treatment availability to improve health outcomes for all patients living with AD.
- Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups—variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27:340-357.
- Lee HH, Patel KR, Singam V, et al. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019;80:1526-1532.E7.
- Adawi W, Cornman H, Kambala A, et al. Diagnosing atopic dermatitis in skin of color. Dermatol Clin. 2023;41:417-429.
- Narla S, Silverberg JI. Current updates in the epidemiology and comorbidities of atopic dermatitis. Ann Allergy Asthma Immunol. 2025;135:511-520.
- Croce EA, Levy ML, Adamson AS, et al. Reframing racial and ethnic disparities in atopic dermatitis in Black and Latinx populations. J Allergy Clin Immunol. 2021;148:1104-1111.
- Kim Y, Blomberg M, Rifas-Shiman SL, et al. Racial/ethnic differences in incidence and persistence of childhood atopic dermatitis. J Invest Dermatol. 2019;139:827-834.
- Nomura T, Wu J, Kabashima K, et al. Endophenotypic variations of atopic dermatitis by age, race, and ethnicity. J Allergy Clin Immunol. 2020;8:1840-1852.
- McColl M, Boozalis E, Aguh C, et al. Pruritus in Black skin: unique molecular characteristics and clinical features. J Natl Med Assoc. 2021;114:30-38.
- Silverberg JI, Margolis DJ, Boguniewicz M, et al. Distribution of atopic dermatitis lesions in United States adults. J Eur Acad Dermatol Venereol. 2019;33:1341-1348.
- Summey BT, Bowen SE, Allen HB. Lichen planus-like atopic dermatitis: expanding the differential diagnosis of spongiotic dermatitis. J Cutan Pathol. 2008;35:311-314.
- Odhiambo JA, Williams HC, Clayton TO, et al; ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124:1251-1258.E23.
- Gallagher K, Halperin-Goldstein S, Paller AS. New treatments in atopic dermatitis update. Ann Allergy Asthma Immunol. 2025;135:498-510.E10.
- Shaw ML. FDA expands roflumilast use for atopic dermatitis to children aged 2 to 5 years. Am J Managed Care. October 6, 2025. Accessed April 30, 2026. https://www.ajmc.com/view/fda-expands -roflumilast-use-for-atopic-dermatitis-to-children-aged-2-to-5-years
- Eichenfield LF, Stein Gold LF, Simpson EL, et al. Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: results from TRuE-AD3, a phase 3, randomized double-blind study. J Am Acad of Dermatol. 2025;93:689-698.
- Heath CR, Dosono B, Shi VY, et al. Variability in skin tone changes by race and ethnicity among US adults with atopic dermatitis. Presented at: Skin of Color Update 2024, September 13-15, 2024, New York, NY.
- Tackett KJ, Jenkins F, Morrell DS, et al. Structural racism and its influence on the severity of atopic dermatitis in African American children. Pediatr Dermatol. 2020;37:142-146.
- Narla S, Silverberg JI. The role of environmental exposures in atopic dermatitis. Curr Allergy Asthma Rep. 2020;20:74.
- Bauer SJ, Spoer BR, Ehrman R, et al. A systematic review of historic neighborhood redlining and contemporary health outcomes. Public Health. 2025;238:181-187.
- Chung J, Simpson EL. The socioeconomics of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122:360-366.
- Martinez A, de la Rosa R, Mujahid M, et al. Structural racism and its pathways to asthma and atopic dermatitis. J Allergy Clin Immunol. 2021;148:1112-1120.
- Bell MA, Whang KA, Thomas J, et al. Racial and ethnic disparities in access to emerging and frontline therapies in common dermatological conditions: a cross-sectional study. J Natl Med Assoc. 2020;112:650-653.
Atopic dermatitis (AD) is a chronic skin condition generally characterized by pruritic and erythematous papules and plaques.1 While AD commonly manifests in childhood, 1 in 4 patients living with AD report adult onset of the disease.2 The clinical presentation and prevalence of AD vary across age groups, skin tones, and racial and ethnic groups. Globally, AD is estimated to have a prevalence of 2.6%; however, rates vary widely by region.1 Morphology and distribution of AD lesions also vary by population; therefore, defining one classic presentation of AD is not sufficient in diverse patient populations.3
Epidemiology
The prevalence of AD ranges from 0.2% to 24.6% worldwide, with higher rates in Africa and Oceania and lower rates in India and Northern and Eastern Europe.1 In the United States, AD affects all racial and ethnic groups; however, prevalence and severity are increased in Black children compared with White children.4 In one prospective cohort study, Hispanic children and non-Hispanic Black children aged 3 years and younger had greater odds of AD persisting into mid childhood (approximately age 7 years) compared with non-Hispanic White children.5,6
Key Clinical Features
Clinical features of AD are heterogeneous and may include differences in color, morphology, and distribution. Brown, hyperpigmented, gray, and/or violaceous plaques may predominate in patients with skin of color (SOC) compared with the erythematous plaques commonly described in lighter skin tones.1,3 Established scoring systems for AD rely on erythema as a key diagnostic feature, but because erythema can be difficult to detect in darker skin tones, disease severity may be underestimated and diagnosis may be delayed in this population.4
Atopic dermatitis in SOC may manifest as lichenoid plaques,7 prurigo nodules,7,8 lichenification,1 and follicular accentuation.9 Lichen planus–like AD is a distinct variant characterized by lichenoid plaques with a predilection for the extensor surfaces and face in patients with darker skin tones1,8 occurring in approximately 9% of patients in one study.10
Other key clinical features of AD in patients with SOC include pityriasis alba,10 increased risk for postinflammatory pigment alteration (including hyperpigmentation and/or hypopigmentation),1 and greater trunk and extensor involvement.1,11
Worth Noting
The scientific landscape for AD has grown rapidly, increasing our understanding of its pathophysiology, treatment, and social impact. Nonsteroidal treatments available for pediatric and adult patients with AD have increased in recent years, including crisaborole (approved for use in those ages ≥ 3 months), tacrolimus (≥ 2 years), and pimecrolimus (≥ 2 years). Injectable options include dupilumab (≥ 6 months), lebrikizumab (≥ 12 years), nemolizumab (≥ 12 years), and tralokinumab (≥ 12 years). Oral options include abrocitinib (≥ 12 years) and upadacitinib (≥ 12 years).12 Topical options include roflumilast 0.15% cream (≥ 6 years)12 and 0.05% cream (≥ 2-5 years),13 ruxolitinib 1.5% cream (≥ 2 years),14 and tapinarof 1% cream (≥ 2 years).12
For some patients, postinflammatory pigment alteration associated with AD has a higher impact on quality of life than the AD itself.7 In a study of 260 US adults with AD, the emotional impact of pigmentary changes was greatest in Black patients, with 53.3% reporting that pigment changes bothered them “a lot” or “very much.”15
Genome-wide association studies have not identified a single determinant that explains racial and ethnic differences in susceptibility to AD.4 Instead, social determinants of health are thought to play a role in the difference in AD prevalence and severity across groups in the United States.16
Health Disparity Highlight
In an analysis of 20 US metropolitan cities, urban and inner-city residence was associated with approximately 1.7-fold increased odds of AD.4 Among pediatric patients with moderate to severe AD, Black children were more likely to be exposed to tobacco smoke17 and traffic-related air pollution.18 Low socioeconomic status and low income also have been associated with moderate16 and severe19 AD. At the same education level, Black individuals in the United States receive less income than their White counterparts and have markedly less wealth at equivalent incomes.20
In utero exposure to maternal stress is associated with AD.4 Increased IgE levels have been recorded in children who develop AD, with Black children having the highest IgE levels overall compared to other children.18
An analysis of medical records from an urban medical center in Baltimore, Maryland, from 2013 through 2018 showed that Black patients with AD were less likely to receive topical corticosteroids, topical calcineurin inhibitors, a topical phosphodiesterase 4 inhibitor, and a biologic compared to White patients with AD.21
Since the disproportionate burden experienced by patients with AD is not physiologic, it is imperative to address these systemic complexities and address the barriers impacting treatment availability to improve health outcomes for all patients living with AD.
Atopic dermatitis (AD) is a chronic skin condition generally characterized by pruritic and erythematous papules and plaques.1 While AD commonly manifests in childhood, 1 in 4 patients living with AD report adult onset of the disease.2 The clinical presentation and prevalence of AD vary across age groups, skin tones, and racial and ethnic groups. Globally, AD is estimated to have a prevalence of 2.6%; however, rates vary widely by region.1 Morphology and distribution of AD lesions also vary by population; therefore, defining one classic presentation of AD is not sufficient in diverse patient populations.3
Epidemiology
The prevalence of AD ranges from 0.2% to 24.6% worldwide, with higher rates in Africa and Oceania and lower rates in India and Northern and Eastern Europe.1 In the United States, AD affects all racial and ethnic groups; however, prevalence and severity are increased in Black children compared with White children.4 In one prospective cohort study, Hispanic children and non-Hispanic Black children aged 3 years and younger had greater odds of AD persisting into mid childhood (approximately age 7 years) compared with non-Hispanic White children.5,6
Key Clinical Features
Clinical features of AD are heterogeneous and may include differences in color, morphology, and distribution. Brown, hyperpigmented, gray, and/or violaceous plaques may predominate in patients with skin of color (SOC) compared with the erythematous plaques commonly described in lighter skin tones.1,3 Established scoring systems for AD rely on erythema as a key diagnostic feature, but because erythema can be difficult to detect in darker skin tones, disease severity may be underestimated and diagnosis may be delayed in this population.4
Atopic dermatitis in SOC may manifest as lichenoid plaques,7 prurigo nodules,7,8 lichenification,1 and follicular accentuation.9 Lichen planus–like AD is a distinct variant characterized by lichenoid plaques with a predilection for the extensor surfaces and face in patients with darker skin tones1,8 occurring in approximately 9% of patients in one study.10
Other key clinical features of AD in patients with SOC include pityriasis alba,10 increased risk for postinflammatory pigment alteration (including hyperpigmentation and/or hypopigmentation),1 and greater trunk and extensor involvement.1,11
Worth Noting
The scientific landscape for AD has grown rapidly, increasing our understanding of its pathophysiology, treatment, and social impact. Nonsteroidal treatments available for pediatric and adult patients with AD have increased in recent years, including crisaborole (approved for use in those ages ≥ 3 months), tacrolimus (≥ 2 years), and pimecrolimus (≥ 2 years). Injectable options include dupilumab (≥ 6 months), lebrikizumab (≥ 12 years), nemolizumab (≥ 12 years), and tralokinumab (≥ 12 years). Oral options include abrocitinib (≥ 12 years) and upadacitinib (≥ 12 years).12 Topical options include roflumilast 0.15% cream (≥ 6 years)12 and 0.05% cream (≥ 2-5 years),13 ruxolitinib 1.5% cream (≥ 2 years),14 and tapinarof 1% cream (≥ 2 years).12
For some patients, postinflammatory pigment alteration associated with AD has a higher impact on quality of life than the AD itself.7 In a study of 260 US adults with AD, the emotional impact of pigmentary changes was greatest in Black patients, with 53.3% reporting that pigment changes bothered them “a lot” or “very much.”15
Genome-wide association studies have not identified a single determinant that explains racial and ethnic differences in susceptibility to AD.4 Instead, social determinants of health are thought to play a role in the difference in AD prevalence and severity across groups in the United States.16
Health Disparity Highlight
In an analysis of 20 US metropolitan cities, urban and inner-city residence was associated with approximately 1.7-fold increased odds of AD.4 Among pediatric patients with moderate to severe AD, Black children were more likely to be exposed to tobacco smoke17 and traffic-related air pollution.18 Low socioeconomic status and low income also have been associated with moderate16 and severe19 AD. At the same education level, Black individuals in the United States receive less income than their White counterparts and have markedly less wealth at equivalent incomes.20
In utero exposure to maternal stress is associated with AD.4 Increased IgE levels have been recorded in children who develop AD, with Black children having the highest IgE levels overall compared to other children.18
An analysis of medical records from an urban medical center in Baltimore, Maryland, from 2013 through 2018 showed that Black patients with AD were less likely to receive topical corticosteroids, topical calcineurin inhibitors, a topical phosphodiesterase 4 inhibitor, and a biologic compared to White patients with AD.21
Since the disproportionate burden experienced by patients with AD is not physiologic, it is imperative to address these systemic complexities and address the barriers impacting treatment availability to improve health outcomes for all patients living with AD.
- Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups—variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27:340-357.
- Lee HH, Patel KR, Singam V, et al. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019;80:1526-1532.E7.
- Adawi W, Cornman H, Kambala A, et al. Diagnosing atopic dermatitis in skin of color. Dermatol Clin. 2023;41:417-429.
- Narla S, Silverberg JI. Current updates in the epidemiology and comorbidities of atopic dermatitis. Ann Allergy Asthma Immunol. 2025;135:511-520.
- Croce EA, Levy ML, Adamson AS, et al. Reframing racial and ethnic disparities in atopic dermatitis in Black and Latinx populations. J Allergy Clin Immunol. 2021;148:1104-1111.
- Kim Y, Blomberg M, Rifas-Shiman SL, et al. Racial/ethnic differences in incidence and persistence of childhood atopic dermatitis. J Invest Dermatol. 2019;139:827-834.
- Nomura T, Wu J, Kabashima K, et al. Endophenotypic variations of atopic dermatitis by age, race, and ethnicity. J Allergy Clin Immunol. 2020;8:1840-1852.
- McColl M, Boozalis E, Aguh C, et al. Pruritus in Black skin: unique molecular characteristics and clinical features. J Natl Med Assoc. 2021;114:30-38.
- Silverberg JI, Margolis DJ, Boguniewicz M, et al. Distribution of atopic dermatitis lesions in United States adults. J Eur Acad Dermatol Venereol. 2019;33:1341-1348.
- Summey BT, Bowen SE, Allen HB. Lichen planus-like atopic dermatitis: expanding the differential diagnosis of spongiotic dermatitis. J Cutan Pathol. 2008;35:311-314.
- Odhiambo JA, Williams HC, Clayton TO, et al; ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124:1251-1258.E23.
- Gallagher K, Halperin-Goldstein S, Paller AS. New treatments in atopic dermatitis update. Ann Allergy Asthma Immunol. 2025;135:498-510.E10.
- Shaw ML. FDA expands roflumilast use for atopic dermatitis to children aged 2 to 5 years. Am J Managed Care. October 6, 2025. Accessed April 30, 2026. https://www.ajmc.com/view/fda-expands -roflumilast-use-for-atopic-dermatitis-to-children-aged-2-to-5-years
- Eichenfield LF, Stein Gold LF, Simpson EL, et al. Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: results from TRuE-AD3, a phase 3, randomized double-blind study. J Am Acad of Dermatol. 2025;93:689-698.
- Heath CR, Dosono B, Shi VY, et al. Variability in skin tone changes by race and ethnicity among US adults with atopic dermatitis. Presented at: Skin of Color Update 2024, September 13-15, 2024, New York, NY.
- Tackett KJ, Jenkins F, Morrell DS, et al. Structural racism and its influence on the severity of atopic dermatitis in African American children. Pediatr Dermatol. 2020;37:142-146.
- Narla S, Silverberg JI. The role of environmental exposures in atopic dermatitis. Curr Allergy Asthma Rep. 2020;20:74.
- Bauer SJ, Spoer BR, Ehrman R, et al. A systematic review of historic neighborhood redlining and contemporary health outcomes. Public Health. 2025;238:181-187.
- Chung J, Simpson EL. The socioeconomics of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122:360-366.
- Martinez A, de la Rosa R, Mujahid M, et al. Structural racism and its pathways to asthma and atopic dermatitis. J Allergy Clin Immunol. 2021;148:1112-1120.
- Bell MA, Whang KA, Thomas J, et al. Racial and ethnic disparities in access to emerging and frontline therapies in common dermatological conditions: a cross-sectional study. J Natl Med Assoc. 2020;112:650-653.
- Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups—variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27:340-357.
- Lee HH, Patel KR, Singam V, et al. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019;80:1526-1532.E7.
- Adawi W, Cornman H, Kambala A, et al. Diagnosing atopic dermatitis in skin of color. Dermatol Clin. 2023;41:417-429.
- Narla S, Silverberg JI. Current updates in the epidemiology and comorbidities of atopic dermatitis. Ann Allergy Asthma Immunol. 2025;135:511-520.
- Croce EA, Levy ML, Adamson AS, et al. Reframing racial and ethnic disparities in atopic dermatitis in Black and Latinx populations. J Allergy Clin Immunol. 2021;148:1104-1111.
- Kim Y, Blomberg M, Rifas-Shiman SL, et al. Racial/ethnic differences in incidence and persistence of childhood atopic dermatitis. J Invest Dermatol. 2019;139:827-834.
- Nomura T, Wu J, Kabashima K, et al. Endophenotypic variations of atopic dermatitis by age, race, and ethnicity. J Allergy Clin Immunol. 2020;8:1840-1852.
- McColl M, Boozalis E, Aguh C, et al. Pruritus in Black skin: unique molecular characteristics and clinical features. J Natl Med Assoc. 2021;114:30-38.
- Silverberg JI, Margolis DJ, Boguniewicz M, et al. Distribution of atopic dermatitis lesions in United States adults. J Eur Acad Dermatol Venereol. 2019;33:1341-1348.
- Summey BT, Bowen SE, Allen HB. Lichen planus-like atopic dermatitis: expanding the differential diagnosis of spongiotic dermatitis. J Cutan Pathol. 2008;35:311-314.
- Odhiambo JA, Williams HC, Clayton TO, et al; ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124:1251-1258.E23.
- Gallagher K, Halperin-Goldstein S, Paller AS. New treatments in atopic dermatitis update. Ann Allergy Asthma Immunol. 2025;135:498-510.E10.
- Shaw ML. FDA expands roflumilast use for atopic dermatitis to children aged 2 to 5 years. Am J Managed Care. October 6, 2025. Accessed April 30, 2026. https://www.ajmc.com/view/fda-expands -roflumilast-use-for-atopic-dermatitis-to-children-aged-2-to-5-years
- Eichenfield LF, Stein Gold LF, Simpson EL, et al. Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: results from TRuE-AD3, a phase 3, randomized double-blind study. J Am Acad of Dermatol. 2025;93:689-698.
- Heath CR, Dosono B, Shi VY, et al. Variability in skin tone changes by race and ethnicity among US adults with atopic dermatitis. Presented at: Skin of Color Update 2024, September 13-15, 2024, New York, NY.
- Tackett KJ, Jenkins F, Morrell DS, et al. Structural racism and its influence on the severity of atopic dermatitis in African American children. Pediatr Dermatol. 2020;37:142-146.
- Narla S, Silverberg JI. The role of environmental exposures in atopic dermatitis. Curr Allergy Asthma Rep. 2020;20:74.
- Bauer SJ, Spoer BR, Ehrman R, et al. A systematic review of historic neighborhood redlining and contemporary health outcomes. Public Health. 2025;238:181-187.
- Chung J, Simpson EL. The socioeconomics of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122:360-366.
- Martinez A, de la Rosa R, Mujahid M, et al. Structural racism and its pathways to asthma and atopic dermatitis. J Allergy Clin Immunol. 2021;148:1112-1120.
- Bell MA, Whang KA, Thomas J, et al. Racial and ethnic disparities in access to emerging and frontline therapies in common dermatological conditions: a cross-sectional study. J Natl Med Assoc. 2020;112:650-653.
Atopic Dermatitis: New Insights and Expanded Treatment Options
Atopic Dermatitis: New Insights and Expanded Treatment Options
VA Advanced Training for Clinician Researchers and Data Scientists in Mental Health
VA Advanced Training for Clinician Researchers and Data Scientists in Mental Health
The US Department of Veterans Affairs (VA) mission realizes President Abraham Lincoln’s promise to “to care for him who shall have borne the battle, and for his widow, and his orphan.”1 Evidence-based care fulfills this promise and is the backbone of Veterans Health Administration (VHA) mental health care.2,3 To ensure veterans receive state-of-the-art clinical care, a skilled workforce and investment in data-driven approaches are necessary to identify best treatments and strategies to implement them in practice.
Through scientific and clinical training tailored to VA, the 23 VA Advanced Fellowships have secured a steady flow of highly trained PhD professionals (ie, psychologists and other allied health professionals), and medical doctors (ie, psychiatrists and neurologists) into the VA workforce.4 The VA Advanced Fellows are funded by the Office of Academic Affiliations (OAA) and offer 2-year training opportunities for postresidency MDs and postdoctoral PhDs. This article describes a VA Advanced Fellowship in mental health as an example of how these programs can have a broad and positive impact on the VA health care system.
Advanced Fellows Program
The VA Advanced Fellowship in Mental Illness Research and Treatment (AF MIRT), formerly known as the VA Special Fellowship Program in Advanced Psychiatry and Psychology, educates and trains clinician and nonclinician researchers to meet VA priority mental health care needs.5 Clinical AF MIRT fellows dedicate 75% of their time to training and research activities and 25% to direct clinical services. Data science fellows complete projects that inform veteran clinical care through qualitative data collection, program evaluation, and analysis of large datasets. The full translational pathway to evidence-based clinical care is represented by fellow research spanning basic animal models, genetics, and neuroimaging to implementation science and applied clinical care for veterans.
In 2025, AF MIRT marked its 25th year of training postdoctoral-level mental health scientific practitioners and scholars. This investment in clinical research training has had profound benefits for innovation and retention of clinicians and scientists within the VA system. As of April 1, 2026, AF MIRT trained 700 fellows, including 152 MD or MD/PhD fellows, 544 PhD or PsyD fellows, 3 PharmDs fellows, and 1 doctor of nursing practice fellow.
Fellowship Structure
The AF MIRT coordinating center provides key administrative support to fellowship site directors and topical didactic training to Advanced Fellows, ensuring consistent standard of quality training across locations in 15 states and 4 times zones. The training provided by the AF MIRT coordinating center deepens the nationally-mandated focus of local translational clinical centers (eg, Mental Illness Research Education and Clinical Centers, Centers of Excellence) on posttraumatic stress disorder (PTSD), serious mental illness, dementia, and other areas.
The AF MIRT coordinating center also promotes VA workforce sustainability. Advanced Fellows in programs with a coordinating center are much more likely to be retained in VA for postfellowship employment compared with fellows in programs without such a coordinating center (60% vs 38%) according to unpublished Office of Academic Affiliations data (Joel Schmidt, oral communication, May 15, 2025). The AF MIRT coordinating center provides central standardization and uses evidence-based approaches to ensure fellows receive consistent support, resources, and training. More specifically, the coordinating center develops and delivers a standardized, core curriculum to the program’s 28 sites. The program pioneered video delivery of integrated didactics that enlist national experts, many of them VA researchers and clinicians themselves. Didactics include high priority veteran mental health topics, such as suicide prevention, new and emerging evidence-based treatments (eg, neurostimulation for treatment resistant PTSD, psychotherapeutic approaches for traumatic brain injury), and VA health system considerations for mental health treatment delivery.
This curated didactic series also covers professional and technical issues, such as statistical and methodological considerations for clinical trials, scientific writing, and grant-writing skill development. These offerings support the career pathways of advanced fellows to pursue careers as researchers, scientifically-informed clinicians, or data scientists at VA or academic medical centers. The coordinating center prepares fellows to apply for mentored career award funding or independent investigator awards through the VA, National Institutes of Health (NIH), US Department of Defense, and other organizations by offering an annual mock grant review session and monthly reviews and discussions of fellows’ grant applications.
AF MIRT continuously fine tunes the didactic series curriculum based on feedback from fellows on how the program meets their training needs. For example, learning about the strategies Advanced Fellows used to remain productive during COVID-19 pandemic lockdowns revealed a strong trend toward use of secondary data (eg, publicly available data or VA electronic health record data). This fueled curriculum adjustments to include more topics relevant to fellow interests and needs for accessing secondary data resources for high priority veteran mental health topics.6
VA Advanced Fellowships Successes
From July 2020 to June 2025, MIRT advanced fellows published 906 peer-reviewed articles in psychiatry, psychology, and other disciplines. Each year, about 20 to 25 articles are published in high-impact journals. In this 5-year period, fellows have received 153 grants (114 VA grants) as principal investigators– many examining new innovations to improve the quality of care of veterans. Of the 165 fellows who graduated since 2020, 63% continued working in veteran health care: 38% transitioned to full-time VA employment and 25% moved to VA employment with an academic-affiliated role. Nineteen percent transitioned to academic positions, 12% transitioned to the private sector, and 5% transitioned to other government, industry, or nonprofit employment where these professionals contribute to scientific and clinical innovation benefiting the US public; 1% did not provide postfellowship employment information. The Figure displays geographic locations of graduated fellows’ postfellowship employment from July 2020 to June 2025.
employment across all settings, July 2020 to June 2025.
The accomplishments of fellows are wide-ranging and aligned with VA’s mission. Each year, roughly 15 fellows receive new investigator awards, travel awards, and poster or presentation awards from prominent professional societies. Fellows have obtained VA Career Development Awards in diverse topics, including suicide prevention through clinician resources and training programs, firearm safety discussions, digital phenotyping and neuroimaging to enhance social integration in veterans with schizophrenia, rapid transcranial magnetic stimulation to treat nicotine use and PTSD, and evidence-based psychotherapy techniques for female veterans experiencing issues in menopause.
Several recent MIRT fellows have also received highly competitive NIH K Career Development Awards. One notable example is a fellow who studied pharmacologic approaches for treatment-resistant depression informed by novel brain circuit findings, first testing these approaches in community samples through a NIH K grant and translating findings to veterans. Fellows have gone on to become directors of important national research centers and studies, chairs of academic departments, and presidents of national medical organizations. Importantly, many MIRT fellows have become local directors and mentors to a new generation of VA fellows and researchers.
Conclusions
The AF MIRT coordinating center supports the VA’s mission of fulfilling President Lincoln’s promise to care for veterans. There are multiple benefits to evidence-based work that helps veterans and fosters a highly skilled VA workforce. Veterans are at the center of the MIRT data-driven approach, which is critical given their complex needs. Approaches to building the AF MIRT’s evidence base include randomized controlled trials open to veteran participants; program evaluation of current local, regional, or national VHA clinical services through measurement-based care and evaluation of national clinician training programs; and even smaller quality improvement projects in local VA clinics. These efforts support effective, efficient, and accessible provision of treatments that benefit veterans.
- US Department of Veterans Affairs. Our VA mission and core values. Updated April 17, 2025. Accessed March 2, 2026. https://department.va.gov/icare/
- Holliday R, Holder N. VA is a leader in mental health and social service research and operations. Fed Pract. 2025;42:S5. doi:10.12788/fp.0578
- Zeiss AM, Karlin BE. Integrating mental health and primary care services in the Department of Veterans Affairs health care system. J Clin Psychol Med Settings. 2008;15:73-78. doi:10.1007/s10880-008-9100-4
- O’Hara R, Cassidy-Eagle EL, Beaudreau SA, et al. Increasing the ranks of academic researchers in mental health: a multisite approach to postdoctoral fellowship training. Acad Med. 2010;85:41-47. doi:10.1097/ACM.0b013e3181c47c51
- US Department of Veterans Affairs. Office of Academic Affiliations. Updated March 13, 2025. Accessed March 2, 2026. https://www.va.gov/oaa/advancedfellowships /advanced-fellowships.asp
- Hantke NC, Samarina V, Hallmayer J, et al. Preparing the next generation of academic researchers during the pandemic: lessons from a national mental health research postdoctoral fellowship. Acad Psychiatry. 2022;46:466- 469. doi:10.1007/s40596-022-01613-4
The US Department of Veterans Affairs (VA) mission realizes President Abraham Lincoln’s promise to “to care for him who shall have borne the battle, and for his widow, and his orphan.”1 Evidence-based care fulfills this promise and is the backbone of Veterans Health Administration (VHA) mental health care.2,3 To ensure veterans receive state-of-the-art clinical care, a skilled workforce and investment in data-driven approaches are necessary to identify best treatments and strategies to implement them in practice.
Through scientific and clinical training tailored to VA, the 23 VA Advanced Fellowships have secured a steady flow of highly trained PhD professionals (ie, psychologists and other allied health professionals), and medical doctors (ie, psychiatrists and neurologists) into the VA workforce.4 The VA Advanced Fellows are funded by the Office of Academic Affiliations (OAA) and offer 2-year training opportunities for postresidency MDs and postdoctoral PhDs. This article describes a VA Advanced Fellowship in mental health as an example of how these programs can have a broad and positive impact on the VA health care system.
Advanced Fellows Program
The VA Advanced Fellowship in Mental Illness Research and Treatment (AF MIRT), formerly known as the VA Special Fellowship Program in Advanced Psychiatry and Psychology, educates and trains clinician and nonclinician researchers to meet VA priority mental health care needs.5 Clinical AF MIRT fellows dedicate 75% of their time to training and research activities and 25% to direct clinical services. Data science fellows complete projects that inform veteran clinical care through qualitative data collection, program evaluation, and analysis of large datasets. The full translational pathway to evidence-based clinical care is represented by fellow research spanning basic animal models, genetics, and neuroimaging to implementation science and applied clinical care for veterans.
In 2025, AF MIRT marked its 25th year of training postdoctoral-level mental health scientific practitioners and scholars. This investment in clinical research training has had profound benefits for innovation and retention of clinicians and scientists within the VA system. As of April 1, 2026, AF MIRT trained 700 fellows, including 152 MD or MD/PhD fellows, 544 PhD or PsyD fellows, 3 PharmDs fellows, and 1 doctor of nursing practice fellow.
Fellowship Structure
The AF MIRT coordinating center provides key administrative support to fellowship site directors and topical didactic training to Advanced Fellows, ensuring consistent standard of quality training across locations in 15 states and 4 times zones. The training provided by the AF MIRT coordinating center deepens the nationally-mandated focus of local translational clinical centers (eg, Mental Illness Research Education and Clinical Centers, Centers of Excellence) on posttraumatic stress disorder (PTSD), serious mental illness, dementia, and other areas.
The AF MIRT coordinating center also promotes VA workforce sustainability. Advanced Fellows in programs with a coordinating center are much more likely to be retained in VA for postfellowship employment compared with fellows in programs without such a coordinating center (60% vs 38%) according to unpublished Office of Academic Affiliations data (Joel Schmidt, oral communication, May 15, 2025). The AF MIRT coordinating center provides central standardization and uses evidence-based approaches to ensure fellows receive consistent support, resources, and training. More specifically, the coordinating center develops and delivers a standardized, core curriculum to the program’s 28 sites. The program pioneered video delivery of integrated didactics that enlist national experts, many of them VA researchers and clinicians themselves. Didactics include high priority veteran mental health topics, such as suicide prevention, new and emerging evidence-based treatments (eg, neurostimulation for treatment resistant PTSD, psychotherapeutic approaches for traumatic brain injury), and VA health system considerations for mental health treatment delivery.
This curated didactic series also covers professional and technical issues, such as statistical and methodological considerations for clinical trials, scientific writing, and grant-writing skill development. These offerings support the career pathways of advanced fellows to pursue careers as researchers, scientifically-informed clinicians, or data scientists at VA or academic medical centers. The coordinating center prepares fellows to apply for mentored career award funding or independent investigator awards through the VA, National Institutes of Health (NIH), US Department of Defense, and other organizations by offering an annual mock grant review session and monthly reviews and discussions of fellows’ grant applications.
AF MIRT continuously fine tunes the didactic series curriculum based on feedback from fellows on how the program meets their training needs. For example, learning about the strategies Advanced Fellows used to remain productive during COVID-19 pandemic lockdowns revealed a strong trend toward use of secondary data (eg, publicly available data or VA electronic health record data). This fueled curriculum adjustments to include more topics relevant to fellow interests and needs for accessing secondary data resources for high priority veteran mental health topics.6
VA Advanced Fellowships Successes
From July 2020 to June 2025, MIRT advanced fellows published 906 peer-reviewed articles in psychiatry, psychology, and other disciplines. Each year, about 20 to 25 articles are published in high-impact journals. In this 5-year period, fellows have received 153 grants (114 VA grants) as principal investigators– many examining new innovations to improve the quality of care of veterans. Of the 165 fellows who graduated since 2020, 63% continued working in veteran health care: 38% transitioned to full-time VA employment and 25% moved to VA employment with an academic-affiliated role. Nineteen percent transitioned to academic positions, 12% transitioned to the private sector, and 5% transitioned to other government, industry, or nonprofit employment where these professionals contribute to scientific and clinical innovation benefiting the US public; 1% did not provide postfellowship employment information. The Figure displays geographic locations of graduated fellows’ postfellowship employment from July 2020 to June 2025.
employment across all settings, July 2020 to June 2025.
The accomplishments of fellows are wide-ranging and aligned with VA’s mission. Each year, roughly 15 fellows receive new investigator awards, travel awards, and poster or presentation awards from prominent professional societies. Fellows have obtained VA Career Development Awards in diverse topics, including suicide prevention through clinician resources and training programs, firearm safety discussions, digital phenotyping and neuroimaging to enhance social integration in veterans with schizophrenia, rapid transcranial magnetic stimulation to treat nicotine use and PTSD, and evidence-based psychotherapy techniques for female veterans experiencing issues in menopause.
Several recent MIRT fellows have also received highly competitive NIH K Career Development Awards. One notable example is a fellow who studied pharmacologic approaches for treatment-resistant depression informed by novel brain circuit findings, first testing these approaches in community samples through a NIH K grant and translating findings to veterans. Fellows have gone on to become directors of important national research centers and studies, chairs of academic departments, and presidents of national medical organizations. Importantly, many MIRT fellows have become local directors and mentors to a new generation of VA fellows and researchers.
Conclusions
The AF MIRT coordinating center supports the VA’s mission of fulfilling President Lincoln’s promise to care for veterans. There are multiple benefits to evidence-based work that helps veterans and fosters a highly skilled VA workforce. Veterans are at the center of the MIRT data-driven approach, which is critical given their complex needs. Approaches to building the AF MIRT’s evidence base include randomized controlled trials open to veteran participants; program evaluation of current local, regional, or national VHA clinical services through measurement-based care and evaluation of national clinician training programs; and even smaller quality improvement projects in local VA clinics. These efforts support effective, efficient, and accessible provision of treatments that benefit veterans.
The US Department of Veterans Affairs (VA) mission realizes President Abraham Lincoln’s promise to “to care for him who shall have borne the battle, and for his widow, and his orphan.”1 Evidence-based care fulfills this promise and is the backbone of Veterans Health Administration (VHA) mental health care.2,3 To ensure veterans receive state-of-the-art clinical care, a skilled workforce and investment in data-driven approaches are necessary to identify best treatments and strategies to implement them in practice.
Through scientific and clinical training tailored to VA, the 23 VA Advanced Fellowships have secured a steady flow of highly trained PhD professionals (ie, psychologists and other allied health professionals), and medical doctors (ie, psychiatrists and neurologists) into the VA workforce.4 The VA Advanced Fellows are funded by the Office of Academic Affiliations (OAA) and offer 2-year training opportunities for postresidency MDs and postdoctoral PhDs. This article describes a VA Advanced Fellowship in mental health as an example of how these programs can have a broad and positive impact on the VA health care system.
Advanced Fellows Program
The VA Advanced Fellowship in Mental Illness Research and Treatment (AF MIRT), formerly known as the VA Special Fellowship Program in Advanced Psychiatry and Psychology, educates and trains clinician and nonclinician researchers to meet VA priority mental health care needs.5 Clinical AF MIRT fellows dedicate 75% of their time to training and research activities and 25% to direct clinical services. Data science fellows complete projects that inform veteran clinical care through qualitative data collection, program evaluation, and analysis of large datasets. The full translational pathway to evidence-based clinical care is represented by fellow research spanning basic animal models, genetics, and neuroimaging to implementation science and applied clinical care for veterans.
In 2025, AF MIRT marked its 25th year of training postdoctoral-level mental health scientific practitioners and scholars. This investment in clinical research training has had profound benefits for innovation and retention of clinicians and scientists within the VA system. As of April 1, 2026, AF MIRT trained 700 fellows, including 152 MD or MD/PhD fellows, 544 PhD or PsyD fellows, 3 PharmDs fellows, and 1 doctor of nursing practice fellow.
Fellowship Structure
The AF MIRT coordinating center provides key administrative support to fellowship site directors and topical didactic training to Advanced Fellows, ensuring consistent standard of quality training across locations in 15 states and 4 times zones. The training provided by the AF MIRT coordinating center deepens the nationally-mandated focus of local translational clinical centers (eg, Mental Illness Research Education and Clinical Centers, Centers of Excellence) on posttraumatic stress disorder (PTSD), serious mental illness, dementia, and other areas.
The AF MIRT coordinating center also promotes VA workforce sustainability. Advanced Fellows in programs with a coordinating center are much more likely to be retained in VA for postfellowship employment compared with fellows in programs without such a coordinating center (60% vs 38%) according to unpublished Office of Academic Affiliations data (Joel Schmidt, oral communication, May 15, 2025). The AF MIRT coordinating center provides central standardization and uses evidence-based approaches to ensure fellows receive consistent support, resources, and training. More specifically, the coordinating center develops and delivers a standardized, core curriculum to the program’s 28 sites. The program pioneered video delivery of integrated didactics that enlist national experts, many of them VA researchers and clinicians themselves. Didactics include high priority veteran mental health topics, such as suicide prevention, new and emerging evidence-based treatments (eg, neurostimulation for treatment resistant PTSD, psychotherapeutic approaches for traumatic brain injury), and VA health system considerations for mental health treatment delivery.
This curated didactic series also covers professional and technical issues, such as statistical and methodological considerations for clinical trials, scientific writing, and grant-writing skill development. These offerings support the career pathways of advanced fellows to pursue careers as researchers, scientifically-informed clinicians, or data scientists at VA or academic medical centers. The coordinating center prepares fellows to apply for mentored career award funding or independent investigator awards through the VA, National Institutes of Health (NIH), US Department of Defense, and other organizations by offering an annual mock grant review session and monthly reviews and discussions of fellows’ grant applications.
AF MIRT continuously fine tunes the didactic series curriculum based on feedback from fellows on how the program meets their training needs. For example, learning about the strategies Advanced Fellows used to remain productive during COVID-19 pandemic lockdowns revealed a strong trend toward use of secondary data (eg, publicly available data or VA electronic health record data). This fueled curriculum adjustments to include more topics relevant to fellow interests and needs for accessing secondary data resources for high priority veteran mental health topics.6
VA Advanced Fellowships Successes
From July 2020 to June 2025, MIRT advanced fellows published 906 peer-reviewed articles in psychiatry, psychology, and other disciplines. Each year, about 20 to 25 articles are published in high-impact journals. In this 5-year period, fellows have received 153 grants (114 VA grants) as principal investigators– many examining new innovations to improve the quality of care of veterans. Of the 165 fellows who graduated since 2020, 63% continued working in veteran health care: 38% transitioned to full-time VA employment and 25% moved to VA employment with an academic-affiliated role. Nineteen percent transitioned to academic positions, 12% transitioned to the private sector, and 5% transitioned to other government, industry, or nonprofit employment where these professionals contribute to scientific and clinical innovation benefiting the US public; 1% did not provide postfellowship employment information. The Figure displays geographic locations of graduated fellows’ postfellowship employment from July 2020 to June 2025.
employment across all settings, July 2020 to June 2025.
The accomplishments of fellows are wide-ranging and aligned with VA’s mission. Each year, roughly 15 fellows receive new investigator awards, travel awards, and poster or presentation awards from prominent professional societies. Fellows have obtained VA Career Development Awards in diverse topics, including suicide prevention through clinician resources and training programs, firearm safety discussions, digital phenotyping and neuroimaging to enhance social integration in veterans with schizophrenia, rapid transcranial magnetic stimulation to treat nicotine use and PTSD, and evidence-based psychotherapy techniques for female veterans experiencing issues in menopause.
Several recent MIRT fellows have also received highly competitive NIH K Career Development Awards. One notable example is a fellow who studied pharmacologic approaches for treatment-resistant depression informed by novel brain circuit findings, first testing these approaches in community samples through a NIH K grant and translating findings to veterans. Fellows have gone on to become directors of important national research centers and studies, chairs of academic departments, and presidents of national medical organizations. Importantly, many MIRT fellows have become local directors and mentors to a new generation of VA fellows and researchers.
Conclusions
The AF MIRT coordinating center supports the VA’s mission of fulfilling President Lincoln’s promise to care for veterans. There are multiple benefits to evidence-based work that helps veterans and fosters a highly skilled VA workforce. Veterans are at the center of the MIRT data-driven approach, which is critical given their complex needs. Approaches to building the AF MIRT’s evidence base include randomized controlled trials open to veteran participants; program evaluation of current local, regional, or national VHA clinical services through measurement-based care and evaluation of national clinician training programs; and even smaller quality improvement projects in local VA clinics. These efforts support effective, efficient, and accessible provision of treatments that benefit veterans.
- US Department of Veterans Affairs. Our VA mission and core values. Updated April 17, 2025. Accessed March 2, 2026. https://department.va.gov/icare/
- Holliday R, Holder N. VA is a leader in mental health and social service research and operations. Fed Pract. 2025;42:S5. doi:10.12788/fp.0578
- Zeiss AM, Karlin BE. Integrating mental health and primary care services in the Department of Veterans Affairs health care system. J Clin Psychol Med Settings. 2008;15:73-78. doi:10.1007/s10880-008-9100-4
- O’Hara R, Cassidy-Eagle EL, Beaudreau SA, et al. Increasing the ranks of academic researchers in mental health: a multisite approach to postdoctoral fellowship training. Acad Med. 2010;85:41-47. doi:10.1097/ACM.0b013e3181c47c51
- US Department of Veterans Affairs. Office of Academic Affiliations. Updated March 13, 2025. Accessed March 2, 2026. https://www.va.gov/oaa/advancedfellowships /advanced-fellowships.asp
- Hantke NC, Samarina V, Hallmayer J, et al. Preparing the next generation of academic researchers during the pandemic: lessons from a national mental health research postdoctoral fellowship. Acad Psychiatry. 2022;46:466- 469. doi:10.1007/s40596-022-01613-4
- US Department of Veterans Affairs. Our VA mission and core values. Updated April 17, 2025. Accessed March 2, 2026. https://department.va.gov/icare/
- Holliday R, Holder N. VA is a leader in mental health and social service research and operations. Fed Pract. 2025;42:S5. doi:10.12788/fp.0578
- Zeiss AM, Karlin BE. Integrating mental health and primary care services in the Department of Veterans Affairs health care system. J Clin Psychol Med Settings. 2008;15:73-78. doi:10.1007/s10880-008-9100-4
- O’Hara R, Cassidy-Eagle EL, Beaudreau SA, et al. Increasing the ranks of academic researchers in mental health: a multisite approach to postdoctoral fellowship training. Acad Med. 2010;85:41-47. doi:10.1097/ACM.0b013e3181c47c51
- US Department of Veterans Affairs. Office of Academic Affiliations. Updated March 13, 2025. Accessed March 2, 2026. https://www.va.gov/oaa/advancedfellowships /advanced-fellowships.asp
- Hantke NC, Samarina V, Hallmayer J, et al. Preparing the next generation of academic researchers during the pandemic: lessons from a national mental health research postdoctoral fellowship. Acad Psychiatry. 2022;46:466- 469. doi:10.1007/s40596-022-01613-4
VA Advanced Training for Clinician Researchers and Data Scientists in Mental Health
VA Advanced Training for Clinician Researchers and Data Scientists in Mental Health
The Home Improvements and Structural Alterations Program: Overview and Future Implications
The Home Improvements and Structural Alterations Program: Overview and Future Implications
The Veterans Health Administration (VHA) Home Improvements and Structural Alterations (HISA) program is a primary means through which veterans can obtain home modifications necessary to continue safe and independent living in their home, including fall risk reduction and accessibility to essential parts of the home. However, not all eligible veterans who may benefit from this program participate, for a variety of reasons.1-6 Historically, the HISA program has been administered in a decentralized and nonstandardized fashion dictated by the organizational structure of each US Department of Veterans Affairs (VA) medical center (VAMC) within a certain region or Veterans Integrated Service Network (VISN). Previous research found differential access to the HISA program by younger veterans, women, minorities, veterans with certain disability types, and veterans living in rural vs urban settings. These disparities in access and use of benefits conferred by the HISA program suggests an area of unmet need, which may improve veterans’ health care outcomes and reduce costs associated with their care.2-8
The purpose of this article is to provide information to improve equitable provision and effective eligible use of resources available through the HISA program in a more generalizable manner by providing insight to highlight common program process deficiencies and care provision gaps relevant to VAMCs nationwide. This information can be used to inform the VA Physical Medicine and Rehabilitation (PM&R) and Prosthetic and Sensory Aid Service (PSAS) national policy initiatives, as well as hiring practices, clinic organization, specific care provision, and administrative goals and metrics at each VISN and at the VA Healthcare System level.
Methods
Veterans who participated in the HISA program, VHA administrators, and VHA clinicians from select VAMCs were identified and interviewed to better understand what helps increase access to the program, barriers to access, and how existing program components and processes impact use of the service. These interviews were taken from a directed convenience sample of selected VAMCs. To obtain this directed convenience sample, 167 VAMCs that participated in the HISA program were categorized as facilities that provided either a high or low number of HISA program prescriptions based on data from 2010 to 2018. Ten facilities from the top quartiles and 10 from the bottom quartiles of prescribing locations were selected. This facility selection was driven by the proportion of rural veterans served by each facility, favoring those serving a greater proportion of rural veterans, as well geographic location, with the aim of avoiding overrepresentation of any specific region. The convenience sample included 45 individuals (20 VHA employees and 25 veterans) across 22 states from the Northeast, West, South, and Midwest US Census regions.
Interview Process
Interviews underwent a coding process. The development of topical themes followed a systematic, 2-phase approach. Initially, researchers analyzed responses to semistructured interview questions addressing specific aspects of the HISA program, such as program awareness and accessibility. These responses naturally clustered into preliminary categories based on the interview guide structure. For example, responses related to program discovery formed a marketing-related category, while recommendations about program implementation contributed to a training and development category.
Following this initial categorization, the research team conducted a more rigorous coding process. A team of 3 researchers systematically reviewed assigned interview transcripts to extract practical recommendations for the guide. The researchers first identified relevant responses individually and then convened during group meetings to discuss and finalize selections. This second phase refined the preliminary categorization while maintaining alignment with the original interview structure.
This approach allowed the team to preserve the practical utility of participant feedback while ensuring methodological rigor in the analysis process. Resulting themes reflect both the structured nature of the original inquiry and the practical recommendations identified for improving the HISA program. Information on the following areas were collected: education about the HISA program, the contracting process, use of telehealth, interaction between VHA clinical care and the PSAS, marketing of the program, program funding, and revising the application process.
Results
Interview respondents provided several recommendations for improving the HISA program (Table). Regarding training and education, respondents noted deficiencies in VHA employee communication about the HISA program to veterans. Some employees did not know details or were unaware the HISA program existed. Additionally, a lack of knowledge about HISA program alternatives, including other available programs for obtaining home modifications or other durable medical equipment alternatives (eg, provision of a portable ramp rather than construction of a permanent one), was apparent. It was strongly recommended to provide additional education to effectively disseminate knowledge about the HISA program. Specifically, VHA employees, especially those in Primary Care, Geriatrics, Home Based Primary Care, the Caregiver Support Program, and Blind Rehabilitation Services, require greater awareness of the program and its processes.

PSAS and PM&R professionals, including physicians, nurse practitioners, physician assistants, and physical and occupational therapists, would be expected to have some knowledge of the HISA program, and therefore be more likely to connect a veteran with it. However, they may lack specific details about the program such as correct contact persons in the other service (PSAS or PM&R, respectively), facility- specific processes, such as how to enter a HISA consultation within the veteran’s electronic health record, how the entered consultation would progress through the system and avoid cancellation, and what should routinely be done to avoid HISA consultation cancellation, such as referral to Occupational Therapy for a functional assessment so appropriate durable medical equipment can be trialed with the veteran prior to proceeding with more costly and time-consuming home modifications.
In addition, there is no routine standard work process to ensure that PM&R staff are aware of updates in HISA program regulations and policy. Further recommendations in this area include having supervisory employees in PSAS and PM&R work both individually and together to develop effective information dissemination methods for key stakeholders. These include targeted in-services (ie, educational trainings often scheduled and conducted during recurring meetings), whether faceto- face or virtually in real time, or recorded, that occur on an ongoing and regular basis with sister services such as Primary Care, Geriatrics, Home Based Primary Care, the Caregiver Support Program, and Blind Rehabilitation Services (eg, the facility Vision Impairment Services Team coordinator). Regularly updated educational materials should be provided to veterans and VHA adjacent stakeholders such as Veteran Service Organizations and Veteran County Service Officers, via a variety of platforms.
Successfully navigating the provision of home modifications via the HISA program involves identifying a contractor to perform the home modification and obtaining service and construction plan pricing. A key barrier in this area is that veterans and VHA clinicians perceive the funds available through HISA as insufficient, regardless of whether they have serviceconnected status or not. Service connection refers to designation of ≥ 1 medical conditions determined to be related to military service and thus eligible to receive VHA care.9 Service-connected veterans receive a lifetime maximum award of $6800 from HISA while veterans without service connection receive a lifetime maximum award of $2000.1,2
Rural veterans face a greater challenge than urban veterans, as there are fewer contractors located nearby. Thus, providing higher funding for rural veterans, or specific funding such as for travel expenses, would be especially helpful to find a willing contractor to perform home medications.1 The current requirement of working with a licensed contractor was also a barrier, especially for smaller jobs, and could result in VHA employees (including clinicians) feeling pressured to become overly involved to assist veterans to move through the process.
To that point, respondents requested resources such as a regularly updated list of licensed contractors in the area, especially those familiar with working with the HISA program, be provided to veterans and their assisting groups. In addition, respondents asked that VHA take on greater responsibility and liability with regard to contractors accessing HISA funding, such as not releasing final payment until VHA approved the completed home modification. On the other hand, respondents also expressed concerns about the length of time associated with HISA program payment and noted it should be sped up to allow contractors who participate to receive payment sooner, which many believed would increase the number of contractors willing to take on this work.
The role of telehealth was noted as a great facilitator of increased access to care, especially following the COVID-19 pandemic. Telehealth modalities adapted for the HISA program could help increase access to the program and improve processing speed. Barriers include lack of appropriate veteran telehealth equipment and poor understanding of information needed to move the process forward. Recommendations included providing veterans tablets to connect to virtual services, and developing information on home measurements needed, assistance in obtaining and sending photographs, and detailed information on successfully using telehealth for the HISA application process. Of note, some clinicians, representing home-based primary care, prosthetics services, geriatrics, rehabilitation therapy, mobile clinic, and the telehealth division, and including both clinical staff (eg, occupational therapists) and nonclinical staff (eg, prosthetics representatives and administrative personnel), have found patients expressed comparable satisfaction with the process whether faceto- face or via telehealth.
The essential relationship between PSAS and PM&R regarding the HISA program was a key finding. Both services are integral to helping veterans successfully obtain home modifications via the HISA program.1,2 Barriers include insufficient communication and a lack of clearly defined points of contact for each service, poorly defined roles, and inefficiencies because 2 services are involved in navigating the process. Recommendations therefore include addressing these issues, such as adopting a case management or liaison model between the services to better manage the process.
Respondents indicated that insufficient program funding was a concern. Veterans living in poorer quality housing, such as older homes, often require more expensive home modifications, necessitating greater out-of-pocket expenses. Veterans and VHA employees advocated for the creation of an exception to the lower funding cap for veterans without service connection in cases of financial hardship. Overall, the funding limits for both service-connected veterans and those without service connection were thought to be insufficient, especially as the COVID-19 pandemic increased the cost of construction materials.
Respondents also noted that veterans would benefit from clear messaging that receiving HISA funds does not impact eligibility for other VA benefits and services. Veterans must understand that home modifications work must be approved by VHA before being started and should be aware that if their disability rating increases so that they become eligible for the higher level service-connected benefits, they would then become eligible for the higher maximum benefit. Respondents recommended veterans should receive assistance in understanding the full costs of the home modification and ongoing maintenance, and the HISA research team recommended that the National Program develop a fact sheet that can be used to advise veterans.
Respondents consistently indicated that information about the HISA program was not disseminated effectively to key internal and external stakeholders, and opportunities to highlight the program on VHA websites, brochures throughout VHA facilities, and other outlets such as direct mailing should be used. Veterans who have used the program are overwhelmingly older (mean age 71 years), White, and male, suggesting missed opportunities and unmet need for underrepresented groups. Therefore, targeted marketing interventions would especially benefit these groups.
Respondents also noted inefficiencies throughout the HISA program application process and advocated for changes such as national standard operating procedures (SOPs) to guide navigation through the HISA process. The national SOPs could include home evaluation prior to HISA application submission, clearly identified points of contact for the HISA program in PSAS and PM&R, and standardized documentation.
Future Directions
Information from respondents provided several avenues for future studies. Recommendations were obtained from each of the 7 broad topical areas: training and educational needs, potential, contracting challenges and opportunities, telehealth as a conduit to facilitate the availability of the HISA program, PSAS, and clinical services collaboration, marketing, need for increased funding, and revision of the application process. Input from stakeholders can help direct efficient use of resources to guide future studies for the greatest impact and highlight current and future priorities. Easy areas of intervention indicated by respondents include creating a national standard work process regarding the HISA program with standardized educational materials for key stakeholders, revised at regular intervals, and readily available on national websites. A pre- and postimplementation survey could help provide quantifiable information about the benefits of such an intervention.
Conclusions
A qualitative analysis of interviews with veterans and VHA clinicians provides evidence of potential barriers for the HISA program. Addressing these barriers could allow HISA to better meet the VHA goal of providing home modifications that allow veterans to live safely and independently in their homes. There is a need for ongoing review and assessment of the program to ensure optimization and efficient use of resources across the spectrum of veteran needs.
- Semeah LM, Ahrentzen S, Jia H, et al. The Home Improvements and Structural Alterations Benefits Program: veterans with disabilities and home accessibility. J Disabil Policy Stud. 2017;28:43-51. doi:10.1177/1044207317696275
- Semeah LM, Wang X, Cowper Ripley DC, et al. Improving health through a home modification service for veterans. In: Fiedler BA, ed. Three Facets of Public Health and Paths to Improvements. 2020:381-416. doi:10.1016/B978-0-12-819008-1.00014-6
- Semeah LM, Ganesh SP, Wang X, et al. Home modification and health services utilization by rural and urban veterans with disabilities. Housing Policy Debate. 2021;31:862-874. doi:10.1080/10511482.2020.1858923
- Semeah LM, Orozco T, Wang X, et al. Home modifications for rural veterans with disabilities. Fed Pract. 2021;38:300- 310. doi:10.12788/fp.0153
- Semeah LM, Orozco T, Wang X, et al. Predictors of countylevel home modification use across the US. Fed Pract. 2022;39:274-280. doi:10.12788/fp.0279
- Semeah LM, Orozco T, Wang X, et al. Rural and urban home modification program users: a comparative study. HERD. 2023;16:223-235. doi:10.1177/19375867221142627
- US Department of of Veterans Affairs. Home Improvements and Structural Alterations (HISA) benefits program: final rule. Fed Regist. 2014;79:71658-71663
- US Department of Veterans Affairs. Home Improvement and Structural Alterations (HISA): increase in the limit for home improvement and structural alterations (HISA)-VA: final regulations. Fed Regist. 1993;58:25565.
- US Department of Veterans Affairs. Eligibility for VA disability benefits. Updated April 25, 2025. Accessed April 1, 2026. https://www.va.gov/disability/eligibility
The Veterans Health Administration (VHA) Home Improvements and Structural Alterations (HISA) program is a primary means through which veterans can obtain home modifications necessary to continue safe and independent living in their home, including fall risk reduction and accessibility to essential parts of the home. However, not all eligible veterans who may benefit from this program participate, for a variety of reasons.1-6 Historically, the HISA program has been administered in a decentralized and nonstandardized fashion dictated by the organizational structure of each US Department of Veterans Affairs (VA) medical center (VAMC) within a certain region or Veterans Integrated Service Network (VISN). Previous research found differential access to the HISA program by younger veterans, women, minorities, veterans with certain disability types, and veterans living in rural vs urban settings. These disparities in access and use of benefits conferred by the HISA program suggests an area of unmet need, which may improve veterans’ health care outcomes and reduce costs associated with their care.2-8
The purpose of this article is to provide information to improve equitable provision and effective eligible use of resources available through the HISA program in a more generalizable manner by providing insight to highlight common program process deficiencies and care provision gaps relevant to VAMCs nationwide. This information can be used to inform the VA Physical Medicine and Rehabilitation (PM&R) and Prosthetic and Sensory Aid Service (PSAS) national policy initiatives, as well as hiring practices, clinic organization, specific care provision, and administrative goals and metrics at each VISN and at the VA Healthcare System level.
Methods
Veterans who participated in the HISA program, VHA administrators, and VHA clinicians from select VAMCs were identified and interviewed to better understand what helps increase access to the program, barriers to access, and how existing program components and processes impact use of the service. These interviews were taken from a directed convenience sample of selected VAMCs. To obtain this directed convenience sample, 167 VAMCs that participated in the HISA program were categorized as facilities that provided either a high or low number of HISA program prescriptions based on data from 2010 to 2018. Ten facilities from the top quartiles and 10 from the bottom quartiles of prescribing locations were selected. This facility selection was driven by the proportion of rural veterans served by each facility, favoring those serving a greater proportion of rural veterans, as well geographic location, with the aim of avoiding overrepresentation of any specific region. The convenience sample included 45 individuals (20 VHA employees and 25 veterans) across 22 states from the Northeast, West, South, and Midwest US Census regions.
Interview Process
Interviews underwent a coding process. The development of topical themes followed a systematic, 2-phase approach. Initially, researchers analyzed responses to semistructured interview questions addressing specific aspects of the HISA program, such as program awareness and accessibility. These responses naturally clustered into preliminary categories based on the interview guide structure. For example, responses related to program discovery formed a marketing-related category, while recommendations about program implementation contributed to a training and development category.
Following this initial categorization, the research team conducted a more rigorous coding process. A team of 3 researchers systematically reviewed assigned interview transcripts to extract practical recommendations for the guide. The researchers first identified relevant responses individually and then convened during group meetings to discuss and finalize selections. This second phase refined the preliminary categorization while maintaining alignment with the original interview structure.
This approach allowed the team to preserve the practical utility of participant feedback while ensuring methodological rigor in the analysis process. Resulting themes reflect both the structured nature of the original inquiry and the practical recommendations identified for improving the HISA program. Information on the following areas were collected: education about the HISA program, the contracting process, use of telehealth, interaction between VHA clinical care and the PSAS, marketing of the program, program funding, and revising the application process.
Results
Interview respondents provided several recommendations for improving the HISA program (Table). Regarding training and education, respondents noted deficiencies in VHA employee communication about the HISA program to veterans. Some employees did not know details or were unaware the HISA program existed. Additionally, a lack of knowledge about HISA program alternatives, including other available programs for obtaining home modifications or other durable medical equipment alternatives (eg, provision of a portable ramp rather than construction of a permanent one), was apparent. It was strongly recommended to provide additional education to effectively disseminate knowledge about the HISA program. Specifically, VHA employees, especially those in Primary Care, Geriatrics, Home Based Primary Care, the Caregiver Support Program, and Blind Rehabilitation Services, require greater awareness of the program and its processes.

PSAS and PM&R professionals, including physicians, nurse practitioners, physician assistants, and physical and occupational therapists, would be expected to have some knowledge of the HISA program, and therefore be more likely to connect a veteran with it. However, they may lack specific details about the program such as correct contact persons in the other service (PSAS or PM&R, respectively), facility- specific processes, such as how to enter a HISA consultation within the veteran’s electronic health record, how the entered consultation would progress through the system and avoid cancellation, and what should routinely be done to avoid HISA consultation cancellation, such as referral to Occupational Therapy for a functional assessment so appropriate durable medical equipment can be trialed with the veteran prior to proceeding with more costly and time-consuming home modifications.
In addition, there is no routine standard work process to ensure that PM&R staff are aware of updates in HISA program regulations and policy. Further recommendations in this area include having supervisory employees in PSAS and PM&R work both individually and together to develop effective information dissemination methods for key stakeholders. These include targeted in-services (ie, educational trainings often scheduled and conducted during recurring meetings), whether faceto- face or virtually in real time, or recorded, that occur on an ongoing and regular basis with sister services such as Primary Care, Geriatrics, Home Based Primary Care, the Caregiver Support Program, and Blind Rehabilitation Services (eg, the facility Vision Impairment Services Team coordinator). Regularly updated educational materials should be provided to veterans and VHA adjacent stakeholders such as Veteran Service Organizations and Veteran County Service Officers, via a variety of platforms.
Successfully navigating the provision of home modifications via the HISA program involves identifying a contractor to perform the home modification and obtaining service and construction plan pricing. A key barrier in this area is that veterans and VHA clinicians perceive the funds available through HISA as insufficient, regardless of whether they have serviceconnected status or not. Service connection refers to designation of ≥ 1 medical conditions determined to be related to military service and thus eligible to receive VHA care.9 Service-connected veterans receive a lifetime maximum award of $6800 from HISA while veterans without service connection receive a lifetime maximum award of $2000.1,2
Rural veterans face a greater challenge than urban veterans, as there are fewer contractors located nearby. Thus, providing higher funding for rural veterans, or specific funding such as for travel expenses, would be especially helpful to find a willing contractor to perform home medications.1 The current requirement of working with a licensed contractor was also a barrier, especially for smaller jobs, and could result in VHA employees (including clinicians) feeling pressured to become overly involved to assist veterans to move through the process.
To that point, respondents requested resources such as a regularly updated list of licensed contractors in the area, especially those familiar with working with the HISA program, be provided to veterans and their assisting groups. In addition, respondents asked that VHA take on greater responsibility and liability with regard to contractors accessing HISA funding, such as not releasing final payment until VHA approved the completed home modification. On the other hand, respondents also expressed concerns about the length of time associated with HISA program payment and noted it should be sped up to allow contractors who participate to receive payment sooner, which many believed would increase the number of contractors willing to take on this work.
The role of telehealth was noted as a great facilitator of increased access to care, especially following the COVID-19 pandemic. Telehealth modalities adapted for the HISA program could help increase access to the program and improve processing speed. Barriers include lack of appropriate veteran telehealth equipment and poor understanding of information needed to move the process forward. Recommendations included providing veterans tablets to connect to virtual services, and developing information on home measurements needed, assistance in obtaining and sending photographs, and detailed information on successfully using telehealth for the HISA application process. Of note, some clinicians, representing home-based primary care, prosthetics services, geriatrics, rehabilitation therapy, mobile clinic, and the telehealth division, and including both clinical staff (eg, occupational therapists) and nonclinical staff (eg, prosthetics representatives and administrative personnel), have found patients expressed comparable satisfaction with the process whether faceto- face or via telehealth.
The essential relationship between PSAS and PM&R regarding the HISA program was a key finding. Both services are integral to helping veterans successfully obtain home modifications via the HISA program.1,2 Barriers include insufficient communication and a lack of clearly defined points of contact for each service, poorly defined roles, and inefficiencies because 2 services are involved in navigating the process. Recommendations therefore include addressing these issues, such as adopting a case management or liaison model between the services to better manage the process.
Respondents indicated that insufficient program funding was a concern. Veterans living in poorer quality housing, such as older homes, often require more expensive home modifications, necessitating greater out-of-pocket expenses. Veterans and VHA employees advocated for the creation of an exception to the lower funding cap for veterans without service connection in cases of financial hardship. Overall, the funding limits for both service-connected veterans and those without service connection were thought to be insufficient, especially as the COVID-19 pandemic increased the cost of construction materials.
Respondents also noted that veterans would benefit from clear messaging that receiving HISA funds does not impact eligibility for other VA benefits and services. Veterans must understand that home modifications work must be approved by VHA before being started and should be aware that if their disability rating increases so that they become eligible for the higher level service-connected benefits, they would then become eligible for the higher maximum benefit. Respondents recommended veterans should receive assistance in understanding the full costs of the home modification and ongoing maintenance, and the HISA research team recommended that the National Program develop a fact sheet that can be used to advise veterans.
Respondents consistently indicated that information about the HISA program was not disseminated effectively to key internal and external stakeholders, and opportunities to highlight the program on VHA websites, brochures throughout VHA facilities, and other outlets such as direct mailing should be used. Veterans who have used the program are overwhelmingly older (mean age 71 years), White, and male, suggesting missed opportunities and unmet need for underrepresented groups. Therefore, targeted marketing interventions would especially benefit these groups.
Respondents also noted inefficiencies throughout the HISA program application process and advocated for changes such as national standard operating procedures (SOPs) to guide navigation through the HISA process. The national SOPs could include home evaluation prior to HISA application submission, clearly identified points of contact for the HISA program in PSAS and PM&R, and standardized documentation.
Future Directions
Information from respondents provided several avenues for future studies. Recommendations were obtained from each of the 7 broad topical areas: training and educational needs, potential, contracting challenges and opportunities, telehealth as a conduit to facilitate the availability of the HISA program, PSAS, and clinical services collaboration, marketing, need for increased funding, and revision of the application process. Input from stakeholders can help direct efficient use of resources to guide future studies for the greatest impact and highlight current and future priorities. Easy areas of intervention indicated by respondents include creating a national standard work process regarding the HISA program with standardized educational materials for key stakeholders, revised at regular intervals, and readily available on national websites. A pre- and postimplementation survey could help provide quantifiable information about the benefits of such an intervention.
Conclusions
A qualitative analysis of interviews with veterans and VHA clinicians provides evidence of potential barriers for the HISA program. Addressing these barriers could allow HISA to better meet the VHA goal of providing home modifications that allow veterans to live safely and independently in their homes. There is a need for ongoing review and assessment of the program to ensure optimization and efficient use of resources across the spectrum of veteran needs.
The Veterans Health Administration (VHA) Home Improvements and Structural Alterations (HISA) program is a primary means through which veterans can obtain home modifications necessary to continue safe and independent living in their home, including fall risk reduction and accessibility to essential parts of the home. However, not all eligible veterans who may benefit from this program participate, for a variety of reasons.1-6 Historically, the HISA program has been administered in a decentralized and nonstandardized fashion dictated by the organizational structure of each US Department of Veterans Affairs (VA) medical center (VAMC) within a certain region or Veterans Integrated Service Network (VISN). Previous research found differential access to the HISA program by younger veterans, women, minorities, veterans with certain disability types, and veterans living in rural vs urban settings. These disparities in access and use of benefits conferred by the HISA program suggests an area of unmet need, which may improve veterans’ health care outcomes and reduce costs associated with their care.2-8
The purpose of this article is to provide information to improve equitable provision and effective eligible use of resources available through the HISA program in a more generalizable manner by providing insight to highlight common program process deficiencies and care provision gaps relevant to VAMCs nationwide. This information can be used to inform the VA Physical Medicine and Rehabilitation (PM&R) and Prosthetic and Sensory Aid Service (PSAS) national policy initiatives, as well as hiring practices, clinic organization, specific care provision, and administrative goals and metrics at each VISN and at the VA Healthcare System level.
Methods
Veterans who participated in the HISA program, VHA administrators, and VHA clinicians from select VAMCs were identified and interviewed to better understand what helps increase access to the program, barriers to access, and how existing program components and processes impact use of the service. These interviews were taken from a directed convenience sample of selected VAMCs. To obtain this directed convenience sample, 167 VAMCs that participated in the HISA program were categorized as facilities that provided either a high or low number of HISA program prescriptions based on data from 2010 to 2018. Ten facilities from the top quartiles and 10 from the bottom quartiles of prescribing locations were selected. This facility selection was driven by the proportion of rural veterans served by each facility, favoring those serving a greater proportion of rural veterans, as well geographic location, with the aim of avoiding overrepresentation of any specific region. The convenience sample included 45 individuals (20 VHA employees and 25 veterans) across 22 states from the Northeast, West, South, and Midwest US Census regions.
Interview Process
Interviews underwent a coding process. The development of topical themes followed a systematic, 2-phase approach. Initially, researchers analyzed responses to semistructured interview questions addressing specific aspects of the HISA program, such as program awareness and accessibility. These responses naturally clustered into preliminary categories based on the interview guide structure. For example, responses related to program discovery formed a marketing-related category, while recommendations about program implementation contributed to a training and development category.
Following this initial categorization, the research team conducted a more rigorous coding process. A team of 3 researchers systematically reviewed assigned interview transcripts to extract practical recommendations for the guide. The researchers first identified relevant responses individually and then convened during group meetings to discuss and finalize selections. This second phase refined the preliminary categorization while maintaining alignment with the original interview structure.
This approach allowed the team to preserve the practical utility of participant feedback while ensuring methodological rigor in the analysis process. Resulting themes reflect both the structured nature of the original inquiry and the practical recommendations identified for improving the HISA program. Information on the following areas were collected: education about the HISA program, the contracting process, use of telehealth, interaction between VHA clinical care and the PSAS, marketing of the program, program funding, and revising the application process.
Results
Interview respondents provided several recommendations for improving the HISA program (Table). Regarding training and education, respondents noted deficiencies in VHA employee communication about the HISA program to veterans. Some employees did not know details or were unaware the HISA program existed. Additionally, a lack of knowledge about HISA program alternatives, including other available programs for obtaining home modifications or other durable medical equipment alternatives (eg, provision of a portable ramp rather than construction of a permanent one), was apparent. It was strongly recommended to provide additional education to effectively disseminate knowledge about the HISA program. Specifically, VHA employees, especially those in Primary Care, Geriatrics, Home Based Primary Care, the Caregiver Support Program, and Blind Rehabilitation Services, require greater awareness of the program and its processes.

PSAS and PM&R professionals, including physicians, nurse practitioners, physician assistants, and physical and occupational therapists, would be expected to have some knowledge of the HISA program, and therefore be more likely to connect a veteran with it. However, they may lack specific details about the program such as correct contact persons in the other service (PSAS or PM&R, respectively), facility- specific processes, such as how to enter a HISA consultation within the veteran’s electronic health record, how the entered consultation would progress through the system and avoid cancellation, and what should routinely be done to avoid HISA consultation cancellation, such as referral to Occupational Therapy for a functional assessment so appropriate durable medical equipment can be trialed with the veteran prior to proceeding with more costly and time-consuming home modifications.
In addition, there is no routine standard work process to ensure that PM&R staff are aware of updates in HISA program regulations and policy. Further recommendations in this area include having supervisory employees in PSAS and PM&R work both individually and together to develop effective information dissemination methods for key stakeholders. These include targeted in-services (ie, educational trainings often scheduled and conducted during recurring meetings), whether faceto- face or virtually in real time, or recorded, that occur on an ongoing and regular basis with sister services such as Primary Care, Geriatrics, Home Based Primary Care, the Caregiver Support Program, and Blind Rehabilitation Services (eg, the facility Vision Impairment Services Team coordinator). Regularly updated educational materials should be provided to veterans and VHA adjacent stakeholders such as Veteran Service Organizations and Veteran County Service Officers, via a variety of platforms.
Successfully navigating the provision of home modifications via the HISA program involves identifying a contractor to perform the home modification and obtaining service and construction plan pricing. A key barrier in this area is that veterans and VHA clinicians perceive the funds available through HISA as insufficient, regardless of whether they have serviceconnected status or not. Service connection refers to designation of ≥ 1 medical conditions determined to be related to military service and thus eligible to receive VHA care.9 Service-connected veterans receive a lifetime maximum award of $6800 from HISA while veterans without service connection receive a lifetime maximum award of $2000.1,2
Rural veterans face a greater challenge than urban veterans, as there are fewer contractors located nearby. Thus, providing higher funding for rural veterans, or specific funding such as for travel expenses, would be especially helpful to find a willing contractor to perform home medications.1 The current requirement of working with a licensed contractor was also a barrier, especially for smaller jobs, and could result in VHA employees (including clinicians) feeling pressured to become overly involved to assist veterans to move through the process.
To that point, respondents requested resources such as a regularly updated list of licensed contractors in the area, especially those familiar with working with the HISA program, be provided to veterans and their assisting groups. In addition, respondents asked that VHA take on greater responsibility and liability with regard to contractors accessing HISA funding, such as not releasing final payment until VHA approved the completed home modification. On the other hand, respondents also expressed concerns about the length of time associated with HISA program payment and noted it should be sped up to allow contractors who participate to receive payment sooner, which many believed would increase the number of contractors willing to take on this work.
The role of telehealth was noted as a great facilitator of increased access to care, especially following the COVID-19 pandemic. Telehealth modalities adapted for the HISA program could help increase access to the program and improve processing speed. Barriers include lack of appropriate veteran telehealth equipment and poor understanding of information needed to move the process forward. Recommendations included providing veterans tablets to connect to virtual services, and developing information on home measurements needed, assistance in obtaining and sending photographs, and detailed information on successfully using telehealth for the HISA application process. Of note, some clinicians, representing home-based primary care, prosthetics services, geriatrics, rehabilitation therapy, mobile clinic, and the telehealth division, and including both clinical staff (eg, occupational therapists) and nonclinical staff (eg, prosthetics representatives and administrative personnel), have found patients expressed comparable satisfaction with the process whether faceto- face or via telehealth.
The essential relationship between PSAS and PM&R regarding the HISA program was a key finding. Both services are integral to helping veterans successfully obtain home modifications via the HISA program.1,2 Barriers include insufficient communication and a lack of clearly defined points of contact for each service, poorly defined roles, and inefficiencies because 2 services are involved in navigating the process. Recommendations therefore include addressing these issues, such as adopting a case management or liaison model between the services to better manage the process.
Respondents indicated that insufficient program funding was a concern. Veterans living in poorer quality housing, such as older homes, often require more expensive home modifications, necessitating greater out-of-pocket expenses. Veterans and VHA employees advocated for the creation of an exception to the lower funding cap for veterans without service connection in cases of financial hardship. Overall, the funding limits for both service-connected veterans and those without service connection were thought to be insufficient, especially as the COVID-19 pandemic increased the cost of construction materials.
Respondents also noted that veterans would benefit from clear messaging that receiving HISA funds does not impact eligibility for other VA benefits and services. Veterans must understand that home modifications work must be approved by VHA before being started and should be aware that if their disability rating increases so that they become eligible for the higher level service-connected benefits, they would then become eligible for the higher maximum benefit. Respondents recommended veterans should receive assistance in understanding the full costs of the home modification and ongoing maintenance, and the HISA research team recommended that the National Program develop a fact sheet that can be used to advise veterans.
Respondents consistently indicated that information about the HISA program was not disseminated effectively to key internal and external stakeholders, and opportunities to highlight the program on VHA websites, brochures throughout VHA facilities, and other outlets such as direct mailing should be used. Veterans who have used the program are overwhelmingly older (mean age 71 years), White, and male, suggesting missed opportunities and unmet need for underrepresented groups. Therefore, targeted marketing interventions would especially benefit these groups.
Respondents also noted inefficiencies throughout the HISA program application process and advocated for changes such as national standard operating procedures (SOPs) to guide navigation through the HISA process. The national SOPs could include home evaluation prior to HISA application submission, clearly identified points of contact for the HISA program in PSAS and PM&R, and standardized documentation.
Future Directions
Information from respondents provided several avenues for future studies. Recommendations were obtained from each of the 7 broad topical areas: training and educational needs, potential, contracting challenges and opportunities, telehealth as a conduit to facilitate the availability of the HISA program, PSAS, and clinical services collaboration, marketing, need for increased funding, and revision of the application process. Input from stakeholders can help direct efficient use of resources to guide future studies for the greatest impact and highlight current and future priorities. Easy areas of intervention indicated by respondents include creating a national standard work process regarding the HISA program with standardized educational materials for key stakeholders, revised at regular intervals, and readily available on national websites. A pre- and postimplementation survey could help provide quantifiable information about the benefits of such an intervention.
Conclusions
A qualitative analysis of interviews with veterans and VHA clinicians provides evidence of potential barriers for the HISA program. Addressing these barriers could allow HISA to better meet the VHA goal of providing home modifications that allow veterans to live safely and independently in their homes. There is a need for ongoing review and assessment of the program to ensure optimization and efficient use of resources across the spectrum of veteran needs.
- Semeah LM, Ahrentzen S, Jia H, et al. The Home Improvements and Structural Alterations Benefits Program: veterans with disabilities and home accessibility. J Disabil Policy Stud. 2017;28:43-51. doi:10.1177/1044207317696275
- Semeah LM, Wang X, Cowper Ripley DC, et al. Improving health through a home modification service for veterans. In: Fiedler BA, ed. Three Facets of Public Health and Paths to Improvements. 2020:381-416. doi:10.1016/B978-0-12-819008-1.00014-6
- Semeah LM, Ganesh SP, Wang X, et al. Home modification and health services utilization by rural and urban veterans with disabilities. Housing Policy Debate. 2021;31:862-874. doi:10.1080/10511482.2020.1858923
- Semeah LM, Orozco T, Wang X, et al. Home modifications for rural veterans with disabilities. Fed Pract. 2021;38:300- 310. doi:10.12788/fp.0153
- Semeah LM, Orozco T, Wang X, et al. Predictors of countylevel home modification use across the US. Fed Pract. 2022;39:274-280. doi:10.12788/fp.0279
- Semeah LM, Orozco T, Wang X, et al. Rural and urban home modification program users: a comparative study. HERD. 2023;16:223-235. doi:10.1177/19375867221142627
- US Department of of Veterans Affairs. Home Improvements and Structural Alterations (HISA) benefits program: final rule. Fed Regist. 2014;79:71658-71663
- US Department of Veterans Affairs. Home Improvement and Structural Alterations (HISA): increase in the limit for home improvement and structural alterations (HISA)-VA: final regulations. Fed Regist. 1993;58:25565.
- US Department of Veterans Affairs. Eligibility for VA disability benefits. Updated April 25, 2025. Accessed April 1, 2026. https://www.va.gov/disability/eligibility
- Semeah LM, Ahrentzen S, Jia H, et al. The Home Improvements and Structural Alterations Benefits Program: veterans with disabilities and home accessibility. J Disabil Policy Stud. 2017;28:43-51. doi:10.1177/1044207317696275
- Semeah LM, Wang X, Cowper Ripley DC, et al. Improving health through a home modification service for veterans. In: Fiedler BA, ed. Three Facets of Public Health and Paths to Improvements. 2020:381-416. doi:10.1016/B978-0-12-819008-1.00014-6
- Semeah LM, Ganesh SP, Wang X, et al. Home modification and health services utilization by rural and urban veterans with disabilities. Housing Policy Debate. 2021;31:862-874. doi:10.1080/10511482.2020.1858923
- Semeah LM, Orozco T, Wang X, et al. Home modifications for rural veterans with disabilities. Fed Pract. 2021;38:300- 310. doi:10.12788/fp.0153
- Semeah LM, Orozco T, Wang X, et al. Predictors of countylevel home modification use across the US. Fed Pract. 2022;39:274-280. doi:10.12788/fp.0279
- Semeah LM, Orozco T, Wang X, et al. Rural and urban home modification program users: a comparative study. HERD. 2023;16:223-235. doi:10.1177/19375867221142627
- US Department of of Veterans Affairs. Home Improvements and Structural Alterations (HISA) benefits program: final rule. Fed Regist. 2014;79:71658-71663
- US Department of Veterans Affairs. Home Improvement and Structural Alterations (HISA): increase in the limit for home improvement and structural alterations (HISA)-VA: final regulations. Fed Regist. 1993;58:25565.
- US Department of Veterans Affairs. Eligibility for VA disability benefits. Updated April 25, 2025. Accessed April 1, 2026. https://www.va.gov/disability/eligibility
The Home Improvements and Structural Alterations Program: Overview and Future Implications
The Home Improvements and Structural Alterations Program: Overview and Future Implications
The Development of a Comprehensive Wound Care Fellowship Curriculum
The Development of a Comprehensive Wound Care Fellowship Curriculum
Often disguised as comorbid conditions, nonhealing and chronic wounds have emerged as a silent epidemic that affects about 6.5 million Americans.1-3 In 2023, estimated US wound care costs were $126.86 billion.4 About 1% to 2% of individuals worldwide will experience a chronic wound in their lifetime. The Veterans Health Administration reported 277,000 inpatient and outpatient encounters for ulcers in 2011, including chronic ulcers of the lower extremity due to diabetes, venous disease, or arterial disease.5 Associated costs of chronic wounds are expected to increase as the populations of developed countries age.6 Effective treatment of chronic wounds requires a nuanced understanding of complex wound pathophysiology, best practices in interdisciplinary and multidisciplinary wound care, and advanced wound care technologies.7,8
The typical 4-year medical school curriculum, followed by residency, offers little in the way of formal didactic training in wound care.9,10 Without specialized and advanced fellowship training dedicated to wound care, health care will lack specialists prepared to manage complex wounds. As a result, wound care-related difficulties may be exacerbated by prolonged recovery time, increased costs, productivity loss, and increased mortality risk.8 Wound care is a growing field of study and practice, and there is a critical need for rigorous training, research, and quality improvement efforts to enhance outcomes for patients with nonhealing wounds.5
One of the most direct ways to address the need for more physicians with specialty training in wound medicine is to implement a comprehensive training curriculum for advanced wound care practice. Although specialized advanced wound care fellowships are available, the curricula primarily detail rotation names and areas for practice without accompanying competencies, milestones, or entrustable professional activities.11 Furthermore, wound care is not recognized as a subspecialty by the Accreditation Council for Graduate Medical Education (ACGME).
This article synthesized the literature and integrated innovative, evidence-based practices into a curriculum for a formal advanced fellowship training program. To our knowledge, no comprehensive wound care curriculum is publicly available that includes rotations, competencies, milestones, entrustable professional activities, and 360-degree evaluation forms.
Program Development
The advanced wound care fellowship program started in January 2014 at the Michael E. DeBakey Veterans Affairs Medical Center in affiliation with the Baylor College of Medicine. The fellowship program was originally designed for geriatrics fellows to extend the 1-year fellowship for an additional year to learn wound care. It has been adjusted to address formal program goals and objectives, competencies, milestones, entrustable professional activities, and evaluations, with the goal of developing an example curriculum for wound care fellowships across specialties. Although the ACGME does not recognize a wound care subspecialty, this curriculum complies with the ACGME 1-year fellowship common program requirements.12,13
Scoping Review
A scoping literature review of Google Scholar and PubMed was performed using the medical subject heading terms “wound care + curriculum” and “wound + care + curriculum” to find advanced wound care medical training, fellowship programs, boards, and related ACGME-accredited specialty curricula. The local wound care fellowship program was initially implemented based on an informal literature review by faculty and their respective contributions to curriculum (ie, process establishing wound care-specific competency domains in accordance with ACGME accreditation competency requirements of 1-year fellowships). 12,13 Standing program practice-based competencies and activities were examined and determined to align with best practices. This scoping review considered additional competencies, competency domains, and entrustable professional activities of reputable wound care fellowship training programs (eg, University of Chicago at Illinois and Wake Forest School of Medicine),8,11,14 a specialty wound care board (American Board of Wound Medicine and Surgery),15 an international wound specialist professional society (European Union of Medical Specialists), 16 and recommended curriculum guidelines for wound care residency programs.17 ACGME-accredited specialty and subspecialty milestones professional activities were examined, including vascular surgery,18 plastic surgery,19 dermatology, 20 foot and ankle,21 orthopedic surgery,22 spinal cord injury,23 and geriatric medicine.24
The competencies, milestones, and entrustable professional activities were compiled and redundancies were eliminated. Wound care specialists from geriatrics, family medicine, internal medicine, undersea and hyperbaric medicine, general surgery, podiatry, and physical therapy examined the findings and suggested eliminating redundancies, irrelevant content, and content that fell below the minimal expected level of competence for an advanced medical specialist in wound care. An expert consensus meeting further refined items presented to the panel before unanimous consensus resulted in the final set of curriculum competencies, milestones, and entrustable professional activities.
Training Program Feedback
We developed a comprehensive wound care curriculum for an advanced physician fellowship training program based on the streamlined competencies, milestones, and entrustable professional activities (Appendix). Multiple wound care experts from various interdisciplinary backgrounds reached consensus to establish this fellowship curriculum as adaptable for use across training settings. The training program is 12 core rotations and 2 elective rotations (Table 1). Additionally, we developed wound care evaluation forms for faculty-, peer-, and self-assessment of trainees which were adapted from an evidence-based 360-degree evaluation template.25 Suggestions for structured, advanced didactics are in Table 2.


Seventeen fellows have successfully matriculated through the wound care training program. Although wound care certification is not required to work as a wound care specialist, after completion of this fellowship, graduates are able to sit for a wound care certification examination. The American Board of Wound Medicine and Surgery (ABWMS) and the American Board of Wound Management (ABWM) allow physicians to take a certification examination after 1 year of a dedicated wound fellowship program, instead of the typical wound care practice experience ≥ 3 years.
The Clinical Wound Care Fellowship Program collected data for program improvement, and 15 alumni responded (response rate, 88%) to a survey using a 5-point Likert scale. Respondents indicated high mean scores for overall satisfaction (4.7), instructional methods (4.7), program enjoyment (4.7), teaching materials (4.6), and relevance (4.6). All respondents indicated that the fellowship prepared them for a career in wound care as well as their current employment, and 13 of 15 (87%) reported they obtained immediate relevant postfellowship wound care positions and stated that the fellowship prepared them for their current roles. Nine respondents (69%) reported that they were engaged in wound care ≥ 26% of work time. Six respondents (46%) worked in private practice, 3 (23%) at academic medical centers, and 2 (15%) at government- funded hospitals. Four respondents indicated they were board certified in wound care. Program alumni are currently involved in scholarly activities, including 8 in quality improvement and 3 in research.
Discussion
An easily accessible, comprehensive wound care fellowship curriculum has not been previously developed or published. This limited the sources that informed this curriculum. However, the developmental process for this curriculum was robust, as the authors reviewed previously published materials related to wound care, including: 1) descriptive overviews of wound care fellowships; 2) details of month-long rotations for medical students and residents; and 3) practices of the specific environment in which this curriculum was created. Confidence in the practical nature of the curriculum can be assumed, as the experts involved in the development process represented diverse physician specializations, including geriatrics, family medicine, internal medicine, undersea and hyperbaric medicine, general surgery, podiatry, and physical therapy.
Most wound care clinicians have not completed a formal comprehensive fellowship program. Instead, due to the lack of a comprehensive training curriculum, clinicians have had to use various continuing medical education programs and practice in a wound care setting for ≥ 3 years to be eligible for certification in the specialty. This curriculum will help academic medical centers develop their own fellowship programs, enabling new wound care clinicians to attain certifications more efficiently. As more fellowship programs develop, the goal would be to obtain recognition as an ACGME specialty and standardize the training and competencies for graduates of wound care fellowships.
Conclusions
As new wound care fellowships develop, wound care may become formally acknowledged as its own specialty within medicine and surgery. This will provide wound care with a voice at the national level, particularly in an era of value-based care. Wound care clinicians will be able to advocate for specialty-specific quality metrics and avoid potential penalization for not meeting quality metrics that are irrelevant to wound care.
- Fife CE, Eckert KA, Carter MJ. Publicly Reported wound healing rates: the fantasy and the reality. Adv Wound Care (New Rochelle). 2018;7:77-94. doi:10.1089/wound.2017.0743
- Fife CE, Carter MJ, Walker D. Why is it so hard to do the right thing in wound care?. Wound Repair Regen. 2010;18:154-158. doi:10.1111/j.1524-475X.2010.00571.x
- Sen CK, Gordillo GM, Roy S, et al. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 2009;17:763-771. doi:10.1111/j.1524-475X.2009.00543.x
- Queen D, Harding K. What’s the true costs of wounds faced by different healthcare systems around the world?. Int Wound J. 2023;20:3935-3938. doi:10.1111/iwj.14491
- Greer N, Foman N, Dorrian J, et al. Advanced Wound Care Therapies for Non-Healing Diabetic, Venous, and Arterial Ulcers: A Systematic Review [Internet]. US Dept of Veterans Affairs; November 2012. https://www.ncbi.nlm.nih.gov/books/NBK132238/
- Simman R, McNevin AJ. Pursuing the path to specialized wound care: the ABWMS perspective. Todays Wound Clin. 2017;8:10,12.
- Shahin ES, Dassen T, Halfens RJ. Pressure ulcer prevalence in intensive care patients: a cross-sectional study. J Eval Clin Pract. 2008;14:563-568. doi:10.1111/j.1365-2753.2007.00918.x
- Ennis WJ, Valdes W, Meneses P. Wound care specialization: a proposal for a comprehensive fellowship program. Wound Repair Regen. 2004;12:120-128. doi:10.1111/j.1067-1927.2004.012203.x
- Patel NP, Granick MS. Wound education: American medical students are inadequately trained in wound care. Ann Plast Surg. 2007;59:53-55. doi:10.1097/SAP.0b013e31802dd43b
- Patel NP, Granick MS, Kanakaris NK, et al. Comparison of wound education in medical schools in the United States, United Kingdom, and Germany. Eplasty. 2008;8:e8.
- Ennis WJ. Wound care specialization: the current status and future plans to move wound care into the medical community. Adv Wound Care (New Rochelle). 2012;1:184- 188. doi:10.1089/wound.2011.0346
- Accreditation Council for Graduate Medical Education. ACGME common program requirements (fellowship). Updated September 3, 2025. Accessed January 15, 2026. https://www.acgme.org/globalassets/pfassets /programrequirements/2025-reformatted-requirements/cprfellowship_2025_reformatted.pdf
- Accreditation Council for Graduate Medical Education. Program directors’ guide to the common program requirements (fellowship). Updated December 2025. Accessed May 27, 2026. https://www .acgme.org/globalassets/pdfs/guide-to-the-common -program-requirements-fellowship.pdf
- Curriculum overview - wound care and hyperbaric medicine fellowship. Wake Forest University School of Medicine. 2026. Accessed January 5, 2026. https://school .wakehealth.edu/Education-and-Training/Residencies -and-Fellowships/Wound-Care-and-Hyperbaric-Medicine -Fellowship/Curriculum-Overview
- Curriculum overview - American Board of Wound Medicine and Surgery. Core Curriculum for Fellowships in Wound Care. American Board of Wound Medicine and Surgery. 2022. Accessed January 5, 2026. https://abwms.org /curriculum-overview/
- European Wound Management Association. EWMA Wound healing curriculum for physicians. February 13, 2017. Accessed January 15, 2026. https://ewma.org /wp-content/uploads/2024/02/ETR-TF-Wound-Healing -UEMS-approved.pdf
- Accreditation Council for Graduate Medical Education. Recommended Curriculum Guidelines for Family Medicine Residents. Accessed January 5, 2026. https://www.aafp .org/dam/AAFP/documents/medical_education_residency /program_directors/Wound_Care.pdf
- Accreditation Council for Graduate Medical Education. Vascular Surgery Milestones the Accreditation Council for Graduate Medical Education. Accessed January 5, 2026. https://www.acgme.org/Portals/0/PDFs/Milestones /VascularSurgeryMilestones2.0.pdf
- Accreditation Council for Graduate Medical Education. Plastic Surgery Milestones the Accreditation Council for Graduate Medical Education. Accessed January 5, 2026. https://www.acgme.org/Portals/0/PDFs /Milestones/PlasticSurgeryMilestones.pdf
- Accreditation Council for Graduate Medical Education. Dermatology Milestones the Accreditation Council for Graduate Medical Education. Accessed January 5, 2026. https://www.acgme.org/Portals/0/PDFs/Milestones /DermatologyMilestones.pdf
- Accreditation Council for Graduate Medical Education. The Foot and Ankle Milestone Project a joint initiative of the Accreditation Council for Graduate Medical Education and the American Board of Orthopaedic Surgery. July 2015. Accessed January 5, 2026. https://www.acgme.org /Portals/0/PDFs/Milestones/FootandAnkleMilestones.pdf
- Accreditation Council for Graduate Medical Education. Orthopaedic Surgery Milestones the Accreditation Council for Graduate Medical Education. Accessed January 5, 2026. https://www.acgme.org/Portals/0/PDFs/Milestones /OrthopaedicSurgeryMilestones.pdf
- Accreditation Council for Graduate Medical Education. Spinal Cord Injury Medicine Milestones the Accreditation Council for Graduate Medical Education. Accessed January 5, 2026. https://www.acgme.org/Portals/0/PDFs /Milestones/SpinalCordInjuryMedicineMilestones.pdf
- Accreditation Council for Graduate Medical Education. Geriatric Medicine Milestones the Accreditation Council for Graduate Medical Education. Accessed January 5, 2026. https://www.acgme.org/Portals/0/PDFs/Milestones /GeriatricMedicineMilestones.pdf
- Goldhamer ME, Baker K, Anne Rigg DW, et al. Development and implementation of multi-source assessment tools for ACGME residents and fellows. MedEDPORTAL. 2014. Accessed May 14, 2026. doi:10.15766/mep_2374-8265.9839
Often disguised as comorbid conditions, nonhealing and chronic wounds have emerged as a silent epidemic that affects about 6.5 million Americans.1-3 In 2023, estimated US wound care costs were $126.86 billion.4 About 1% to 2% of individuals worldwide will experience a chronic wound in their lifetime. The Veterans Health Administration reported 277,000 inpatient and outpatient encounters for ulcers in 2011, including chronic ulcers of the lower extremity due to diabetes, venous disease, or arterial disease.5 Associated costs of chronic wounds are expected to increase as the populations of developed countries age.6 Effective treatment of chronic wounds requires a nuanced understanding of complex wound pathophysiology, best practices in interdisciplinary and multidisciplinary wound care, and advanced wound care technologies.7,8
The typical 4-year medical school curriculum, followed by residency, offers little in the way of formal didactic training in wound care.9,10 Without specialized and advanced fellowship training dedicated to wound care, health care will lack specialists prepared to manage complex wounds. As a result, wound care-related difficulties may be exacerbated by prolonged recovery time, increased costs, productivity loss, and increased mortality risk.8 Wound care is a growing field of study and practice, and there is a critical need for rigorous training, research, and quality improvement efforts to enhance outcomes for patients with nonhealing wounds.5
One of the most direct ways to address the need for more physicians with specialty training in wound medicine is to implement a comprehensive training curriculum for advanced wound care practice. Although specialized advanced wound care fellowships are available, the curricula primarily detail rotation names and areas for practice without accompanying competencies, milestones, or entrustable professional activities.11 Furthermore, wound care is not recognized as a subspecialty by the Accreditation Council for Graduate Medical Education (ACGME).
This article synthesized the literature and integrated innovative, evidence-based practices into a curriculum for a formal advanced fellowship training program. To our knowledge, no comprehensive wound care curriculum is publicly available that includes rotations, competencies, milestones, entrustable professional activities, and 360-degree evaluation forms.
Program Development
The advanced wound care fellowship program started in January 2014 at the Michael E. DeBakey Veterans Affairs Medical Center in affiliation with the Baylor College of Medicine. The fellowship program was originally designed for geriatrics fellows to extend the 1-year fellowship for an additional year to learn wound care. It has been adjusted to address formal program goals and objectives, competencies, milestones, entrustable professional activities, and evaluations, with the goal of developing an example curriculum for wound care fellowships across specialties. Although the ACGME does not recognize a wound care subspecialty, this curriculum complies with the ACGME 1-year fellowship common program requirements.12,13
Scoping Review
A scoping literature review of Google Scholar and PubMed was performed using the medical subject heading terms “wound care + curriculum” and “wound + care + curriculum” to find advanced wound care medical training, fellowship programs, boards, and related ACGME-accredited specialty curricula. The local wound care fellowship program was initially implemented based on an informal literature review by faculty and their respective contributions to curriculum (ie, process establishing wound care-specific competency domains in accordance with ACGME accreditation competency requirements of 1-year fellowships). 12,13 Standing program practice-based competencies and activities were examined and determined to align with best practices. This scoping review considered additional competencies, competency domains, and entrustable professional activities of reputable wound care fellowship training programs (eg, University of Chicago at Illinois and Wake Forest School of Medicine),8,11,14 a specialty wound care board (American Board of Wound Medicine and Surgery),15 an international wound specialist professional society (European Union of Medical Specialists), 16 and recommended curriculum guidelines for wound care residency programs.17 ACGME-accredited specialty and subspecialty milestones professional activities were examined, including vascular surgery,18 plastic surgery,19 dermatology, 20 foot and ankle,21 orthopedic surgery,22 spinal cord injury,23 and geriatric medicine.24
The competencies, milestones, and entrustable professional activities were compiled and redundancies were eliminated. Wound care specialists from geriatrics, family medicine, internal medicine, undersea and hyperbaric medicine, general surgery, podiatry, and physical therapy examined the findings and suggested eliminating redundancies, irrelevant content, and content that fell below the minimal expected level of competence for an advanced medical specialist in wound care. An expert consensus meeting further refined items presented to the panel before unanimous consensus resulted in the final set of curriculum competencies, milestones, and entrustable professional activities.
Training Program Feedback
We developed a comprehensive wound care curriculum for an advanced physician fellowship training program based on the streamlined competencies, milestones, and entrustable professional activities (Appendix). Multiple wound care experts from various interdisciplinary backgrounds reached consensus to establish this fellowship curriculum as adaptable for use across training settings. The training program is 12 core rotations and 2 elective rotations (Table 1). Additionally, we developed wound care evaluation forms for faculty-, peer-, and self-assessment of trainees which were adapted from an evidence-based 360-degree evaluation template.25 Suggestions for structured, advanced didactics are in Table 2.


Seventeen fellows have successfully matriculated through the wound care training program. Although wound care certification is not required to work as a wound care specialist, after completion of this fellowship, graduates are able to sit for a wound care certification examination. The American Board of Wound Medicine and Surgery (ABWMS) and the American Board of Wound Management (ABWM) allow physicians to take a certification examination after 1 year of a dedicated wound fellowship program, instead of the typical wound care practice experience ≥ 3 years.
The Clinical Wound Care Fellowship Program collected data for program improvement, and 15 alumni responded (response rate, 88%) to a survey using a 5-point Likert scale. Respondents indicated high mean scores for overall satisfaction (4.7), instructional methods (4.7), program enjoyment (4.7), teaching materials (4.6), and relevance (4.6). All respondents indicated that the fellowship prepared them for a career in wound care as well as their current employment, and 13 of 15 (87%) reported they obtained immediate relevant postfellowship wound care positions and stated that the fellowship prepared them for their current roles. Nine respondents (69%) reported that they were engaged in wound care ≥ 26% of work time. Six respondents (46%) worked in private practice, 3 (23%) at academic medical centers, and 2 (15%) at government- funded hospitals. Four respondents indicated they were board certified in wound care. Program alumni are currently involved in scholarly activities, including 8 in quality improvement and 3 in research.
Discussion
An easily accessible, comprehensive wound care fellowship curriculum has not been previously developed or published. This limited the sources that informed this curriculum. However, the developmental process for this curriculum was robust, as the authors reviewed previously published materials related to wound care, including: 1) descriptive overviews of wound care fellowships; 2) details of month-long rotations for medical students and residents; and 3) practices of the specific environment in which this curriculum was created. Confidence in the practical nature of the curriculum can be assumed, as the experts involved in the development process represented diverse physician specializations, including geriatrics, family medicine, internal medicine, undersea and hyperbaric medicine, general surgery, podiatry, and physical therapy.
Most wound care clinicians have not completed a formal comprehensive fellowship program. Instead, due to the lack of a comprehensive training curriculum, clinicians have had to use various continuing medical education programs and practice in a wound care setting for ≥ 3 years to be eligible for certification in the specialty. This curriculum will help academic medical centers develop their own fellowship programs, enabling new wound care clinicians to attain certifications more efficiently. As more fellowship programs develop, the goal would be to obtain recognition as an ACGME specialty and standardize the training and competencies for graduates of wound care fellowships.
Conclusions
As new wound care fellowships develop, wound care may become formally acknowledged as its own specialty within medicine and surgery. This will provide wound care with a voice at the national level, particularly in an era of value-based care. Wound care clinicians will be able to advocate for specialty-specific quality metrics and avoid potential penalization for not meeting quality metrics that are irrelevant to wound care.
Often disguised as comorbid conditions, nonhealing and chronic wounds have emerged as a silent epidemic that affects about 6.5 million Americans.1-3 In 2023, estimated US wound care costs were $126.86 billion.4 About 1% to 2% of individuals worldwide will experience a chronic wound in their lifetime. The Veterans Health Administration reported 277,000 inpatient and outpatient encounters for ulcers in 2011, including chronic ulcers of the lower extremity due to diabetes, venous disease, or arterial disease.5 Associated costs of chronic wounds are expected to increase as the populations of developed countries age.6 Effective treatment of chronic wounds requires a nuanced understanding of complex wound pathophysiology, best practices in interdisciplinary and multidisciplinary wound care, and advanced wound care technologies.7,8
The typical 4-year medical school curriculum, followed by residency, offers little in the way of formal didactic training in wound care.9,10 Without specialized and advanced fellowship training dedicated to wound care, health care will lack specialists prepared to manage complex wounds. As a result, wound care-related difficulties may be exacerbated by prolonged recovery time, increased costs, productivity loss, and increased mortality risk.8 Wound care is a growing field of study and practice, and there is a critical need for rigorous training, research, and quality improvement efforts to enhance outcomes for patients with nonhealing wounds.5
One of the most direct ways to address the need for more physicians with specialty training in wound medicine is to implement a comprehensive training curriculum for advanced wound care practice. Although specialized advanced wound care fellowships are available, the curricula primarily detail rotation names and areas for practice without accompanying competencies, milestones, or entrustable professional activities.11 Furthermore, wound care is not recognized as a subspecialty by the Accreditation Council for Graduate Medical Education (ACGME).
This article synthesized the literature and integrated innovative, evidence-based practices into a curriculum for a formal advanced fellowship training program. To our knowledge, no comprehensive wound care curriculum is publicly available that includes rotations, competencies, milestones, entrustable professional activities, and 360-degree evaluation forms.
Program Development
The advanced wound care fellowship program started in January 2014 at the Michael E. DeBakey Veterans Affairs Medical Center in affiliation with the Baylor College of Medicine. The fellowship program was originally designed for geriatrics fellows to extend the 1-year fellowship for an additional year to learn wound care. It has been adjusted to address formal program goals and objectives, competencies, milestones, entrustable professional activities, and evaluations, with the goal of developing an example curriculum for wound care fellowships across specialties. Although the ACGME does not recognize a wound care subspecialty, this curriculum complies with the ACGME 1-year fellowship common program requirements.12,13
Scoping Review
A scoping literature review of Google Scholar and PubMed was performed using the medical subject heading terms “wound care + curriculum” and “wound + care + curriculum” to find advanced wound care medical training, fellowship programs, boards, and related ACGME-accredited specialty curricula. The local wound care fellowship program was initially implemented based on an informal literature review by faculty and their respective contributions to curriculum (ie, process establishing wound care-specific competency domains in accordance with ACGME accreditation competency requirements of 1-year fellowships). 12,13 Standing program practice-based competencies and activities were examined and determined to align with best practices. This scoping review considered additional competencies, competency domains, and entrustable professional activities of reputable wound care fellowship training programs (eg, University of Chicago at Illinois and Wake Forest School of Medicine),8,11,14 a specialty wound care board (American Board of Wound Medicine and Surgery),15 an international wound specialist professional society (European Union of Medical Specialists), 16 and recommended curriculum guidelines for wound care residency programs.17 ACGME-accredited specialty and subspecialty milestones professional activities were examined, including vascular surgery,18 plastic surgery,19 dermatology, 20 foot and ankle,21 orthopedic surgery,22 spinal cord injury,23 and geriatric medicine.24
The competencies, milestones, and entrustable professional activities were compiled and redundancies were eliminated. Wound care specialists from geriatrics, family medicine, internal medicine, undersea and hyperbaric medicine, general surgery, podiatry, and physical therapy examined the findings and suggested eliminating redundancies, irrelevant content, and content that fell below the minimal expected level of competence for an advanced medical specialist in wound care. An expert consensus meeting further refined items presented to the panel before unanimous consensus resulted in the final set of curriculum competencies, milestones, and entrustable professional activities.
Training Program Feedback
We developed a comprehensive wound care curriculum for an advanced physician fellowship training program based on the streamlined competencies, milestones, and entrustable professional activities (Appendix). Multiple wound care experts from various interdisciplinary backgrounds reached consensus to establish this fellowship curriculum as adaptable for use across training settings. The training program is 12 core rotations and 2 elective rotations (Table 1). Additionally, we developed wound care evaluation forms for faculty-, peer-, and self-assessment of trainees which were adapted from an evidence-based 360-degree evaluation template.25 Suggestions for structured, advanced didactics are in Table 2.


Seventeen fellows have successfully matriculated through the wound care training program. Although wound care certification is not required to work as a wound care specialist, after completion of this fellowship, graduates are able to sit for a wound care certification examination. The American Board of Wound Medicine and Surgery (ABWMS) and the American Board of Wound Management (ABWM) allow physicians to take a certification examination after 1 year of a dedicated wound fellowship program, instead of the typical wound care practice experience ≥ 3 years.
The Clinical Wound Care Fellowship Program collected data for program improvement, and 15 alumni responded (response rate, 88%) to a survey using a 5-point Likert scale. Respondents indicated high mean scores for overall satisfaction (4.7), instructional methods (4.7), program enjoyment (4.7), teaching materials (4.6), and relevance (4.6). All respondents indicated that the fellowship prepared them for a career in wound care as well as their current employment, and 13 of 15 (87%) reported they obtained immediate relevant postfellowship wound care positions and stated that the fellowship prepared them for their current roles. Nine respondents (69%) reported that they were engaged in wound care ≥ 26% of work time. Six respondents (46%) worked in private practice, 3 (23%) at academic medical centers, and 2 (15%) at government- funded hospitals. Four respondents indicated they were board certified in wound care. Program alumni are currently involved in scholarly activities, including 8 in quality improvement and 3 in research.
Discussion
An easily accessible, comprehensive wound care fellowship curriculum has not been previously developed or published. This limited the sources that informed this curriculum. However, the developmental process for this curriculum was robust, as the authors reviewed previously published materials related to wound care, including: 1) descriptive overviews of wound care fellowships; 2) details of month-long rotations for medical students and residents; and 3) practices of the specific environment in which this curriculum was created. Confidence in the practical nature of the curriculum can be assumed, as the experts involved in the development process represented diverse physician specializations, including geriatrics, family medicine, internal medicine, undersea and hyperbaric medicine, general surgery, podiatry, and physical therapy.
Most wound care clinicians have not completed a formal comprehensive fellowship program. Instead, due to the lack of a comprehensive training curriculum, clinicians have had to use various continuing medical education programs and practice in a wound care setting for ≥ 3 years to be eligible for certification in the specialty. This curriculum will help academic medical centers develop their own fellowship programs, enabling new wound care clinicians to attain certifications more efficiently. As more fellowship programs develop, the goal would be to obtain recognition as an ACGME specialty and standardize the training and competencies for graduates of wound care fellowships.
Conclusions
As new wound care fellowships develop, wound care may become formally acknowledged as its own specialty within medicine and surgery. This will provide wound care with a voice at the national level, particularly in an era of value-based care. Wound care clinicians will be able to advocate for specialty-specific quality metrics and avoid potential penalization for not meeting quality metrics that are irrelevant to wound care.
- Fife CE, Eckert KA, Carter MJ. Publicly Reported wound healing rates: the fantasy and the reality. Adv Wound Care (New Rochelle). 2018;7:77-94. doi:10.1089/wound.2017.0743
- Fife CE, Carter MJ, Walker D. Why is it so hard to do the right thing in wound care?. Wound Repair Regen. 2010;18:154-158. doi:10.1111/j.1524-475X.2010.00571.x
- Sen CK, Gordillo GM, Roy S, et al. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 2009;17:763-771. doi:10.1111/j.1524-475X.2009.00543.x
- Queen D, Harding K. What’s the true costs of wounds faced by different healthcare systems around the world?. Int Wound J. 2023;20:3935-3938. doi:10.1111/iwj.14491
- Greer N, Foman N, Dorrian J, et al. Advanced Wound Care Therapies for Non-Healing Diabetic, Venous, and Arterial Ulcers: A Systematic Review [Internet]. US Dept of Veterans Affairs; November 2012. https://www.ncbi.nlm.nih.gov/books/NBK132238/
- Simman R, McNevin AJ. Pursuing the path to specialized wound care: the ABWMS perspective. Todays Wound Clin. 2017;8:10,12.
- Shahin ES, Dassen T, Halfens RJ. Pressure ulcer prevalence in intensive care patients: a cross-sectional study. J Eval Clin Pract. 2008;14:563-568. doi:10.1111/j.1365-2753.2007.00918.x
- Ennis WJ, Valdes W, Meneses P. Wound care specialization: a proposal for a comprehensive fellowship program. Wound Repair Regen. 2004;12:120-128. doi:10.1111/j.1067-1927.2004.012203.x
- Patel NP, Granick MS. Wound education: American medical students are inadequately trained in wound care. Ann Plast Surg. 2007;59:53-55. doi:10.1097/SAP.0b013e31802dd43b
- Patel NP, Granick MS, Kanakaris NK, et al. Comparison of wound education in medical schools in the United States, United Kingdom, and Germany. Eplasty. 2008;8:e8.
- Ennis WJ. Wound care specialization: the current status and future plans to move wound care into the medical community. Adv Wound Care (New Rochelle). 2012;1:184- 188. doi:10.1089/wound.2011.0346
- Accreditation Council for Graduate Medical Education. ACGME common program requirements (fellowship). Updated September 3, 2025. Accessed January 15, 2026. https://www.acgme.org/globalassets/pfassets /programrequirements/2025-reformatted-requirements/cprfellowship_2025_reformatted.pdf
- Accreditation Council for Graduate Medical Education. Program directors’ guide to the common program requirements (fellowship). Updated December 2025. Accessed May 27, 2026. https://www .acgme.org/globalassets/pdfs/guide-to-the-common -program-requirements-fellowship.pdf
- Curriculum overview - wound care and hyperbaric medicine fellowship. Wake Forest University School of Medicine. 2026. Accessed January 5, 2026. https://school .wakehealth.edu/Education-and-Training/Residencies -and-Fellowships/Wound-Care-and-Hyperbaric-Medicine -Fellowship/Curriculum-Overview
- Curriculum overview - American Board of Wound Medicine and Surgery. Core Curriculum for Fellowships in Wound Care. American Board of Wound Medicine and Surgery. 2022. Accessed January 5, 2026. https://abwms.org /curriculum-overview/
- European Wound Management Association. EWMA Wound healing curriculum for physicians. February 13, 2017. Accessed January 15, 2026. https://ewma.org /wp-content/uploads/2024/02/ETR-TF-Wound-Healing -UEMS-approved.pdf
- Accreditation Council for Graduate Medical Education. Recommended Curriculum Guidelines for Family Medicine Residents. Accessed January 5, 2026. https://www.aafp .org/dam/AAFP/documents/medical_education_residency /program_directors/Wound_Care.pdf
- Accreditation Council for Graduate Medical Education. Vascular Surgery Milestones the Accreditation Council for Graduate Medical Education. Accessed January 5, 2026. https://www.acgme.org/Portals/0/PDFs/Milestones /VascularSurgeryMilestones2.0.pdf
- Accreditation Council for Graduate Medical Education. Plastic Surgery Milestones the Accreditation Council for Graduate Medical Education. Accessed January 5, 2026. https://www.acgme.org/Portals/0/PDFs /Milestones/PlasticSurgeryMilestones.pdf
- Accreditation Council for Graduate Medical Education. Dermatology Milestones the Accreditation Council for Graduate Medical Education. Accessed January 5, 2026. https://www.acgme.org/Portals/0/PDFs/Milestones /DermatologyMilestones.pdf
- Accreditation Council for Graduate Medical Education. The Foot and Ankle Milestone Project a joint initiative of the Accreditation Council for Graduate Medical Education and the American Board of Orthopaedic Surgery. July 2015. Accessed January 5, 2026. https://www.acgme.org /Portals/0/PDFs/Milestones/FootandAnkleMilestones.pdf
- Accreditation Council for Graduate Medical Education. Orthopaedic Surgery Milestones the Accreditation Council for Graduate Medical Education. Accessed January 5, 2026. https://www.acgme.org/Portals/0/PDFs/Milestones /OrthopaedicSurgeryMilestones.pdf
- Accreditation Council for Graduate Medical Education. Spinal Cord Injury Medicine Milestones the Accreditation Council for Graduate Medical Education. Accessed January 5, 2026. https://www.acgme.org/Portals/0/PDFs /Milestones/SpinalCordInjuryMedicineMilestones.pdf
- Accreditation Council for Graduate Medical Education. Geriatric Medicine Milestones the Accreditation Council for Graduate Medical Education. Accessed January 5, 2026. https://www.acgme.org/Portals/0/PDFs/Milestones /GeriatricMedicineMilestones.pdf
- Goldhamer ME, Baker K, Anne Rigg DW, et al. Development and implementation of multi-source assessment tools for ACGME residents and fellows. MedEDPORTAL. 2014. Accessed May 14, 2026. doi:10.15766/mep_2374-8265.9839
- Fife CE, Eckert KA, Carter MJ. Publicly Reported wound healing rates: the fantasy and the reality. Adv Wound Care (New Rochelle). 2018;7:77-94. doi:10.1089/wound.2017.0743
- Fife CE, Carter MJ, Walker D. Why is it so hard to do the right thing in wound care?. Wound Repair Regen. 2010;18:154-158. doi:10.1111/j.1524-475X.2010.00571.x
- Sen CK, Gordillo GM, Roy S, et al. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 2009;17:763-771. doi:10.1111/j.1524-475X.2009.00543.x
- Queen D, Harding K. What’s the true costs of wounds faced by different healthcare systems around the world?. Int Wound J. 2023;20:3935-3938. doi:10.1111/iwj.14491
- Greer N, Foman N, Dorrian J, et al. Advanced Wound Care Therapies for Non-Healing Diabetic, Venous, and Arterial Ulcers: A Systematic Review [Internet]. US Dept of Veterans Affairs; November 2012. https://www.ncbi.nlm.nih.gov/books/NBK132238/
- Simman R, McNevin AJ. Pursuing the path to specialized wound care: the ABWMS perspective. Todays Wound Clin. 2017;8:10,12.
- Shahin ES, Dassen T, Halfens RJ. Pressure ulcer prevalence in intensive care patients: a cross-sectional study. J Eval Clin Pract. 2008;14:563-568. doi:10.1111/j.1365-2753.2007.00918.x
- Ennis WJ, Valdes W, Meneses P. Wound care specialization: a proposal for a comprehensive fellowship program. Wound Repair Regen. 2004;12:120-128. doi:10.1111/j.1067-1927.2004.012203.x
- Patel NP, Granick MS. Wound education: American medical students are inadequately trained in wound care. Ann Plast Surg. 2007;59:53-55. doi:10.1097/SAP.0b013e31802dd43b
- Patel NP, Granick MS, Kanakaris NK, et al. Comparison of wound education in medical schools in the United States, United Kingdom, and Germany. Eplasty. 2008;8:e8.
- Ennis WJ. Wound care specialization: the current status and future plans to move wound care into the medical community. Adv Wound Care (New Rochelle). 2012;1:184- 188. doi:10.1089/wound.2011.0346
- Accreditation Council for Graduate Medical Education. ACGME common program requirements (fellowship). Updated September 3, 2025. Accessed January 15, 2026. https://www.acgme.org/globalassets/pfassets /programrequirements/2025-reformatted-requirements/cprfellowship_2025_reformatted.pdf
- Accreditation Council for Graduate Medical Education. Program directors’ guide to the common program requirements (fellowship). Updated December 2025. Accessed May 27, 2026. https://www .acgme.org/globalassets/pdfs/guide-to-the-common -program-requirements-fellowship.pdf
- Curriculum overview - wound care and hyperbaric medicine fellowship. Wake Forest University School of Medicine. 2026. Accessed January 5, 2026. https://school .wakehealth.edu/Education-and-Training/Residencies -and-Fellowships/Wound-Care-and-Hyperbaric-Medicine -Fellowship/Curriculum-Overview
- Curriculum overview - American Board of Wound Medicine and Surgery. Core Curriculum for Fellowships in Wound Care. American Board of Wound Medicine and Surgery. 2022. Accessed January 5, 2026. https://abwms.org /curriculum-overview/
- European Wound Management Association. EWMA Wound healing curriculum for physicians. February 13, 2017. Accessed January 15, 2026. https://ewma.org /wp-content/uploads/2024/02/ETR-TF-Wound-Healing -UEMS-approved.pdf
- Accreditation Council for Graduate Medical Education. Recommended Curriculum Guidelines for Family Medicine Residents. Accessed January 5, 2026. https://www.aafp .org/dam/AAFP/documents/medical_education_residency /program_directors/Wound_Care.pdf
- Accreditation Council for Graduate Medical Education. Vascular Surgery Milestones the Accreditation Council for Graduate Medical Education. Accessed January 5, 2026. https://www.acgme.org/Portals/0/PDFs/Milestones /VascularSurgeryMilestones2.0.pdf
- Accreditation Council for Graduate Medical Education. Plastic Surgery Milestones the Accreditation Council for Graduate Medical Education. Accessed January 5, 2026. https://www.acgme.org/Portals/0/PDFs /Milestones/PlasticSurgeryMilestones.pdf
- Accreditation Council for Graduate Medical Education. Dermatology Milestones the Accreditation Council for Graduate Medical Education. Accessed January 5, 2026. https://www.acgme.org/Portals/0/PDFs/Milestones /DermatologyMilestones.pdf
- Accreditation Council for Graduate Medical Education. The Foot and Ankle Milestone Project a joint initiative of the Accreditation Council for Graduate Medical Education and the American Board of Orthopaedic Surgery. July 2015. Accessed January 5, 2026. https://www.acgme.org /Portals/0/PDFs/Milestones/FootandAnkleMilestones.pdf
- Accreditation Council for Graduate Medical Education. Orthopaedic Surgery Milestones the Accreditation Council for Graduate Medical Education. Accessed January 5, 2026. https://www.acgme.org/Portals/0/PDFs/Milestones /OrthopaedicSurgeryMilestones.pdf
- Accreditation Council for Graduate Medical Education. Spinal Cord Injury Medicine Milestones the Accreditation Council for Graduate Medical Education. Accessed January 5, 2026. https://www.acgme.org/Portals/0/PDFs /Milestones/SpinalCordInjuryMedicineMilestones.pdf
- Accreditation Council for Graduate Medical Education. Geriatric Medicine Milestones the Accreditation Council for Graduate Medical Education. Accessed January 5, 2026. https://www.acgme.org/Portals/0/PDFs/Milestones /GeriatricMedicineMilestones.pdf
- Goldhamer ME, Baker K, Anne Rigg DW, et al. Development and implementation of multi-source assessment tools for ACGME residents and fellows. MedEDPORTAL. 2014. Accessed May 14, 2026. doi:10.15766/mep_2374-8265.9839
The Development of a Comprehensive Wound Care Fellowship Curriculum
The Development of a Comprehensive Wound Care Fellowship Curriculum
Characteristics of Applicants and Recipients of the Veterans Affairs Home Loan Program
Characteristics of Applicants and Recipients of the Veterans Affairs Home Loan Program
The US Department of Veterans Affairs (VA) Home Loan Program, administered by the Veterans Benefits Administration (VBA), is a unique benefit for veterans, active-duty service members, National Guard and Reserve members, and eligible surviving spouses. Established in 1944, the program aims to help these individuals achieve homeownership by leveraging a third-party guarantee, typically from a government agency, to enhance access to credit and improve loan terms for borrowers who may not meet conventional loan qualifications.1 Since its inception, the VA has guaranteed > 28.5 million loans, enabling millions of veterans to buy, build, repair, retain, or adapt homes for personal occupancy.2 The program is designed to support veterans and eligible individuals to become homeowners, recognizing homeownership as a pathway to financial stability and community integration. VA home loans are provided by private lenders (eg, banks, mortgage companies) with a portion guaranteed by the VA, which reduces the risk for lenders and enables them to offer competitive terms, such as no down payment and lower interest rates, making homeownership more accessible to veterans.2
Eligibility criteria for the VA Home Loan Program include military service criteria such as active-duty service members with ≥ 90 continuous days of service; veterans with an honorable discharge meeting minimum service requirements; individuals who served in the National Guard/Reserve for ≥ 90 days of active service or 6 years of service with an honorable discharge; and surviving spouses of veterans who died in service or from a service-connected disability, were designated as missing in action/ prisoner of war, and the spouse is receiving Dependency and Indemnity Compensation. Financial criteria also apply: borrowers must meet lender requirements for credit and income (although VA loans are more flexible than conventional loans) and the home must be for personal occupancy rather than an investment property.3
A June 2025 PubMed literature search did not reveal any prior research on the VA Home Loan Program, although a limited number of studies tackled a wide range of issues related to federal and private home loans.4-12 To our knowledge, there is no prior published examination of the VA Home Loan Program. Understanding VA Home Loan Program usage among Veterans Health Administration (VHA) users can inform the future direction of the program. The VHA operates the largest integrated US health care system, serving > 9 million enrolled veterans annually at 1321 facilities, including 172 medical centers and 1138 outpatient clinics, providing primary and specialized health care, and related medical and social support services for enrolled veterans, including those who are experiencing housing instability or homelessness.13 Specialized VHA programs for homeless veterans include housing, employment, health care, justice, and re-entryrelated services in collaboration with federal and community partners.14 Housing instability has been defined as the state of being at risk of losing housing due to challenges such as difficulties paying rent, overcrowding, frequent relocation, and a substantial proportion of income spent on housing.15,16 Homelessness is a severe manifestation of housing instability that has been defined as the lack of stable, safe, and functioning housing.17,18
Health care and social services, including those that address housing instability and homelessness, are major priorities for the VHA and VBA.19 The VA Home Loan Program may represent an important resource to help veterans achieve long-term housing stability through home ownership. There has been wide public concern about housing affordability and the ability of many Americans, including veterans, to achieve home ownership.20 Homeownership is considered an important part of developing financial assets and achieving financial stability. Lowincome veterans, in particular, may benefit from this program as a national study found that 8.0% of low-income veterans and 13.9% of veterans with a history of homelessness have previously experienced a home foreclosure. 21 A greater understanding of who applies for and receives assistance from the VA Home Loan Program would inform homelessness prevention services and future planning for this program.
We conducted a quality improvement (QI) project on behalf of the VHA Homeless Programs Office and in partnership with the VBA. Our goals were to: (1) describe the annual number of applicants and recipients of the VA Home Loan Program by age group, sex, race/ethnicity, presence of any diagnosed substance use and/or mental health disorder, and history of homelessness; and (2) compare demographic, clinical, and homelessness characteristics among individuals who apply and are granted a loan through this program, individuals who apply and are denied a loan through this program, and individuals who do not apply for a loan through this program.
Methods
This project involved linked VA administrative national databases and was undertaken by the VHA Homeless Programs Office in partnership with the VBA. Specifically, VHA and VBA databases were linked together using veteran identifiers and all data were managed and analyzed on secure VA servers. The project followed VA’s Program Guide 1200.21 for nonresearch activities and institutional review board approval was waived through sponsorship by the VA Homeless Programs Office. The VHA Corporate Data Warehouse (CDW) was accessed to obtain data from the Homeless Operations Management and Evaluation System (HOMES) and other clinical data systems used by VHA clinicians and administrators that capture diagnoses, workload, and other health care data.22,23 HOMES collects intake, progress, and outcome data on homeless veterans within its care system that enables the VA to assess the effectiveness of programs and strategically allocate resources to prevent homelessness.24,25
A list of veterans who filed disability compensation and pension claims was obtained from the VBA Office of Performance Analysis and Integrity, including Social Security number, name, city and state, date of claim submission, grant or increase in benefits, homeless status, VA home loan approval, and homeless aid for dependent children from fiscal year (FY) 2022 through FY 2024. VBA data were linked to VHA CDW electronic health record data from veterans who sought VA health care services and HOMES data on veteran participation in homeless programs who were also experiencing homelessness. VHA data included demographic characteristics (eg, sex, age, race, marital status, combat service) at an index date (earliest visit to the VHA between October 1, 2021, and September 30, 2024); military sexual trauma; clinical characteristics within 12 months prior to the index date (VHA disability rating, substance use disorder [SUD] diagnosis, mental health disorder diagnosis, Charlson Comorbidity Index [CCI] score), and homelessness experience ≤ 5 years prior to the index date.
History of homelessness ≤ 5 years prior to the index date was determined using an operational definition of homelessness based on multiple indicators, including International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnostic code Z59.0; clinic stop codes or HOMES records indicating VA homeless programs clinical encounters; or a positive screen on an annual homelessness screener.16 US Department of Housing and Urban Development-VA Supportive Housing enrollees were excluded because they are considered to no longer be experiencing homelessness, and Veterans Justice Program enrollees were excluded because the program primarily focuses on serving criminal justice-involved veterans. The CCI predicts the risk of death ≤ 1 year by assessing the number and severity of a patient’s coexisting health conditions and is a valuable tool for understanding a patient’s overall health burden, aiding in clinical decision-making and evaluation research studies.26-29 Diagnoses based on ICD-10-CM codes were used to determine SUDs, mental health disorders, and CCI score, using methods that have been described in other publications.30
Population
The VBA cohort of veterans requesting benefits was further restricted to those who met the following eligibility criteria: (1) requested VA benefits FYs 2022 to 2024; (2) sought VHA services ≥ 1 time between FY 2022 and 2024; (3) had matching VBA/VHA records; (4) had no missing data on claim status and/ or demographic, clinical, and homelessness characteristics; and (5) had known home loan status FYs 2022 to 2024. The original VBA dataset consisted of 4,219,755 records and the original VHA dataset consisted of 7,170,199 records (Figure 1). The final linked VBA/VHA dataset after excluding 29 records with missing data on sex, 7 with missing data on age, 6 with missing data on marital status, and an additional 143,444 with unknown VBA claim status, consisted of 3,089,295 records corresponding to 2,260,851 unique veterans. Specifically, 251,796 records corresponded to veterans who had applied and received a loan, 84,751 to veterans who had applied and were nonrecipients of a loan, and 2,752,748 to veterans who did not apply for a loan.
Abbreviations: FY, fiscal year; VBA, Veterans Benefits Administration; VHA, Veterans Health Administration.
Statistical Analysis
All statistical analyses were performed using SAS Enterprise Guide, an application that provides a point-and-click interface for data access, analysis, and management, accommodating both code-based and visual programming. 31 First, we relied on the final analytic sample to calculate the annual proportions of veterans who applied for and/or received a loan through the VA Home Loan Program. We also generated descriptive statistics stratified by age group, sex, race/ethnicity, SUD, mental health disorder, and homelessness, overall and within each FY. Pearson χ2 and Cochran-Armitage trend tests were applied to examine differences in application and receipt of a home loan by baseline characteristics and FY, respectively. Second, we conducted bivariate and multivariable analyses to compare demographic, clinical, and homelessness characteristics between 3 groups of veterans as they pertain to the VA Home Loan Program. Veterans who applied and were nonrecipients of a loan (group 1), veterans who applied and were recipients of a loan (group 2), and veterans who did not apply for a loan (group 3). Similar analyses compared VA Home Loan Program applicants who were recipients of a home loan vs VA Home Loan Program applicants who were nonrecipients of a home loan. Multinomial and binary logistic regression models were constructed to estimate the relative risk ratio (RR) and odds ratio (OR) with 95% CIs for comparisons between these distinct groups on demographic, clinical, and homelessness characteristics. Two-sided statistical tests were evaluated at α = 0.05.
Results
Tables 1 and 2 present the number of VBA applicants, including those who applied for and received benefits through the VA Home Loan Program, by age group, sex, race/ethnicity, as well as histories of SUDs, mental health disorders, and homelessness, overall, and by FY. As shown in Figure 2, 336,547 of 3,089,295 VBA applications (10.9%) pertained to the VA Home Loan Program, with a statistically significant decline in application rates, from 12.2% in FY 2022 to 9.9% in FY 2024 (P < .001 for trend). Among 336,547 veterans who applied for the VA Home Loan Program, 251,796 (74.8%) received a home loan during FYs 2022 to 2024, ranging between 73.8% for FY 2024 and 75.5% for FY 2023 (P < .001 for trend).

Veterans Affairs Home Loan Program, fiscal years (FY) 2022-2024.


Multinomial logistic regression models for demographic, clinical, and homelessness characteristics as predictors of VA Home Loan Program status are provided in Appendix 1. Based on the fully adjusted model, compared with veterans who did not apply to the VA Home Loan Program, those who applied for a home loan were less likely to be aged ≥ 50 years, unmarried, Hispanic ethnicity, mixed race, or other race, diagnosed with a SUD, or history of homelessness. Veterans with higher VA service-connected disability ratings were more frequently recipients of VA home loans, whereas those who self-identified as non-Hispanic Black and those with higher CCI scores were less frequently recipients of VA home loans. Finally, those with mental health disorders were more likely than their counterparts to be applicants (recipients or nonrecipients) of VA home loans.

Binary logistic regression models for demographic, clinical, and homelessness characteristics as predictors of receipt status among applicants to the VA Home Loan Program are provided in Appendix 2. Among applicants, those who were granted a VA home loan were less likely to be aged ≥ 50 years; have a CCI score > 0; have experienced combat service and/or military sexual trauma; be diagnosed with a SUD and/or mental health disorder; or to have a history of homelessness compared with those denied a VA home loan. Applicants granted a VA home loan were also more likely to be female, non-Hispanic White, single or never married, and/or have a VA service-connected disability ratings > 0%.

Discussion
The VA Home Loan Program is a unique benefit and resource for eligible veterans that may be increasingly important in a time of growing concern about the affordability of housing for many Americans. Research on other federally-supported home loan programs as well as private home mortgage programs has been mostly conducted in the economic realm, and studies focused on understanding these programs from a health care system perspective have been sparse.32,33 However, there is a large body of literature documenting the importance of stable, safe, and secure housing on health and well-being.34-37 This study did not focus on evaluating the effects of the VA Home Loan Program, because we wanted to first examine the characteristics of veterans who benefited from the program and how they differed from veterans who did not apply or did apply but had a denied application.
Our findings suggest that several thousands of veterans benefit from the VA Home Loan Program each year. For historical context, the time period examined was one of economic downturn with rising costs of living, including housing, and steady increases in homelessness as reported in the annual point-in-time count of sheltered and unsheltered people experiencing homelessness on a single night as mandated by the US Department of Housing and Urban Development.38-40 The Sergeant First Class Heath Robinson Honoring Our Promise to Address Comprehensive Toxics (PACT) Act of 2022 expanded health care and benefits for veterans exposed to burn pits, Agent Orange, and other toxic substances, resulting in more VA disability benefit claims, including large retroactive payments.41-43 Anecdotally, the VBA has noted that the PACT Act helped some homeless veterans with funds and stability to exit homelessness and enroll in the VA Home Loan Program.
Our analysis suggests that beneficiaries of the VA Home Loan Program were frequently aged < 50 years, female, of non-Hispanic White race, and did not have histories of psychiatric disorders or homelessness. Most of these demographic and clinical characteristics were not surprising given the composition of the veteran population, although in-depth analyses are needed to examine sex differences that may have led to more females than males benefiting from the VA Home Loan Program. In addition, it was notable that many younger and non-Hispanic Black veterans had applied. While relatively few veterans with SUDs benefited from the VA Home Loan Program, few had applied. Research is warranted into why veterans with SUDs are less likely to apply for home loans. Quite surprisingly, a sizable proportion of veterans with histories of homelessness reported they had applied to the VA Home Loan Program, although they were less likely than veterans who had not experienced homelessness to be granted a loan.
The examination of differences between veterans who did not apply, were granted, and denied a loan through the VA Home Loan Program revealed several key predictors of application outcomes in multivariable models. Specifically, veterans who applied for home loans were less likely to be aged ≥ 50 years, unmarried, of Hispanic, mixed, or other race/ethnicity, diagnosed with an SUD, or have a history of homelessness. Veterans with higher disability ratings were less frequently denied and more frequently approved, while non-Hispanic Black veterans and those with higher CCI scores were more frequently denied and less frequently approved. VBA applicants with mental health disorders were also more likely to apply for a home loan. Conversely, those granted a home loan were more likely than those denied a home loan to be female, non-Hispanic White, single/unmarried, or to have > 0% VA service-connected disability rating, but less likely to be aged ≥ 50 years, have CCI score > 0, be diagnosed with psychiatric disorders, or have a history of homelessness.
Limitations
This analysis was restricted to a subset of FY 2022 to FY 2024 linked VBA/VHA databases (ie, to veterans who had both VBA and VHA records and met prespecified eligibility criteria). Despite the large number of linked records, a small percentage of these records corresponded to veterans who were applicants or recipients of the VA Home Loan Program. Future studies should expand the time frame to examine variations in application outcomes over time and by background characteristics of veterans enrolled in VHA care who applied for VBA benefits. In addition, we relied on data and ICD-10-CM diagnostic codes from existing electronic health records and claims data to define histories of homelessness, comorbidities, SUDs, and mental health disorders. Given the time-varying nature of these conditions, the temporal sequence of events was difficult to ascertain. Third, it is worth noting that these findings can only be generalized to veterans who applied for VBA benefits and met eligibility criteria, and that these veterans may differ in terms of their demographic and clinical characteristics from those who did not apply for these benefits.
Conclusions
This study analyzed data from 251,796 individuals who applied for and received a VA home loan, 84,751 who were denied a VA home loan, and 2,752,748 veterans who did not apply for a VA home loan from FY 2022 to FY 2024. Accordingly, 11% of applications pertained to the VA Home Loan Program, and 75% of VA Home Loan Program applicants received a home loan. Distinct demographic and clinical characteristics were observed for applicants and recipients of the VA Home Loan Program, which can set the stage for future planning and evaluation of the program. Despite the broad accessibility of veterans to the VA Home Loan Program, there were differences in approval rates among applicants based on sociodemographic and clinical characteristics. Further evaluation, perhaps using qualitative methods, is needed to better understand opportunities and challenges to achieving a VA home loan, especially among underserved veteran populations. Investigation and research can guide future recommendations for any development or corrective actions that can help increase access to veterans who can benefit from the program. Future analyses are also needed to compare veterans enrolled and not enrolled in the VA Home Loan Program on health care-related outcomes.
- US Department of Veterans Affairs. Home loans. Accessed April 1, 2026. https://www.benefits.va.gov/homeloans/
- Veterans United Home Loans. VA loans: the complete guide. Accessed April 1, 2026. https://www.veteransunited.com/va-loans/
- US Department of Veterans Affairs. VA-backed veterans home loans. Accessed April 1, 2026. https://www.va.gov/housing-assistance/home-loans/
- Choplin JM, Stark DP. Whispering sweet nothings: a review of verbal behaviors that undermine the effectiveness of government-mandated home-loan disclosures. Cogn Res Princ Implic. 2019;4:6. doi:10.1186/s41235-019-0154-7
- Evans M. Borrowing boon. More explore federal home loan banks backing. Mod Healthc. 2009;39:14.
- Hogarth M. A home loan: how—and how much? Nurs Times. 1973;69:908-909.
- Jacoby SF. Home Owners’ Loan Corporation maps and place-based injury risks: a complex history. Am J Public Health. 2023;113:356-358. doi:10.2105/AJPH.2023.307242
- Merrell C. Finance. Home: a loan. Nurs Times. 1996;92:61-64.
- Namin S, Xu W, Zhou Y, et al. The legacy of the Home Owners’ Loan Corporation and the political ecology of urban trees and air pollution in the United States. Soc Sci Med. 2020;246:112758. doi:10.1016/j.socscimed.2019.112758
- Namin S, Zhou Y, Xu W, et al. Persistence of mortgage lending bias in the United States: 80 years after the Home Owners’ Loan Corporation security maps. J Race Ethn City. 2022;3:70-94. doi:10.1080/26884674.2021.2019568
- Slottow R. The home loan program. J Natl Assoc Hosp Dev. 1990:43-45.
- Wang M, Chen H, Wang L. Locus of control and home mortgage loan behaviour. Int J Psychol. 2008;43:125-129. doi:10.1080/00207590801888760
- US Dept of Veterans Affairs. Veterans Health Administration. About VHA. Updated January 20, 2025. Accessed April 1, 2026. https://www.va.gov/health/aboutvha.asp
- US Dept of Veterans Affairs. VA homeless programs. Updated May 7, 2026. Accessed May 8, 2026. https://department.va.gov/homeless/
- DiTosto JD, Holder K, Soyemi E, et al. Housing instability and adverse perinatal outcomes: a systematic review. Am J Obstet Gynecol MFM. 2021;3:100477. doi:10.1016/j.ajogmf.2021.100477
- Tsai J, Szymkowiak D, Jutkowitz E. Developing an operational definition of housing instability and homelessness in Veterans Health Administration medical records. PLoS One. 2022;17:e0279973. doi:10.1371/journal.pone.0279973
- Fowler PJ, Hovmand PS, Marcal KE, et al. Solving homelessness from a complex systems perspective: insights for prevention responses. Annu Rev Public Health. 2019;40: 465-486. doi:10.1146/annurev-publhealth-040617-013553
- US Department of Health and Human Services. Healthy People 2030: housing instability. Accessed April 1, 2026. https://health.gov/healthypeople/priority-areas/social-determinants-health/literature-summaries/housing-instability
- US Department of Veterans Affairs. VA health care priorities. Accessed April 1, 2026. https://www.va.gov/health/priorities/index.asp
- Tsai J. Federal priorities to address homelessness as a community health problem. Fam Community Health. 2025;48:57-69.
- Tsai J, Hooshyar D. Prevalence of eviction, home foreclosure, and homelessness among low-income US veterans: the National Veteran Homeless and Other Poverty Experiences study. Public Health. 2022;213:181-188. doi:10.1016/j.puhe.2022.10.017
- US Department of Veterans Affairs. Corporate Data Warehouse (CDW). Accessed April 1, 2026. https://www.hsrd.research.va.gov/for_researchers/cdw.cfm
- Price LE, Shea K, Gephart S. The Veterans Affairs Corporate Data Warehouse: uses and implications for nursing research and practice. Nurs Adm Q. 2015;39:311-318. doi:10.1097/NAQ.0000000000000118
- US Department of Veterans Affairs. Homeless Operations Management and Evaluation System (HOMES) User Manual—Phase 1. April 19, 2011. Accessed April 1, 2026. https://www.adldata.org/wp-content/uploads/2016/07/homes.pdf
- Tsai J, Kasprow WJ, Rosenheck RA. Latent homeless risk profiles of a national sample of homeless veterans and their relation to program referral and admission patterns. Am J Public Health. 2013;103:S239-S247. doi:10.2105/AJPH.2013.301322
- Sundararajan V, Henderson T, Perry C, et al. New ICD-10 version of the Charlson comorbidity index predicted inhospital mortality. J Clin Epidemiol. 2004;57:1288-1294. doi:10.1016/j.jclinepi.2004.03.012
- Beydoun HA, Szymkowiak D, Beydoun MA, et al. Comparing major comorbidity indices as predictors of all-cause mortality in the Veterans Affairs health care system. J Clin Epidemiol. 2025;182:111778. doi:10.1016/j.jclinepi.2025.111778
- Charlson ME, Carrozzino D, Guidi J, et al. Charlson Comorbidity Index: a critical review of clinimetric properties. Psychother Psychosom. 2022;91:8-35. doi:10.1159/000521288
- Glasheen WP, Cordier T, Gumpina R, et al. Charlson Comorbidity Index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits. 2019;12:188-197.
- Beydoun HA, Szymkowiak D, Kinney R, et al. Is the risk of Alzheimer’s disease and related dementias among US veterans influenced by the intersectionality of housing status, HIV/AIDS, hepatitis C, and psychiatric disorders? J Gerontol A Biol Sci Med Sci. 2024;79:glae153. doi:10.1093/gerona/glae153
- SAS Institute. SAS Enterprise Guide. Accessed April 1, 2026. https://www.sas.com/en_us/software/enterprise-guide/features-list.html
- Agarwal S, Amromin G, Chomsisengphet S, et al. Mortgage refinancing, consumer spending, and competition: evidence from the Home Affordable Refinance Program. Rev Econ Stud. 2023;90:499-537.
- Ashcraft A, Bech ML, Frame WS. The Federal Home Loan Bank System: the lender of next-to-last resort? J Money Credit Bank. 2010;42:551-583.
- Gibson M, Petticrew M, Bambra C, et al. Housing and health inequalities: a synthesis of systematic reviews of interventions aimed at different pathways linking housing and health. Health Place. 2011;17:175-184. doi:10.1016/j.healthplace.2010.09.011
- Shaw M. Housing and public health. Annu Rev Public Health. 2004; 25:397-418. doi:10.1146/annurev.publhealth.25.101802.123036
- Thomson H, Petticrew M, Morrison D. Health effects of housing improvement: systematic review of intervention studies. BMJ. 2001;323:187-190. doi:10.1136/bmj.323.7306.187
- Tsai J. Theorizing pathways between eviction filings and increased mortality risk. JAMA. 2024;331:570-571. doi:10.1001/jama.2023.27978
- Bernanke B, Blanchard O. What caused the US pandemicera inflation? Am Econ J Macroecon. 2025;17:1-35.
- Hall SG, Tavlas GS, Wang Y. Drivers and spillover effects of inflation: the United States, the euro area, and the United Kingdom. J Int Money Finance. 2023;131:1-13.
- US Department of Housing and Urban Development. Point-in-Time Count and Housing Inventory Count. Accessed April 1, 2026. https://www.hudexchange.info/programs/hdx/pit-hic/
- Beckman AL, Jacobs J, Elnahal SM. The PACT Act: expanding coverage and access for veterans. JAMA. 2024;332:1423-1424. doi:10.1001/jama.2024.16013
- Zychowicz ME. The PACT Act: enhancing health care access for military personnel and veterans. N C Med J. 2023;84:379-380. doi:10.18043/001c.89208
- US Department of Veterans Affairs. The PACT Act and your VA benefits. April 2, 2026. https://www.va.gov/resources/the-pact-act-and-your-va-benefits/
The US Department of Veterans Affairs (VA) Home Loan Program, administered by the Veterans Benefits Administration (VBA), is a unique benefit for veterans, active-duty service members, National Guard and Reserve members, and eligible surviving spouses. Established in 1944, the program aims to help these individuals achieve homeownership by leveraging a third-party guarantee, typically from a government agency, to enhance access to credit and improve loan terms for borrowers who may not meet conventional loan qualifications.1 Since its inception, the VA has guaranteed > 28.5 million loans, enabling millions of veterans to buy, build, repair, retain, or adapt homes for personal occupancy.2 The program is designed to support veterans and eligible individuals to become homeowners, recognizing homeownership as a pathway to financial stability and community integration. VA home loans are provided by private lenders (eg, banks, mortgage companies) with a portion guaranteed by the VA, which reduces the risk for lenders and enables them to offer competitive terms, such as no down payment and lower interest rates, making homeownership more accessible to veterans.2
Eligibility criteria for the VA Home Loan Program include military service criteria such as active-duty service members with ≥ 90 continuous days of service; veterans with an honorable discharge meeting minimum service requirements; individuals who served in the National Guard/Reserve for ≥ 90 days of active service or 6 years of service with an honorable discharge; and surviving spouses of veterans who died in service or from a service-connected disability, were designated as missing in action/ prisoner of war, and the spouse is receiving Dependency and Indemnity Compensation. Financial criteria also apply: borrowers must meet lender requirements for credit and income (although VA loans are more flexible than conventional loans) and the home must be for personal occupancy rather than an investment property.3
A June 2025 PubMed literature search did not reveal any prior research on the VA Home Loan Program, although a limited number of studies tackled a wide range of issues related to federal and private home loans.4-12 To our knowledge, there is no prior published examination of the VA Home Loan Program. Understanding VA Home Loan Program usage among Veterans Health Administration (VHA) users can inform the future direction of the program. The VHA operates the largest integrated US health care system, serving > 9 million enrolled veterans annually at 1321 facilities, including 172 medical centers and 1138 outpatient clinics, providing primary and specialized health care, and related medical and social support services for enrolled veterans, including those who are experiencing housing instability or homelessness.13 Specialized VHA programs for homeless veterans include housing, employment, health care, justice, and re-entryrelated services in collaboration with federal and community partners.14 Housing instability has been defined as the state of being at risk of losing housing due to challenges such as difficulties paying rent, overcrowding, frequent relocation, and a substantial proportion of income spent on housing.15,16 Homelessness is a severe manifestation of housing instability that has been defined as the lack of stable, safe, and functioning housing.17,18
Health care and social services, including those that address housing instability and homelessness, are major priorities for the VHA and VBA.19 The VA Home Loan Program may represent an important resource to help veterans achieve long-term housing stability through home ownership. There has been wide public concern about housing affordability and the ability of many Americans, including veterans, to achieve home ownership.20 Homeownership is considered an important part of developing financial assets and achieving financial stability. Lowincome veterans, in particular, may benefit from this program as a national study found that 8.0% of low-income veterans and 13.9% of veterans with a history of homelessness have previously experienced a home foreclosure. 21 A greater understanding of who applies for and receives assistance from the VA Home Loan Program would inform homelessness prevention services and future planning for this program.
We conducted a quality improvement (QI) project on behalf of the VHA Homeless Programs Office and in partnership with the VBA. Our goals were to: (1) describe the annual number of applicants and recipients of the VA Home Loan Program by age group, sex, race/ethnicity, presence of any diagnosed substance use and/or mental health disorder, and history of homelessness; and (2) compare demographic, clinical, and homelessness characteristics among individuals who apply and are granted a loan through this program, individuals who apply and are denied a loan through this program, and individuals who do not apply for a loan through this program.
Methods
This project involved linked VA administrative national databases and was undertaken by the VHA Homeless Programs Office in partnership with the VBA. Specifically, VHA and VBA databases were linked together using veteran identifiers and all data were managed and analyzed on secure VA servers. The project followed VA’s Program Guide 1200.21 for nonresearch activities and institutional review board approval was waived through sponsorship by the VA Homeless Programs Office. The VHA Corporate Data Warehouse (CDW) was accessed to obtain data from the Homeless Operations Management and Evaluation System (HOMES) and other clinical data systems used by VHA clinicians and administrators that capture diagnoses, workload, and other health care data.22,23 HOMES collects intake, progress, and outcome data on homeless veterans within its care system that enables the VA to assess the effectiveness of programs and strategically allocate resources to prevent homelessness.24,25
A list of veterans who filed disability compensation and pension claims was obtained from the VBA Office of Performance Analysis and Integrity, including Social Security number, name, city and state, date of claim submission, grant or increase in benefits, homeless status, VA home loan approval, and homeless aid for dependent children from fiscal year (FY) 2022 through FY 2024. VBA data were linked to VHA CDW electronic health record data from veterans who sought VA health care services and HOMES data on veteran participation in homeless programs who were also experiencing homelessness. VHA data included demographic characteristics (eg, sex, age, race, marital status, combat service) at an index date (earliest visit to the VHA between October 1, 2021, and September 30, 2024); military sexual trauma; clinical characteristics within 12 months prior to the index date (VHA disability rating, substance use disorder [SUD] diagnosis, mental health disorder diagnosis, Charlson Comorbidity Index [CCI] score), and homelessness experience ≤ 5 years prior to the index date.
History of homelessness ≤ 5 years prior to the index date was determined using an operational definition of homelessness based on multiple indicators, including International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnostic code Z59.0; clinic stop codes or HOMES records indicating VA homeless programs clinical encounters; or a positive screen on an annual homelessness screener.16 US Department of Housing and Urban Development-VA Supportive Housing enrollees were excluded because they are considered to no longer be experiencing homelessness, and Veterans Justice Program enrollees were excluded because the program primarily focuses on serving criminal justice-involved veterans. The CCI predicts the risk of death ≤ 1 year by assessing the number and severity of a patient’s coexisting health conditions and is a valuable tool for understanding a patient’s overall health burden, aiding in clinical decision-making and evaluation research studies.26-29 Diagnoses based on ICD-10-CM codes were used to determine SUDs, mental health disorders, and CCI score, using methods that have been described in other publications.30
Population
The VBA cohort of veterans requesting benefits was further restricted to those who met the following eligibility criteria: (1) requested VA benefits FYs 2022 to 2024; (2) sought VHA services ≥ 1 time between FY 2022 and 2024; (3) had matching VBA/VHA records; (4) had no missing data on claim status and/ or demographic, clinical, and homelessness characteristics; and (5) had known home loan status FYs 2022 to 2024. The original VBA dataset consisted of 4,219,755 records and the original VHA dataset consisted of 7,170,199 records (Figure 1). The final linked VBA/VHA dataset after excluding 29 records with missing data on sex, 7 with missing data on age, 6 with missing data on marital status, and an additional 143,444 with unknown VBA claim status, consisted of 3,089,295 records corresponding to 2,260,851 unique veterans. Specifically, 251,796 records corresponded to veterans who had applied and received a loan, 84,751 to veterans who had applied and were nonrecipients of a loan, and 2,752,748 to veterans who did not apply for a loan.
Abbreviations: FY, fiscal year; VBA, Veterans Benefits Administration; VHA, Veterans Health Administration.
Statistical Analysis
All statistical analyses were performed using SAS Enterprise Guide, an application that provides a point-and-click interface for data access, analysis, and management, accommodating both code-based and visual programming. 31 First, we relied on the final analytic sample to calculate the annual proportions of veterans who applied for and/or received a loan through the VA Home Loan Program. We also generated descriptive statistics stratified by age group, sex, race/ethnicity, SUD, mental health disorder, and homelessness, overall and within each FY. Pearson χ2 and Cochran-Armitage trend tests were applied to examine differences in application and receipt of a home loan by baseline characteristics and FY, respectively. Second, we conducted bivariate and multivariable analyses to compare demographic, clinical, and homelessness characteristics between 3 groups of veterans as they pertain to the VA Home Loan Program. Veterans who applied and were nonrecipients of a loan (group 1), veterans who applied and were recipients of a loan (group 2), and veterans who did not apply for a loan (group 3). Similar analyses compared VA Home Loan Program applicants who were recipients of a home loan vs VA Home Loan Program applicants who were nonrecipients of a home loan. Multinomial and binary logistic regression models were constructed to estimate the relative risk ratio (RR) and odds ratio (OR) with 95% CIs for comparisons between these distinct groups on demographic, clinical, and homelessness characteristics. Two-sided statistical tests were evaluated at α = 0.05.
Results
Tables 1 and 2 present the number of VBA applicants, including those who applied for and received benefits through the VA Home Loan Program, by age group, sex, race/ethnicity, as well as histories of SUDs, mental health disorders, and homelessness, overall, and by FY. As shown in Figure 2, 336,547 of 3,089,295 VBA applications (10.9%) pertained to the VA Home Loan Program, with a statistically significant decline in application rates, from 12.2% in FY 2022 to 9.9% in FY 2024 (P < .001 for trend). Among 336,547 veterans who applied for the VA Home Loan Program, 251,796 (74.8%) received a home loan during FYs 2022 to 2024, ranging between 73.8% for FY 2024 and 75.5% for FY 2023 (P < .001 for trend).

Veterans Affairs Home Loan Program, fiscal years (FY) 2022-2024.


Multinomial logistic regression models for demographic, clinical, and homelessness characteristics as predictors of VA Home Loan Program status are provided in Appendix 1. Based on the fully adjusted model, compared with veterans who did not apply to the VA Home Loan Program, those who applied for a home loan were less likely to be aged ≥ 50 years, unmarried, Hispanic ethnicity, mixed race, or other race, diagnosed with a SUD, or history of homelessness. Veterans with higher VA service-connected disability ratings were more frequently recipients of VA home loans, whereas those who self-identified as non-Hispanic Black and those with higher CCI scores were less frequently recipients of VA home loans. Finally, those with mental health disorders were more likely than their counterparts to be applicants (recipients or nonrecipients) of VA home loans.

Binary logistic regression models for demographic, clinical, and homelessness characteristics as predictors of receipt status among applicants to the VA Home Loan Program are provided in Appendix 2. Among applicants, those who were granted a VA home loan were less likely to be aged ≥ 50 years; have a CCI score > 0; have experienced combat service and/or military sexual trauma; be diagnosed with a SUD and/or mental health disorder; or to have a history of homelessness compared with those denied a VA home loan. Applicants granted a VA home loan were also more likely to be female, non-Hispanic White, single or never married, and/or have a VA service-connected disability ratings > 0%.

Discussion
The VA Home Loan Program is a unique benefit and resource for eligible veterans that may be increasingly important in a time of growing concern about the affordability of housing for many Americans. Research on other federally-supported home loan programs as well as private home mortgage programs has been mostly conducted in the economic realm, and studies focused on understanding these programs from a health care system perspective have been sparse.32,33 However, there is a large body of literature documenting the importance of stable, safe, and secure housing on health and well-being.34-37 This study did not focus on evaluating the effects of the VA Home Loan Program, because we wanted to first examine the characteristics of veterans who benefited from the program and how they differed from veterans who did not apply or did apply but had a denied application.
Our findings suggest that several thousands of veterans benefit from the VA Home Loan Program each year. For historical context, the time period examined was one of economic downturn with rising costs of living, including housing, and steady increases in homelessness as reported in the annual point-in-time count of sheltered and unsheltered people experiencing homelessness on a single night as mandated by the US Department of Housing and Urban Development.38-40 The Sergeant First Class Heath Robinson Honoring Our Promise to Address Comprehensive Toxics (PACT) Act of 2022 expanded health care and benefits for veterans exposed to burn pits, Agent Orange, and other toxic substances, resulting in more VA disability benefit claims, including large retroactive payments.41-43 Anecdotally, the VBA has noted that the PACT Act helped some homeless veterans with funds and stability to exit homelessness and enroll in the VA Home Loan Program.
Our analysis suggests that beneficiaries of the VA Home Loan Program were frequently aged < 50 years, female, of non-Hispanic White race, and did not have histories of psychiatric disorders or homelessness. Most of these demographic and clinical characteristics were not surprising given the composition of the veteran population, although in-depth analyses are needed to examine sex differences that may have led to more females than males benefiting from the VA Home Loan Program. In addition, it was notable that many younger and non-Hispanic Black veterans had applied. While relatively few veterans with SUDs benefited from the VA Home Loan Program, few had applied. Research is warranted into why veterans with SUDs are less likely to apply for home loans. Quite surprisingly, a sizable proportion of veterans with histories of homelessness reported they had applied to the VA Home Loan Program, although they were less likely than veterans who had not experienced homelessness to be granted a loan.
The examination of differences between veterans who did not apply, were granted, and denied a loan through the VA Home Loan Program revealed several key predictors of application outcomes in multivariable models. Specifically, veterans who applied for home loans were less likely to be aged ≥ 50 years, unmarried, of Hispanic, mixed, or other race/ethnicity, diagnosed with an SUD, or have a history of homelessness. Veterans with higher disability ratings were less frequently denied and more frequently approved, while non-Hispanic Black veterans and those with higher CCI scores were more frequently denied and less frequently approved. VBA applicants with mental health disorders were also more likely to apply for a home loan. Conversely, those granted a home loan were more likely than those denied a home loan to be female, non-Hispanic White, single/unmarried, or to have > 0% VA service-connected disability rating, but less likely to be aged ≥ 50 years, have CCI score > 0, be diagnosed with psychiatric disorders, or have a history of homelessness.
Limitations
This analysis was restricted to a subset of FY 2022 to FY 2024 linked VBA/VHA databases (ie, to veterans who had both VBA and VHA records and met prespecified eligibility criteria). Despite the large number of linked records, a small percentage of these records corresponded to veterans who were applicants or recipients of the VA Home Loan Program. Future studies should expand the time frame to examine variations in application outcomes over time and by background characteristics of veterans enrolled in VHA care who applied for VBA benefits. In addition, we relied on data and ICD-10-CM diagnostic codes from existing electronic health records and claims data to define histories of homelessness, comorbidities, SUDs, and mental health disorders. Given the time-varying nature of these conditions, the temporal sequence of events was difficult to ascertain. Third, it is worth noting that these findings can only be generalized to veterans who applied for VBA benefits and met eligibility criteria, and that these veterans may differ in terms of their demographic and clinical characteristics from those who did not apply for these benefits.
Conclusions
This study analyzed data from 251,796 individuals who applied for and received a VA home loan, 84,751 who were denied a VA home loan, and 2,752,748 veterans who did not apply for a VA home loan from FY 2022 to FY 2024. Accordingly, 11% of applications pertained to the VA Home Loan Program, and 75% of VA Home Loan Program applicants received a home loan. Distinct demographic and clinical characteristics were observed for applicants and recipients of the VA Home Loan Program, which can set the stage for future planning and evaluation of the program. Despite the broad accessibility of veterans to the VA Home Loan Program, there were differences in approval rates among applicants based on sociodemographic and clinical characteristics. Further evaluation, perhaps using qualitative methods, is needed to better understand opportunities and challenges to achieving a VA home loan, especially among underserved veteran populations. Investigation and research can guide future recommendations for any development or corrective actions that can help increase access to veterans who can benefit from the program. Future analyses are also needed to compare veterans enrolled and not enrolled in the VA Home Loan Program on health care-related outcomes.
The US Department of Veterans Affairs (VA) Home Loan Program, administered by the Veterans Benefits Administration (VBA), is a unique benefit for veterans, active-duty service members, National Guard and Reserve members, and eligible surviving spouses. Established in 1944, the program aims to help these individuals achieve homeownership by leveraging a third-party guarantee, typically from a government agency, to enhance access to credit and improve loan terms for borrowers who may not meet conventional loan qualifications.1 Since its inception, the VA has guaranteed > 28.5 million loans, enabling millions of veterans to buy, build, repair, retain, or adapt homes for personal occupancy.2 The program is designed to support veterans and eligible individuals to become homeowners, recognizing homeownership as a pathway to financial stability and community integration. VA home loans are provided by private lenders (eg, banks, mortgage companies) with a portion guaranteed by the VA, which reduces the risk for lenders and enables them to offer competitive terms, such as no down payment and lower interest rates, making homeownership more accessible to veterans.2
Eligibility criteria for the VA Home Loan Program include military service criteria such as active-duty service members with ≥ 90 continuous days of service; veterans with an honorable discharge meeting minimum service requirements; individuals who served in the National Guard/Reserve for ≥ 90 days of active service or 6 years of service with an honorable discharge; and surviving spouses of veterans who died in service or from a service-connected disability, were designated as missing in action/ prisoner of war, and the spouse is receiving Dependency and Indemnity Compensation. Financial criteria also apply: borrowers must meet lender requirements for credit and income (although VA loans are more flexible than conventional loans) and the home must be for personal occupancy rather than an investment property.3
A June 2025 PubMed literature search did not reveal any prior research on the VA Home Loan Program, although a limited number of studies tackled a wide range of issues related to federal and private home loans.4-12 To our knowledge, there is no prior published examination of the VA Home Loan Program. Understanding VA Home Loan Program usage among Veterans Health Administration (VHA) users can inform the future direction of the program. The VHA operates the largest integrated US health care system, serving > 9 million enrolled veterans annually at 1321 facilities, including 172 medical centers and 1138 outpatient clinics, providing primary and specialized health care, and related medical and social support services for enrolled veterans, including those who are experiencing housing instability or homelessness.13 Specialized VHA programs for homeless veterans include housing, employment, health care, justice, and re-entryrelated services in collaboration with federal and community partners.14 Housing instability has been defined as the state of being at risk of losing housing due to challenges such as difficulties paying rent, overcrowding, frequent relocation, and a substantial proportion of income spent on housing.15,16 Homelessness is a severe manifestation of housing instability that has been defined as the lack of stable, safe, and functioning housing.17,18
Health care and social services, including those that address housing instability and homelessness, are major priorities for the VHA and VBA.19 The VA Home Loan Program may represent an important resource to help veterans achieve long-term housing stability through home ownership. There has been wide public concern about housing affordability and the ability of many Americans, including veterans, to achieve home ownership.20 Homeownership is considered an important part of developing financial assets and achieving financial stability. Lowincome veterans, in particular, may benefit from this program as a national study found that 8.0% of low-income veterans and 13.9% of veterans with a history of homelessness have previously experienced a home foreclosure. 21 A greater understanding of who applies for and receives assistance from the VA Home Loan Program would inform homelessness prevention services and future planning for this program.
We conducted a quality improvement (QI) project on behalf of the VHA Homeless Programs Office and in partnership with the VBA. Our goals were to: (1) describe the annual number of applicants and recipients of the VA Home Loan Program by age group, sex, race/ethnicity, presence of any diagnosed substance use and/or mental health disorder, and history of homelessness; and (2) compare demographic, clinical, and homelessness characteristics among individuals who apply and are granted a loan through this program, individuals who apply and are denied a loan through this program, and individuals who do not apply for a loan through this program.
Methods
This project involved linked VA administrative national databases and was undertaken by the VHA Homeless Programs Office in partnership with the VBA. Specifically, VHA and VBA databases were linked together using veteran identifiers and all data were managed and analyzed on secure VA servers. The project followed VA’s Program Guide 1200.21 for nonresearch activities and institutional review board approval was waived through sponsorship by the VA Homeless Programs Office. The VHA Corporate Data Warehouse (CDW) was accessed to obtain data from the Homeless Operations Management and Evaluation System (HOMES) and other clinical data systems used by VHA clinicians and administrators that capture diagnoses, workload, and other health care data.22,23 HOMES collects intake, progress, and outcome data on homeless veterans within its care system that enables the VA to assess the effectiveness of programs and strategically allocate resources to prevent homelessness.24,25
A list of veterans who filed disability compensation and pension claims was obtained from the VBA Office of Performance Analysis and Integrity, including Social Security number, name, city and state, date of claim submission, grant or increase in benefits, homeless status, VA home loan approval, and homeless aid for dependent children from fiscal year (FY) 2022 through FY 2024. VBA data were linked to VHA CDW electronic health record data from veterans who sought VA health care services and HOMES data on veteran participation in homeless programs who were also experiencing homelessness. VHA data included demographic characteristics (eg, sex, age, race, marital status, combat service) at an index date (earliest visit to the VHA between October 1, 2021, and September 30, 2024); military sexual trauma; clinical characteristics within 12 months prior to the index date (VHA disability rating, substance use disorder [SUD] diagnosis, mental health disorder diagnosis, Charlson Comorbidity Index [CCI] score), and homelessness experience ≤ 5 years prior to the index date.
History of homelessness ≤ 5 years prior to the index date was determined using an operational definition of homelessness based on multiple indicators, including International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnostic code Z59.0; clinic stop codes or HOMES records indicating VA homeless programs clinical encounters; or a positive screen on an annual homelessness screener.16 US Department of Housing and Urban Development-VA Supportive Housing enrollees were excluded because they are considered to no longer be experiencing homelessness, and Veterans Justice Program enrollees were excluded because the program primarily focuses on serving criminal justice-involved veterans. The CCI predicts the risk of death ≤ 1 year by assessing the number and severity of a patient’s coexisting health conditions and is a valuable tool for understanding a patient’s overall health burden, aiding in clinical decision-making and evaluation research studies.26-29 Diagnoses based on ICD-10-CM codes were used to determine SUDs, mental health disorders, and CCI score, using methods that have been described in other publications.30
Population
The VBA cohort of veterans requesting benefits was further restricted to those who met the following eligibility criteria: (1) requested VA benefits FYs 2022 to 2024; (2) sought VHA services ≥ 1 time between FY 2022 and 2024; (3) had matching VBA/VHA records; (4) had no missing data on claim status and/ or demographic, clinical, and homelessness characteristics; and (5) had known home loan status FYs 2022 to 2024. The original VBA dataset consisted of 4,219,755 records and the original VHA dataset consisted of 7,170,199 records (Figure 1). The final linked VBA/VHA dataset after excluding 29 records with missing data on sex, 7 with missing data on age, 6 with missing data on marital status, and an additional 143,444 with unknown VBA claim status, consisted of 3,089,295 records corresponding to 2,260,851 unique veterans. Specifically, 251,796 records corresponded to veterans who had applied and received a loan, 84,751 to veterans who had applied and were nonrecipients of a loan, and 2,752,748 to veterans who did not apply for a loan.
Abbreviations: FY, fiscal year; VBA, Veterans Benefits Administration; VHA, Veterans Health Administration.
Statistical Analysis
All statistical analyses were performed using SAS Enterprise Guide, an application that provides a point-and-click interface for data access, analysis, and management, accommodating both code-based and visual programming. 31 First, we relied on the final analytic sample to calculate the annual proportions of veterans who applied for and/or received a loan through the VA Home Loan Program. We also generated descriptive statistics stratified by age group, sex, race/ethnicity, SUD, mental health disorder, and homelessness, overall and within each FY. Pearson χ2 and Cochran-Armitage trend tests were applied to examine differences in application and receipt of a home loan by baseline characteristics and FY, respectively. Second, we conducted bivariate and multivariable analyses to compare demographic, clinical, and homelessness characteristics between 3 groups of veterans as they pertain to the VA Home Loan Program. Veterans who applied and were nonrecipients of a loan (group 1), veterans who applied and were recipients of a loan (group 2), and veterans who did not apply for a loan (group 3). Similar analyses compared VA Home Loan Program applicants who were recipients of a home loan vs VA Home Loan Program applicants who were nonrecipients of a home loan. Multinomial and binary logistic regression models were constructed to estimate the relative risk ratio (RR) and odds ratio (OR) with 95% CIs for comparisons between these distinct groups on demographic, clinical, and homelessness characteristics. Two-sided statistical tests were evaluated at α = 0.05.
Results
Tables 1 and 2 present the number of VBA applicants, including those who applied for and received benefits through the VA Home Loan Program, by age group, sex, race/ethnicity, as well as histories of SUDs, mental health disorders, and homelessness, overall, and by FY. As shown in Figure 2, 336,547 of 3,089,295 VBA applications (10.9%) pertained to the VA Home Loan Program, with a statistically significant decline in application rates, from 12.2% in FY 2022 to 9.9% in FY 2024 (P < .001 for trend). Among 336,547 veterans who applied for the VA Home Loan Program, 251,796 (74.8%) received a home loan during FYs 2022 to 2024, ranging between 73.8% for FY 2024 and 75.5% for FY 2023 (P < .001 for trend).

Veterans Affairs Home Loan Program, fiscal years (FY) 2022-2024.


Multinomial logistic regression models for demographic, clinical, and homelessness characteristics as predictors of VA Home Loan Program status are provided in Appendix 1. Based on the fully adjusted model, compared with veterans who did not apply to the VA Home Loan Program, those who applied for a home loan were less likely to be aged ≥ 50 years, unmarried, Hispanic ethnicity, mixed race, or other race, diagnosed with a SUD, or history of homelessness. Veterans with higher VA service-connected disability ratings were more frequently recipients of VA home loans, whereas those who self-identified as non-Hispanic Black and those with higher CCI scores were less frequently recipients of VA home loans. Finally, those with mental health disorders were more likely than their counterparts to be applicants (recipients or nonrecipients) of VA home loans.

Binary logistic regression models for demographic, clinical, and homelessness characteristics as predictors of receipt status among applicants to the VA Home Loan Program are provided in Appendix 2. Among applicants, those who were granted a VA home loan were less likely to be aged ≥ 50 years; have a CCI score > 0; have experienced combat service and/or military sexual trauma; be diagnosed with a SUD and/or mental health disorder; or to have a history of homelessness compared with those denied a VA home loan. Applicants granted a VA home loan were also more likely to be female, non-Hispanic White, single or never married, and/or have a VA service-connected disability ratings > 0%.

Discussion
The VA Home Loan Program is a unique benefit and resource for eligible veterans that may be increasingly important in a time of growing concern about the affordability of housing for many Americans. Research on other federally-supported home loan programs as well as private home mortgage programs has been mostly conducted in the economic realm, and studies focused on understanding these programs from a health care system perspective have been sparse.32,33 However, there is a large body of literature documenting the importance of stable, safe, and secure housing on health and well-being.34-37 This study did not focus on evaluating the effects of the VA Home Loan Program, because we wanted to first examine the characteristics of veterans who benefited from the program and how they differed from veterans who did not apply or did apply but had a denied application.
Our findings suggest that several thousands of veterans benefit from the VA Home Loan Program each year. For historical context, the time period examined was one of economic downturn with rising costs of living, including housing, and steady increases in homelessness as reported in the annual point-in-time count of sheltered and unsheltered people experiencing homelessness on a single night as mandated by the US Department of Housing and Urban Development.38-40 The Sergeant First Class Heath Robinson Honoring Our Promise to Address Comprehensive Toxics (PACT) Act of 2022 expanded health care and benefits for veterans exposed to burn pits, Agent Orange, and other toxic substances, resulting in more VA disability benefit claims, including large retroactive payments.41-43 Anecdotally, the VBA has noted that the PACT Act helped some homeless veterans with funds and stability to exit homelessness and enroll in the VA Home Loan Program.
Our analysis suggests that beneficiaries of the VA Home Loan Program were frequently aged < 50 years, female, of non-Hispanic White race, and did not have histories of psychiatric disorders or homelessness. Most of these demographic and clinical characteristics were not surprising given the composition of the veteran population, although in-depth analyses are needed to examine sex differences that may have led to more females than males benefiting from the VA Home Loan Program. In addition, it was notable that many younger and non-Hispanic Black veterans had applied. While relatively few veterans with SUDs benefited from the VA Home Loan Program, few had applied. Research is warranted into why veterans with SUDs are less likely to apply for home loans. Quite surprisingly, a sizable proportion of veterans with histories of homelessness reported they had applied to the VA Home Loan Program, although they were less likely than veterans who had not experienced homelessness to be granted a loan.
The examination of differences between veterans who did not apply, were granted, and denied a loan through the VA Home Loan Program revealed several key predictors of application outcomes in multivariable models. Specifically, veterans who applied for home loans were less likely to be aged ≥ 50 years, unmarried, of Hispanic, mixed, or other race/ethnicity, diagnosed with an SUD, or have a history of homelessness. Veterans with higher disability ratings were less frequently denied and more frequently approved, while non-Hispanic Black veterans and those with higher CCI scores were more frequently denied and less frequently approved. VBA applicants with mental health disorders were also more likely to apply for a home loan. Conversely, those granted a home loan were more likely than those denied a home loan to be female, non-Hispanic White, single/unmarried, or to have > 0% VA service-connected disability rating, but less likely to be aged ≥ 50 years, have CCI score > 0, be diagnosed with psychiatric disorders, or have a history of homelessness.
Limitations
This analysis was restricted to a subset of FY 2022 to FY 2024 linked VBA/VHA databases (ie, to veterans who had both VBA and VHA records and met prespecified eligibility criteria). Despite the large number of linked records, a small percentage of these records corresponded to veterans who were applicants or recipients of the VA Home Loan Program. Future studies should expand the time frame to examine variations in application outcomes over time and by background characteristics of veterans enrolled in VHA care who applied for VBA benefits. In addition, we relied on data and ICD-10-CM diagnostic codes from existing electronic health records and claims data to define histories of homelessness, comorbidities, SUDs, and mental health disorders. Given the time-varying nature of these conditions, the temporal sequence of events was difficult to ascertain. Third, it is worth noting that these findings can only be generalized to veterans who applied for VBA benefits and met eligibility criteria, and that these veterans may differ in terms of their demographic and clinical characteristics from those who did not apply for these benefits.
Conclusions
This study analyzed data from 251,796 individuals who applied for and received a VA home loan, 84,751 who were denied a VA home loan, and 2,752,748 veterans who did not apply for a VA home loan from FY 2022 to FY 2024. Accordingly, 11% of applications pertained to the VA Home Loan Program, and 75% of VA Home Loan Program applicants received a home loan. Distinct demographic and clinical characteristics were observed for applicants and recipients of the VA Home Loan Program, which can set the stage for future planning and evaluation of the program. Despite the broad accessibility of veterans to the VA Home Loan Program, there were differences in approval rates among applicants based on sociodemographic and clinical characteristics. Further evaluation, perhaps using qualitative methods, is needed to better understand opportunities and challenges to achieving a VA home loan, especially among underserved veteran populations. Investigation and research can guide future recommendations for any development or corrective actions that can help increase access to veterans who can benefit from the program. Future analyses are also needed to compare veterans enrolled and not enrolled in the VA Home Loan Program on health care-related outcomes.
- US Department of Veterans Affairs. Home loans. Accessed April 1, 2026. https://www.benefits.va.gov/homeloans/
- Veterans United Home Loans. VA loans: the complete guide. Accessed April 1, 2026. https://www.veteransunited.com/va-loans/
- US Department of Veterans Affairs. VA-backed veterans home loans. Accessed April 1, 2026. https://www.va.gov/housing-assistance/home-loans/
- Choplin JM, Stark DP. Whispering sweet nothings: a review of verbal behaviors that undermine the effectiveness of government-mandated home-loan disclosures. Cogn Res Princ Implic. 2019;4:6. doi:10.1186/s41235-019-0154-7
- Evans M. Borrowing boon. More explore federal home loan banks backing. Mod Healthc. 2009;39:14.
- Hogarth M. A home loan: how—and how much? Nurs Times. 1973;69:908-909.
- Jacoby SF. Home Owners’ Loan Corporation maps and place-based injury risks: a complex history. Am J Public Health. 2023;113:356-358. doi:10.2105/AJPH.2023.307242
- Merrell C. Finance. Home: a loan. Nurs Times. 1996;92:61-64.
- Namin S, Xu W, Zhou Y, et al. The legacy of the Home Owners’ Loan Corporation and the political ecology of urban trees and air pollution in the United States. Soc Sci Med. 2020;246:112758. doi:10.1016/j.socscimed.2019.112758
- Namin S, Zhou Y, Xu W, et al. Persistence of mortgage lending bias in the United States: 80 years after the Home Owners’ Loan Corporation security maps. J Race Ethn City. 2022;3:70-94. doi:10.1080/26884674.2021.2019568
- Slottow R. The home loan program. J Natl Assoc Hosp Dev. 1990:43-45.
- Wang M, Chen H, Wang L. Locus of control and home mortgage loan behaviour. Int J Psychol. 2008;43:125-129. doi:10.1080/00207590801888760
- US Dept of Veterans Affairs. Veterans Health Administration. About VHA. Updated January 20, 2025. Accessed April 1, 2026. https://www.va.gov/health/aboutvha.asp
- US Dept of Veterans Affairs. VA homeless programs. Updated May 7, 2026. Accessed May 8, 2026. https://department.va.gov/homeless/
- DiTosto JD, Holder K, Soyemi E, et al. Housing instability and adverse perinatal outcomes: a systematic review. Am J Obstet Gynecol MFM. 2021;3:100477. doi:10.1016/j.ajogmf.2021.100477
- Tsai J, Szymkowiak D, Jutkowitz E. Developing an operational definition of housing instability and homelessness in Veterans Health Administration medical records. PLoS One. 2022;17:e0279973. doi:10.1371/journal.pone.0279973
- Fowler PJ, Hovmand PS, Marcal KE, et al. Solving homelessness from a complex systems perspective: insights for prevention responses. Annu Rev Public Health. 2019;40: 465-486. doi:10.1146/annurev-publhealth-040617-013553
- US Department of Health and Human Services. Healthy People 2030: housing instability. Accessed April 1, 2026. https://health.gov/healthypeople/priority-areas/social-determinants-health/literature-summaries/housing-instability
- US Department of Veterans Affairs. VA health care priorities. Accessed April 1, 2026. https://www.va.gov/health/priorities/index.asp
- Tsai J. Federal priorities to address homelessness as a community health problem. Fam Community Health. 2025;48:57-69.
- Tsai J, Hooshyar D. Prevalence of eviction, home foreclosure, and homelessness among low-income US veterans: the National Veteran Homeless and Other Poverty Experiences study. Public Health. 2022;213:181-188. doi:10.1016/j.puhe.2022.10.017
- US Department of Veterans Affairs. Corporate Data Warehouse (CDW). Accessed April 1, 2026. https://www.hsrd.research.va.gov/for_researchers/cdw.cfm
- Price LE, Shea K, Gephart S. The Veterans Affairs Corporate Data Warehouse: uses and implications for nursing research and practice. Nurs Adm Q. 2015;39:311-318. doi:10.1097/NAQ.0000000000000118
- US Department of Veterans Affairs. Homeless Operations Management and Evaluation System (HOMES) User Manual—Phase 1. April 19, 2011. Accessed April 1, 2026. https://www.adldata.org/wp-content/uploads/2016/07/homes.pdf
- Tsai J, Kasprow WJ, Rosenheck RA. Latent homeless risk profiles of a national sample of homeless veterans and their relation to program referral and admission patterns. Am J Public Health. 2013;103:S239-S247. doi:10.2105/AJPH.2013.301322
- Sundararajan V, Henderson T, Perry C, et al. New ICD-10 version of the Charlson comorbidity index predicted inhospital mortality. J Clin Epidemiol. 2004;57:1288-1294. doi:10.1016/j.jclinepi.2004.03.012
- Beydoun HA, Szymkowiak D, Beydoun MA, et al. Comparing major comorbidity indices as predictors of all-cause mortality in the Veterans Affairs health care system. J Clin Epidemiol. 2025;182:111778. doi:10.1016/j.jclinepi.2025.111778
- Charlson ME, Carrozzino D, Guidi J, et al. Charlson Comorbidity Index: a critical review of clinimetric properties. Psychother Psychosom. 2022;91:8-35. doi:10.1159/000521288
- Glasheen WP, Cordier T, Gumpina R, et al. Charlson Comorbidity Index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits. 2019;12:188-197.
- Beydoun HA, Szymkowiak D, Kinney R, et al. Is the risk of Alzheimer’s disease and related dementias among US veterans influenced by the intersectionality of housing status, HIV/AIDS, hepatitis C, and psychiatric disorders? J Gerontol A Biol Sci Med Sci. 2024;79:glae153. doi:10.1093/gerona/glae153
- SAS Institute. SAS Enterprise Guide. Accessed April 1, 2026. https://www.sas.com/en_us/software/enterprise-guide/features-list.html
- Agarwal S, Amromin G, Chomsisengphet S, et al. Mortgage refinancing, consumer spending, and competition: evidence from the Home Affordable Refinance Program. Rev Econ Stud. 2023;90:499-537.
- Ashcraft A, Bech ML, Frame WS. The Federal Home Loan Bank System: the lender of next-to-last resort? J Money Credit Bank. 2010;42:551-583.
- Gibson M, Petticrew M, Bambra C, et al. Housing and health inequalities: a synthesis of systematic reviews of interventions aimed at different pathways linking housing and health. Health Place. 2011;17:175-184. doi:10.1016/j.healthplace.2010.09.011
- Shaw M. Housing and public health. Annu Rev Public Health. 2004; 25:397-418. doi:10.1146/annurev.publhealth.25.101802.123036
- Thomson H, Petticrew M, Morrison D. Health effects of housing improvement: systematic review of intervention studies. BMJ. 2001;323:187-190. doi:10.1136/bmj.323.7306.187
- Tsai J. Theorizing pathways between eviction filings and increased mortality risk. JAMA. 2024;331:570-571. doi:10.1001/jama.2023.27978
- Bernanke B, Blanchard O. What caused the US pandemicera inflation? Am Econ J Macroecon. 2025;17:1-35.
- Hall SG, Tavlas GS, Wang Y. Drivers and spillover effects of inflation: the United States, the euro area, and the United Kingdom. J Int Money Finance. 2023;131:1-13.
- US Department of Housing and Urban Development. Point-in-Time Count and Housing Inventory Count. Accessed April 1, 2026. https://www.hudexchange.info/programs/hdx/pit-hic/
- Beckman AL, Jacobs J, Elnahal SM. The PACT Act: expanding coverage and access for veterans. JAMA. 2024;332:1423-1424. doi:10.1001/jama.2024.16013
- Zychowicz ME. The PACT Act: enhancing health care access for military personnel and veterans. N C Med J. 2023;84:379-380. doi:10.18043/001c.89208
- US Department of Veterans Affairs. The PACT Act and your VA benefits. April 2, 2026. https://www.va.gov/resources/the-pact-act-and-your-va-benefits/
- US Department of Veterans Affairs. Home loans. Accessed April 1, 2026. https://www.benefits.va.gov/homeloans/
- Veterans United Home Loans. VA loans: the complete guide. Accessed April 1, 2026. https://www.veteransunited.com/va-loans/
- US Department of Veterans Affairs. VA-backed veterans home loans. Accessed April 1, 2026. https://www.va.gov/housing-assistance/home-loans/
- Choplin JM, Stark DP. Whispering sweet nothings: a review of verbal behaviors that undermine the effectiveness of government-mandated home-loan disclosures. Cogn Res Princ Implic. 2019;4:6. doi:10.1186/s41235-019-0154-7
- Evans M. Borrowing boon. More explore federal home loan banks backing. Mod Healthc. 2009;39:14.
- Hogarth M. A home loan: how—and how much? Nurs Times. 1973;69:908-909.
- Jacoby SF. Home Owners’ Loan Corporation maps and place-based injury risks: a complex history. Am J Public Health. 2023;113:356-358. doi:10.2105/AJPH.2023.307242
- Merrell C. Finance. Home: a loan. Nurs Times. 1996;92:61-64.
- Namin S, Xu W, Zhou Y, et al. The legacy of the Home Owners’ Loan Corporation and the political ecology of urban trees and air pollution in the United States. Soc Sci Med. 2020;246:112758. doi:10.1016/j.socscimed.2019.112758
- Namin S, Zhou Y, Xu W, et al. Persistence of mortgage lending bias in the United States: 80 years after the Home Owners’ Loan Corporation security maps. J Race Ethn City. 2022;3:70-94. doi:10.1080/26884674.2021.2019568
- Slottow R. The home loan program. J Natl Assoc Hosp Dev. 1990:43-45.
- Wang M, Chen H, Wang L. Locus of control and home mortgage loan behaviour. Int J Psychol. 2008;43:125-129. doi:10.1080/00207590801888760
- US Dept of Veterans Affairs. Veterans Health Administration. About VHA. Updated January 20, 2025. Accessed April 1, 2026. https://www.va.gov/health/aboutvha.asp
- US Dept of Veterans Affairs. VA homeless programs. Updated May 7, 2026. Accessed May 8, 2026. https://department.va.gov/homeless/
- DiTosto JD, Holder K, Soyemi E, et al. Housing instability and adverse perinatal outcomes: a systematic review. Am J Obstet Gynecol MFM. 2021;3:100477. doi:10.1016/j.ajogmf.2021.100477
- Tsai J, Szymkowiak D, Jutkowitz E. Developing an operational definition of housing instability and homelessness in Veterans Health Administration medical records. PLoS One. 2022;17:e0279973. doi:10.1371/journal.pone.0279973
- Fowler PJ, Hovmand PS, Marcal KE, et al. Solving homelessness from a complex systems perspective: insights for prevention responses. Annu Rev Public Health. 2019;40: 465-486. doi:10.1146/annurev-publhealth-040617-013553
- US Department of Health and Human Services. Healthy People 2030: housing instability. Accessed April 1, 2026. https://health.gov/healthypeople/priority-areas/social-determinants-health/literature-summaries/housing-instability
- US Department of Veterans Affairs. VA health care priorities. Accessed April 1, 2026. https://www.va.gov/health/priorities/index.asp
- Tsai J. Federal priorities to address homelessness as a community health problem. Fam Community Health. 2025;48:57-69.
- Tsai J, Hooshyar D. Prevalence of eviction, home foreclosure, and homelessness among low-income US veterans: the National Veteran Homeless and Other Poverty Experiences study. Public Health. 2022;213:181-188. doi:10.1016/j.puhe.2022.10.017
- US Department of Veterans Affairs. Corporate Data Warehouse (CDW). Accessed April 1, 2026. https://www.hsrd.research.va.gov/for_researchers/cdw.cfm
- Price LE, Shea K, Gephart S. The Veterans Affairs Corporate Data Warehouse: uses and implications for nursing research and practice. Nurs Adm Q. 2015;39:311-318. doi:10.1097/NAQ.0000000000000118
- US Department of Veterans Affairs. Homeless Operations Management and Evaluation System (HOMES) User Manual—Phase 1. April 19, 2011. Accessed April 1, 2026. https://www.adldata.org/wp-content/uploads/2016/07/homes.pdf
- Tsai J, Kasprow WJ, Rosenheck RA. Latent homeless risk profiles of a national sample of homeless veterans and their relation to program referral and admission patterns. Am J Public Health. 2013;103:S239-S247. doi:10.2105/AJPH.2013.301322
- Sundararajan V, Henderson T, Perry C, et al. New ICD-10 version of the Charlson comorbidity index predicted inhospital mortality. J Clin Epidemiol. 2004;57:1288-1294. doi:10.1016/j.jclinepi.2004.03.012
- Beydoun HA, Szymkowiak D, Beydoun MA, et al. Comparing major comorbidity indices as predictors of all-cause mortality in the Veterans Affairs health care system. J Clin Epidemiol. 2025;182:111778. doi:10.1016/j.jclinepi.2025.111778
- Charlson ME, Carrozzino D, Guidi J, et al. Charlson Comorbidity Index: a critical review of clinimetric properties. Psychother Psychosom. 2022;91:8-35. doi:10.1159/000521288
- Glasheen WP, Cordier T, Gumpina R, et al. Charlson Comorbidity Index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits. 2019;12:188-197.
- Beydoun HA, Szymkowiak D, Kinney R, et al. Is the risk of Alzheimer’s disease and related dementias among US veterans influenced by the intersectionality of housing status, HIV/AIDS, hepatitis C, and psychiatric disorders? J Gerontol A Biol Sci Med Sci. 2024;79:glae153. doi:10.1093/gerona/glae153
- SAS Institute. SAS Enterprise Guide. Accessed April 1, 2026. https://www.sas.com/en_us/software/enterprise-guide/features-list.html
- Agarwal S, Amromin G, Chomsisengphet S, et al. Mortgage refinancing, consumer spending, and competition: evidence from the Home Affordable Refinance Program. Rev Econ Stud. 2023;90:499-537.
- Ashcraft A, Bech ML, Frame WS. The Federal Home Loan Bank System: the lender of next-to-last resort? J Money Credit Bank. 2010;42:551-583.
- Gibson M, Petticrew M, Bambra C, et al. Housing and health inequalities: a synthesis of systematic reviews of interventions aimed at different pathways linking housing and health. Health Place. 2011;17:175-184. doi:10.1016/j.healthplace.2010.09.011
- Shaw M. Housing and public health. Annu Rev Public Health. 2004; 25:397-418. doi:10.1146/annurev.publhealth.25.101802.123036
- Thomson H, Petticrew M, Morrison D. Health effects of housing improvement: systematic review of intervention studies. BMJ. 2001;323:187-190. doi:10.1136/bmj.323.7306.187
- Tsai J. Theorizing pathways between eviction filings and increased mortality risk. JAMA. 2024;331:570-571. doi:10.1001/jama.2023.27978
- Bernanke B, Blanchard O. What caused the US pandemicera inflation? Am Econ J Macroecon. 2025;17:1-35.
- Hall SG, Tavlas GS, Wang Y. Drivers and spillover effects of inflation: the United States, the euro area, and the United Kingdom. J Int Money Finance. 2023;131:1-13.
- US Department of Housing and Urban Development. Point-in-Time Count and Housing Inventory Count. Accessed April 1, 2026. https://www.hudexchange.info/programs/hdx/pit-hic/
- Beckman AL, Jacobs J, Elnahal SM. The PACT Act: expanding coverage and access for veterans. JAMA. 2024;332:1423-1424. doi:10.1001/jama.2024.16013
- Zychowicz ME. The PACT Act: enhancing health care access for military personnel and veterans. N C Med J. 2023;84:379-380. doi:10.18043/001c.89208
- US Department of Veterans Affairs. The PACT Act and your VA benefits. April 2, 2026. https://www.va.gov/resources/the-pact-act-and-your-va-benefits/
Characteristics of Applicants and Recipients of the Veterans Affairs Home Loan Program
Characteristics of Applicants and Recipients of the Veterans Affairs Home Loan Program
Microcystic Adnexal Carcinoma– like Neoplasm in a Patient With POT1 Mutation
Microcystic Adnexal Carcinoma– like Neoplasm in a Patient With POT1 Mutation
A 72-year-old man with a history of multiple cancers, including melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC), presented to the dermatology clinic for a regularly scheduled full-body skin examination. His family history was negative for malignancy, but due to his personal history of both primary internal cancers and skin cancers, the patient previously had been referred by dermatology to a medical geneticist for evaluation. He tested positive for a pathogenic POT1 (protection of telomeres 1) variant associated with tumor predisposition, which most often is associated with cutaneous melanoma, chronic lymphocytic leukemia (CLL), angiosarcoma, and gliomas.1
At the current presentation, physical examination revealed a small, asymmetric, pink papule on the superior thoracic spine. A biopsy of the lesion was performed (Figure 1). Pathology demonstrated cornifying cystic structures with a granulomatous response at the surface of the tumor, ductal differentiation with depth, and infiltrative strands and cords of hyperchromatic cells within a collagenous stroma at the base of the specimen (Figures 2A and 2B). One unusual finding was the presence of prominent clear-cell change within the superficial portion of the neoplasm (Figure 2C). Immunohistochemical stains revealed strong p63 and p40 positivity. Epithelial membrane antigen staining was positive in the hyperchromatic strands and cords with depth but not in the clear-cell superficial portion. Similarly, periodic acid–Schiff–positive material increased within tumor cells in proportion to depth of infiltration. Additional immunohistochemical staining showed carcinoembryonic antigen was largely negative (with rare positivity in a few ductal lumina), with negative results for S100, SOX10, CD117, BerEP4, factor XIIIa, CD34, and cytokeratin 7 (Figures 2D and 2E).
The differential diagnoses included trichilemmal carcinoma (which may manifest with CD34 expression),2 clear cell BCC, adenoid cystic carcinoma (tubular variant), sebaceous carcinoma, and eccrine carcinoma. Importantly, the patient was under continuous oncologic surveillance, with no evidence of a primary internal tumor to suggest metastasis. Despite negative carcinoembryonic antigen staining, the immunohistochemical and histopathologic findings fit best with a primary cutaneous malignant eccrine tumor, specifically microcystic adnexal carcinoma (MAC), in which p63 typically stains peripheral cells but solid variants have been described.3
Eccrine carcinoma is exceedingly rare, reported in 0.01% of diagnosed cutaneous malignancies, and demonstrates overlapping features to other malignant eccrine tumors. It possesses an inconsistent immunohistochemical staining profile, making the distinction from other malignant sweat gland tumors challenging.4 Given that the morphologic features were otherwise classic for MAC in our patient, we favored a clear-cell variant.
Sixteen years prior to the current presentation, our patient presented to urology with a history of prostatitis and increasing prostate-specific antigen levels. Biopsies were negative until prostate-specific antigen reached 13 ng/mL, confirming stage 1A prostate cancer. The patient subsequently underwent a robot-assisted radical prostatectomy. At age 63 years, dysphagia that was unresponsive to antibiotics led to a tonsillar biopsy revealing T2N2bM0 stage IVA SCC of the right tonsil with confirmed HPV type 16 with extracapsular extension. The patient underwent transoral robotic radical tonsillectomy and right neck dissection, followed by adjuvant chemoradiation consisting of intensity-modulated radiation therapy (IMRT) to a total dose of 63 Gy in 33 fractions, with concurrent weekly cisplatin. At age 67 years, dyspepsia, dysphagia, pyrosis, and gastroesophageal reflux prompted endoscopy, revealing T1aNxMx esophageal adenocarcinoma. Three months later, the patient underwent laparoscopic-assisted esophagectomy, with no recurrence. At age 68 years, an atypical intramelanocytic proliferation was found on the left cheek and was treated with Mohs micrographic surgery.
At age 71 years, acral lentiginous malignant melanoma (Breslow thickness 0.8 mm; Clark level IV; American Joint Committee on Cancer T1b) was diagnosed on the left plantar foot and treated with Mohs micrographic surgery. Sentinel lymph node biopsy was negative. Squamous cell carcinoma in situ on the frontal scalp and nodular BCC on the right upper back also were diagnosed.
While there are no guidelines for surveillance of individuals with POT1, recommendations were given in consensus from a medical genetics team,1 including comprehensive monitoring—specifically baseline imaging utilizing brain and full-body magnetic resonance imaging. Furthermore, considering the crucial role of POT1 in maintaining telomeres, it was advised to measure telomere length as part of the surveillance process. Given the patient’s susceptibility to CLL, routine complete blood count assessments were recommended. Additionally, we advised close monitoring for seizures and consideration of genetic testing in first-degree relatives.
Literature Review
Given our patient’s history of multiple skin cancers, including the most recent MAC, we sought to conduct a review of the literature to evaluate existing skin cancer associations and reports for patients with known POT1 mutations to guide recommendations for dermatologic surveillance (Table). A search of PubMed articles indexed for MEDLINE through April 2023 using the terms microcystic adnexal carcinoma, POT1, melanoma, basal cell carcinoma, squamous cell carcinoma, and skin cancer yielded no reported cases of MAC associated with POT1 mutations. POT1 is one of 6 proteins (TERF1, TERF2, RAP1, TIN2, TPP1, and POT1) belonging to the shelterin complex, which plays a crucial role in telomeric DNA remodeling and regulation of telomere length.5 Mutation in the POT1 gene disrupts the shelterin complex, causing telomeres to become elongated and unstable, resulting in chromosomal abnormalities and promoting cancer development.5

While our literature review did not reveal any associations between the shelterin complex genes and MAC, mutations in the POT1 gene have been studied in other types of skin cancer, particularly melanoma.1 One of the earliest studies was conducted in 2014 by Shi et al,6 in which whole-exome sequencing was performed on families with a history of melanoma. Multiple POT1 gene pathogenic variants associated with increased telomere length and fragility were identified in unrelated families. Subsequent studies have confirmed POT1 variants in melanoma-prone families,7 supporting an association between increased telomere length and melanoma risk8-11; however, other studies have yielded nonsignificant findings.12,13 Further investigation also has identified morphologic characteristics consistent with POT1 mutation, including spitzoid morphology.14
The association between POT1 mutations and nonmelanoma skin cancers has been relatively understudied. While a few studies have explored this link, results have shown mixed findings. Some studies have suggested a potential role for POT1 mutations in cutaneous SCC risk,15 while other studies have shown no significant associations for both BCC and SCC risk and telomere gene mutations.16 Additionally, mRNA levels of POT1 were upregulated in BCC cases compared to normal tissue in a gene expression.17
Comment
In the literature, POT1 mutations are well established as high-penetrance alterations associated with melanoma.9,18,19 However, the correlation between POT1 and other forms of skin cancer is not yet delineated. Recent insights suggest that POT1 mutations play a major role in promoting melanoma progression through telomere elongation, an established driver of melanoma progression, thereby extending the proliferative capacity of incipient cancer cells.20 This notion is supported by observations of increased telomere length in melanomaprone families with POT1 mutations. Given this association, research has focused on examining the relationship between telomere length and skin cancer.
Several studies have examined the relationship between telomere length and the risk for various types of skin cancer, including melanoma, BCC, and SCC. Prior investigations have suggested that shorter telomere length is associated with a decreased risk for melanoma and an increased risk for BCC, while no significant association has been observed for SCC.16 However, subsequent reports analyzing POT1 variants have failed to reveal any conclusive associations between BCC and SCC and telomere length.16,21
In contrast, other genetic variants associated with melanoma susceptibility have demonstrated notable associations with BCC and SCC; for instance, the CDKN2A (cyclin-dependent kinase inhibitor 2A) gene, which is the first gene linked to high-risk familial melanoma, exhibits an increased presence of mutations in individuals with BCC and SCC.22 Similarly, the MC1R (melanocortin 1 receptor) variant, a gene involved in human pigmentation and known to increase the risk for melanoma, carries a statistically significantly higher risk for BCC (summary odds ratio, 1.39; 95% CI, 1.15-1.69) and SCC (summary odds ratio, 1.61; 95% CI, 1.35-1.91) when at least one variant is present and an even greater risk with 2 or more variants.23
Considering the potential importance of POT1 mutations and their association with melanoma, as well as the inconsistencies surrounding POT1 mutations and their associations with BCC and SCC, further research may clarify the impact of POT1 mutations on the development and progression of different types of skin cancers and improve understanding of the complex interplay among telomere length, genetic variants, and skin cancer susceptibility. Given the established risk for melanoma with POT1 mutations, regular dermatology surveillance seems prudent. Dermatologists should consider referring patients with multiple skin cancers (especially melanoma) and any strong family history of internal malignancies to genetic testing for POT1. Though melanoma, CLL, angiosarcoma, and gliomas are the most commonly associated malignancies with POT1 mutations, as our case demonstrates, presentations can be heterogeneous, and the spectrum of malignancies associated with POT1 may be more expansive than previously thought.
For our patient, the current surveillance plan is fullbody skin examinations every 3 months. Given no prior family history of malignancies, presumably our patient’s case was a spontaneous mutation. Interestingly, despite his many primary cancer diagnoses and metastases, our patient has responded well to all treatments without recurrence. It is unclear if these characteristics and treatment successes are features of POT1associated cancers. Further research is needed to refine recommendations for screening and management of patients with identified POT1 mutations.
Conclusion
This case report highlights a rare occurrence of MAC in a patient with a POT1 mutation. Given the limited research conducted on investigating POT1 mutations and skin cancer, it is important to consider various forms of skin cancer, in addition to melanoma, when treating patients with a POT1 mutation.
- Accardo ML, Osborne J, Else T. POT1 tumor predisposition. GeneReviews®. October 29, 2020. Updated December 4, 2025. University of Washington.
- Chaichamnan K, Satayasoontorn K, Puttanupaab S, et al. Malignant proliferating trichilemmal tumors with CD34 expression. J Med Assoc Thai. 2010;93(suppl 6):S28-S34.
- Kavand S, Cassarino DS. “Squamoid eccrine ductal carcinoma”: an unusual low-grade case with follicular differentiation. are these tumors squamoid variants of microcystic adnexal carcinoma? Am J Dermatopathol. 2009;31:849-852.
- Kaseb H, Babiker HM. Eccrine carcinoma. StatPearls [Internet]. Updated June 26, 2023. Accessed May 11, 2026. https://www.ncbi.nlm.nih.gov/books/NBK541042
- Ye JZ, Hockemeyer D, Krutchinsky AN, et al. POT1-interacting protein PIP1: a telomere length regulator that recruits POT1 to the TIN2/TRF1 complex. Genes Dev. 2004;18:1649-1654. doi:10.1101/gad.1215404
- Shi J, Yang XR, Ballew B, et al. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet. 2014;46:482-486. doi:10.1038/ng.2941
- Wilson TL, Hattangady N, Lerario AM, et al. A new POT1 germline mutation-expanding the spectrum of POT1-associated cancers. Fam Cancer. 2017;16:561-566. doi:10.1007/s10689-017-9984-y
- Müller C, Krunic M, Wendt J, et al. Germline variants in the POT1- gene in high-risk melanoma patients in Austria. G3 (Bethesda). 2018;8:1475-1480. doi:10.1534/g3.117.300394
- Robles-Espinoza CD, Harland M, Ramsay AJ, et al. POT1 loss-offunction variants predispose to familial melanoma. Nat Genet. 2014;46:478-481. doi:10.1038/ng.2947
- Wong K, Robles-Espinoza CD, Rodriguez D, et al. Association of the POT1 germline missense variant p.I78T with familial melanoma. JAMA Dermatol. 2019;155:604-609. doi:10.1001/jamadermatol.2018.3662
- Simonin-Wilmer I, Ossio R, Leddin EM, et al. Population-based analysis of POT1 variants in a cutaneous melanoma case-control cohort. J Med Genet. 2023;60:692-696. doi:10.1136/jmg-2022-108776
- Potjer TP, Bollen S, Grimbergen AJEM, et al; Dutch Working Group for Clinical Oncogenetics. Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families. Int J Cancer. 2019;144:2453- 2464. doi:10.1002/ijc.31984
- Pellegrini C, Raimondi S, Di Nardo L, et al; Italian Melanoma Intergroup (IMI). Melanoma in children and adolescents: analysis of susceptibility genes in 123 Italian patients. J Eur Acad Dermatol Venereol. 2022;36:213-221. doi:10.1111/jdv.17735
- Sargen MR, Calista D, Elder DE, et al. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain. J Am Acad Dermatol. 2020;83:860-869. doi:10.1016/j.jaad.2020.03.100
- Shen E, Xiu J, Lopez GY, et al. POT1 mutation spectrum in tumour types commonly diagnosed among POT1-associated hereditary cancer syndrome families. J Med Genet. 2020;57:664-670. doi:10.1136 /jmedgenet-2019-106657
- Nan H, Qureshi AA, Prescott J, et al. Genetic variants in telomere-maintaining genes and skin cancer risk. Hum Genet. 2011;129:247-253. doi:10.1007/s00439-010-0921-5
- Zhang L, Huang X, Zhu X, et al. Differential senescence capacities in meibomian gland carcinoma and basal cell carcinoma. Int J Cancer. 2016;138:1442-1452. doi:10.1002/ijc.29882
- Pastorino L, Andreotti V, Dalmasso B, et al. Insights into genetic susceptibility to melanoma by gene panel testing: potential pathogenic variants in ACD, ATM, BAP1, and POT1. Cancers (Basel). 2020;12:1007. doi:10.3390/cancers12041007
- Potrony M, Puig-Butille JA, Ribera-Sola M, et al. POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families. Br J Dermatol. 2019;181:105-113. doi:10.1111/bjd.17443
- Kim WT, Hennick K, Johnson J, et al. Cancer-associated POT1 mutations lead to telomere elongation without induction of a DNA damage response. EMBO J. 2021;40:e107346.
- Ventura A, Pellegrini C, Cardelli L, et al. Telomeres and telomerase in cutaneous squamous cell carcinoma. Int J Mol Sci. 2019;20:1333. doi:10.3390/ijms20061333
- Helgadottir H, Höiom V, Jönsson G, et al. High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J Med Genet. 2014;51:545-552. doi:10.1136/jmedgenet-2014-102320
- Tagliabue E, Fargnoli MC, Gandini S, et al; M-SKIP Study Group. MC1R gene variants and non-melanoma skin cancer: a pooledanalysis from the M-SKIP project. Br J Cancer. 2015;113:354-363. doi:10.1038/bjc.2015.231
A 72-year-old man with a history of multiple cancers, including melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC), presented to the dermatology clinic for a regularly scheduled full-body skin examination. His family history was negative for malignancy, but due to his personal history of both primary internal cancers and skin cancers, the patient previously had been referred by dermatology to a medical geneticist for evaluation. He tested positive for a pathogenic POT1 (protection of telomeres 1) variant associated with tumor predisposition, which most often is associated with cutaneous melanoma, chronic lymphocytic leukemia (CLL), angiosarcoma, and gliomas.1
At the current presentation, physical examination revealed a small, asymmetric, pink papule on the superior thoracic spine. A biopsy of the lesion was performed (Figure 1). Pathology demonstrated cornifying cystic structures with a granulomatous response at the surface of the tumor, ductal differentiation with depth, and infiltrative strands and cords of hyperchromatic cells within a collagenous stroma at the base of the specimen (Figures 2A and 2B). One unusual finding was the presence of prominent clear-cell change within the superficial portion of the neoplasm (Figure 2C). Immunohistochemical stains revealed strong p63 and p40 positivity. Epithelial membrane antigen staining was positive in the hyperchromatic strands and cords with depth but not in the clear-cell superficial portion. Similarly, periodic acid–Schiff–positive material increased within tumor cells in proportion to depth of infiltration. Additional immunohistochemical staining showed carcinoembryonic antigen was largely negative (with rare positivity in a few ductal lumina), with negative results for S100, SOX10, CD117, BerEP4, factor XIIIa, CD34, and cytokeratin 7 (Figures 2D and 2E).
The differential diagnoses included trichilemmal carcinoma (which may manifest with CD34 expression),2 clear cell BCC, adenoid cystic carcinoma (tubular variant), sebaceous carcinoma, and eccrine carcinoma. Importantly, the patient was under continuous oncologic surveillance, with no evidence of a primary internal tumor to suggest metastasis. Despite negative carcinoembryonic antigen staining, the immunohistochemical and histopathologic findings fit best with a primary cutaneous malignant eccrine tumor, specifically microcystic adnexal carcinoma (MAC), in which p63 typically stains peripheral cells but solid variants have been described.3
Eccrine carcinoma is exceedingly rare, reported in 0.01% of diagnosed cutaneous malignancies, and demonstrates overlapping features to other malignant eccrine tumors. It possesses an inconsistent immunohistochemical staining profile, making the distinction from other malignant sweat gland tumors challenging.4 Given that the morphologic features were otherwise classic for MAC in our patient, we favored a clear-cell variant.
Sixteen years prior to the current presentation, our patient presented to urology with a history of prostatitis and increasing prostate-specific antigen levels. Biopsies were negative until prostate-specific antigen reached 13 ng/mL, confirming stage 1A prostate cancer. The patient subsequently underwent a robot-assisted radical prostatectomy. At age 63 years, dysphagia that was unresponsive to antibiotics led to a tonsillar biopsy revealing T2N2bM0 stage IVA SCC of the right tonsil with confirmed HPV type 16 with extracapsular extension. The patient underwent transoral robotic radical tonsillectomy and right neck dissection, followed by adjuvant chemoradiation consisting of intensity-modulated radiation therapy (IMRT) to a total dose of 63 Gy in 33 fractions, with concurrent weekly cisplatin. At age 67 years, dyspepsia, dysphagia, pyrosis, and gastroesophageal reflux prompted endoscopy, revealing T1aNxMx esophageal adenocarcinoma. Three months later, the patient underwent laparoscopic-assisted esophagectomy, with no recurrence. At age 68 years, an atypical intramelanocytic proliferation was found on the left cheek and was treated with Mohs micrographic surgery.
At age 71 years, acral lentiginous malignant melanoma (Breslow thickness 0.8 mm; Clark level IV; American Joint Committee on Cancer T1b) was diagnosed on the left plantar foot and treated with Mohs micrographic surgery. Sentinel lymph node biopsy was negative. Squamous cell carcinoma in situ on the frontal scalp and nodular BCC on the right upper back also were diagnosed.
While there are no guidelines for surveillance of individuals with POT1, recommendations were given in consensus from a medical genetics team,1 including comprehensive monitoring—specifically baseline imaging utilizing brain and full-body magnetic resonance imaging. Furthermore, considering the crucial role of POT1 in maintaining telomeres, it was advised to measure telomere length as part of the surveillance process. Given the patient’s susceptibility to CLL, routine complete blood count assessments were recommended. Additionally, we advised close monitoring for seizures and consideration of genetic testing in first-degree relatives.
Literature Review
Given our patient’s history of multiple skin cancers, including the most recent MAC, we sought to conduct a review of the literature to evaluate existing skin cancer associations and reports for patients with known POT1 mutations to guide recommendations for dermatologic surveillance (Table). A search of PubMed articles indexed for MEDLINE through April 2023 using the terms microcystic adnexal carcinoma, POT1, melanoma, basal cell carcinoma, squamous cell carcinoma, and skin cancer yielded no reported cases of MAC associated with POT1 mutations. POT1 is one of 6 proteins (TERF1, TERF2, RAP1, TIN2, TPP1, and POT1) belonging to the shelterin complex, which plays a crucial role in telomeric DNA remodeling and regulation of telomere length.5 Mutation in the POT1 gene disrupts the shelterin complex, causing telomeres to become elongated and unstable, resulting in chromosomal abnormalities and promoting cancer development.5

While our literature review did not reveal any associations between the shelterin complex genes and MAC, mutations in the POT1 gene have been studied in other types of skin cancer, particularly melanoma.1 One of the earliest studies was conducted in 2014 by Shi et al,6 in which whole-exome sequencing was performed on families with a history of melanoma. Multiple POT1 gene pathogenic variants associated with increased telomere length and fragility were identified in unrelated families. Subsequent studies have confirmed POT1 variants in melanoma-prone families,7 supporting an association between increased telomere length and melanoma risk8-11; however, other studies have yielded nonsignificant findings.12,13 Further investigation also has identified morphologic characteristics consistent with POT1 mutation, including spitzoid morphology.14
The association between POT1 mutations and nonmelanoma skin cancers has been relatively understudied. While a few studies have explored this link, results have shown mixed findings. Some studies have suggested a potential role for POT1 mutations in cutaneous SCC risk,15 while other studies have shown no significant associations for both BCC and SCC risk and telomere gene mutations.16 Additionally, mRNA levels of POT1 were upregulated in BCC cases compared to normal tissue in a gene expression.17
Comment
In the literature, POT1 mutations are well established as high-penetrance alterations associated with melanoma.9,18,19 However, the correlation between POT1 and other forms of skin cancer is not yet delineated. Recent insights suggest that POT1 mutations play a major role in promoting melanoma progression through telomere elongation, an established driver of melanoma progression, thereby extending the proliferative capacity of incipient cancer cells.20 This notion is supported by observations of increased telomere length in melanomaprone families with POT1 mutations. Given this association, research has focused on examining the relationship between telomere length and skin cancer.
Several studies have examined the relationship between telomere length and the risk for various types of skin cancer, including melanoma, BCC, and SCC. Prior investigations have suggested that shorter telomere length is associated with a decreased risk for melanoma and an increased risk for BCC, while no significant association has been observed for SCC.16 However, subsequent reports analyzing POT1 variants have failed to reveal any conclusive associations between BCC and SCC and telomere length.16,21
In contrast, other genetic variants associated with melanoma susceptibility have demonstrated notable associations with BCC and SCC; for instance, the CDKN2A (cyclin-dependent kinase inhibitor 2A) gene, which is the first gene linked to high-risk familial melanoma, exhibits an increased presence of mutations in individuals with BCC and SCC.22 Similarly, the MC1R (melanocortin 1 receptor) variant, a gene involved in human pigmentation and known to increase the risk for melanoma, carries a statistically significantly higher risk for BCC (summary odds ratio, 1.39; 95% CI, 1.15-1.69) and SCC (summary odds ratio, 1.61; 95% CI, 1.35-1.91) when at least one variant is present and an even greater risk with 2 or more variants.23
Considering the potential importance of POT1 mutations and their association with melanoma, as well as the inconsistencies surrounding POT1 mutations and their associations with BCC and SCC, further research may clarify the impact of POT1 mutations on the development and progression of different types of skin cancers and improve understanding of the complex interplay among telomere length, genetic variants, and skin cancer susceptibility. Given the established risk for melanoma with POT1 mutations, regular dermatology surveillance seems prudent. Dermatologists should consider referring patients with multiple skin cancers (especially melanoma) and any strong family history of internal malignancies to genetic testing for POT1. Though melanoma, CLL, angiosarcoma, and gliomas are the most commonly associated malignancies with POT1 mutations, as our case demonstrates, presentations can be heterogeneous, and the spectrum of malignancies associated with POT1 may be more expansive than previously thought.
For our patient, the current surveillance plan is fullbody skin examinations every 3 months. Given no prior family history of malignancies, presumably our patient’s case was a spontaneous mutation. Interestingly, despite his many primary cancer diagnoses and metastases, our patient has responded well to all treatments without recurrence. It is unclear if these characteristics and treatment successes are features of POT1associated cancers. Further research is needed to refine recommendations for screening and management of patients with identified POT1 mutations.
Conclusion
This case report highlights a rare occurrence of MAC in a patient with a POT1 mutation. Given the limited research conducted on investigating POT1 mutations and skin cancer, it is important to consider various forms of skin cancer, in addition to melanoma, when treating patients with a POT1 mutation.
A 72-year-old man with a history of multiple cancers, including melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC), presented to the dermatology clinic for a regularly scheduled full-body skin examination. His family history was negative for malignancy, but due to his personal history of both primary internal cancers and skin cancers, the patient previously had been referred by dermatology to a medical geneticist for evaluation. He tested positive for a pathogenic POT1 (protection of telomeres 1) variant associated with tumor predisposition, which most often is associated with cutaneous melanoma, chronic lymphocytic leukemia (CLL), angiosarcoma, and gliomas.1
At the current presentation, physical examination revealed a small, asymmetric, pink papule on the superior thoracic spine. A biopsy of the lesion was performed (Figure 1). Pathology demonstrated cornifying cystic structures with a granulomatous response at the surface of the tumor, ductal differentiation with depth, and infiltrative strands and cords of hyperchromatic cells within a collagenous stroma at the base of the specimen (Figures 2A and 2B). One unusual finding was the presence of prominent clear-cell change within the superficial portion of the neoplasm (Figure 2C). Immunohistochemical stains revealed strong p63 and p40 positivity. Epithelial membrane antigen staining was positive in the hyperchromatic strands and cords with depth but not in the clear-cell superficial portion. Similarly, periodic acid–Schiff–positive material increased within tumor cells in proportion to depth of infiltration. Additional immunohistochemical staining showed carcinoembryonic antigen was largely negative (with rare positivity in a few ductal lumina), with negative results for S100, SOX10, CD117, BerEP4, factor XIIIa, CD34, and cytokeratin 7 (Figures 2D and 2E).
The differential diagnoses included trichilemmal carcinoma (which may manifest with CD34 expression),2 clear cell BCC, adenoid cystic carcinoma (tubular variant), sebaceous carcinoma, and eccrine carcinoma. Importantly, the patient was under continuous oncologic surveillance, with no evidence of a primary internal tumor to suggest metastasis. Despite negative carcinoembryonic antigen staining, the immunohistochemical and histopathologic findings fit best with a primary cutaneous malignant eccrine tumor, specifically microcystic adnexal carcinoma (MAC), in which p63 typically stains peripheral cells but solid variants have been described.3
Eccrine carcinoma is exceedingly rare, reported in 0.01% of diagnosed cutaneous malignancies, and demonstrates overlapping features to other malignant eccrine tumors. It possesses an inconsistent immunohistochemical staining profile, making the distinction from other malignant sweat gland tumors challenging.4 Given that the morphologic features were otherwise classic for MAC in our patient, we favored a clear-cell variant.
Sixteen years prior to the current presentation, our patient presented to urology with a history of prostatitis and increasing prostate-specific antigen levels. Biopsies were negative until prostate-specific antigen reached 13 ng/mL, confirming stage 1A prostate cancer. The patient subsequently underwent a robot-assisted radical prostatectomy. At age 63 years, dysphagia that was unresponsive to antibiotics led to a tonsillar biopsy revealing T2N2bM0 stage IVA SCC of the right tonsil with confirmed HPV type 16 with extracapsular extension. The patient underwent transoral robotic radical tonsillectomy and right neck dissection, followed by adjuvant chemoradiation consisting of intensity-modulated radiation therapy (IMRT) to a total dose of 63 Gy in 33 fractions, with concurrent weekly cisplatin. At age 67 years, dyspepsia, dysphagia, pyrosis, and gastroesophageal reflux prompted endoscopy, revealing T1aNxMx esophageal adenocarcinoma. Three months later, the patient underwent laparoscopic-assisted esophagectomy, with no recurrence. At age 68 years, an atypical intramelanocytic proliferation was found on the left cheek and was treated with Mohs micrographic surgery.
At age 71 years, acral lentiginous malignant melanoma (Breslow thickness 0.8 mm; Clark level IV; American Joint Committee on Cancer T1b) was diagnosed on the left plantar foot and treated with Mohs micrographic surgery. Sentinel lymph node biopsy was negative. Squamous cell carcinoma in situ on the frontal scalp and nodular BCC on the right upper back also were diagnosed.
While there are no guidelines for surveillance of individuals with POT1, recommendations were given in consensus from a medical genetics team,1 including comprehensive monitoring—specifically baseline imaging utilizing brain and full-body magnetic resonance imaging. Furthermore, considering the crucial role of POT1 in maintaining telomeres, it was advised to measure telomere length as part of the surveillance process. Given the patient’s susceptibility to CLL, routine complete blood count assessments were recommended. Additionally, we advised close monitoring for seizures and consideration of genetic testing in first-degree relatives.
Literature Review
Given our patient’s history of multiple skin cancers, including the most recent MAC, we sought to conduct a review of the literature to evaluate existing skin cancer associations and reports for patients with known POT1 mutations to guide recommendations for dermatologic surveillance (Table). A search of PubMed articles indexed for MEDLINE through April 2023 using the terms microcystic adnexal carcinoma, POT1, melanoma, basal cell carcinoma, squamous cell carcinoma, and skin cancer yielded no reported cases of MAC associated with POT1 mutations. POT1 is one of 6 proteins (TERF1, TERF2, RAP1, TIN2, TPP1, and POT1) belonging to the shelterin complex, which plays a crucial role in telomeric DNA remodeling and regulation of telomere length.5 Mutation in the POT1 gene disrupts the shelterin complex, causing telomeres to become elongated and unstable, resulting in chromosomal abnormalities and promoting cancer development.5

While our literature review did not reveal any associations between the shelterin complex genes and MAC, mutations in the POT1 gene have been studied in other types of skin cancer, particularly melanoma.1 One of the earliest studies was conducted in 2014 by Shi et al,6 in which whole-exome sequencing was performed on families with a history of melanoma. Multiple POT1 gene pathogenic variants associated with increased telomere length and fragility were identified in unrelated families. Subsequent studies have confirmed POT1 variants in melanoma-prone families,7 supporting an association between increased telomere length and melanoma risk8-11; however, other studies have yielded nonsignificant findings.12,13 Further investigation also has identified morphologic characteristics consistent with POT1 mutation, including spitzoid morphology.14
The association between POT1 mutations and nonmelanoma skin cancers has been relatively understudied. While a few studies have explored this link, results have shown mixed findings. Some studies have suggested a potential role for POT1 mutations in cutaneous SCC risk,15 while other studies have shown no significant associations for both BCC and SCC risk and telomere gene mutations.16 Additionally, mRNA levels of POT1 were upregulated in BCC cases compared to normal tissue in a gene expression.17
Comment
In the literature, POT1 mutations are well established as high-penetrance alterations associated with melanoma.9,18,19 However, the correlation between POT1 and other forms of skin cancer is not yet delineated. Recent insights suggest that POT1 mutations play a major role in promoting melanoma progression through telomere elongation, an established driver of melanoma progression, thereby extending the proliferative capacity of incipient cancer cells.20 This notion is supported by observations of increased telomere length in melanomaprone families with POT1 mutations. Given this association, research has focused on examining the relationship between telomere length and skin cancer.
Several studies have examined the relationship between telomere length and the risk for various types of skin cancer, including melanoma, BCC, and SCC. Prior investigations have suggested that shorter telomere length is associated with a decreased risk for melanoma and an increased risk for BCC, while no significant association has been observed for SCC.16 However, subsequent reports analyzing POT1 variants have failed to reveal any conclusive associations between BCC and SCC and telomere length.16,21
In contrast, other genetic variants associated with melanoma susceptibility have demonstrated notable associations with BCC and SCC; for instance, the CDKN2A (cyclin-dependent kinase inhibitor 2A) gene, which is the first gene linked to high-risk familial melanoma, exhibits an increased presence of mutations in individuals with BCC and SCC.22 Similarly, the MC1R (melanocortin 1 receptor) variant, a gene involved in human pigmentation and known to increase the risk for melanoma, carries a statistically significantly higher risk for BCC (summary odds ratio, 1.39; 95% CI, 1.15-1.69) and SCC (summary odds ratio, 1.61; 95% CI, 1.35-1.91) when at least one variant is present and an even greater risk with 2 or more variants.23
Considering the potential importance of POT1 mutations and their association with melanoma, as well as the inconsistencies surrounding POT1 mutations and their associations with BCC and SCC, further research may clarify the impact of POT1 mutations on the development and progression of different types of skin cancers and improve understanding of the complex interplay among telomere length, genetic variants, and skin cancer susceptibility. Given the established risk for melanoma with POT1 mutations, regular dermatology surveillance seems prudent. Dermatologists should consider referring patients with multiple skin cancers (especially melanoma) and any strong family history of internal malignancies to genetic testing for POT1. Though melanoma, CLL, angiosarcoma, and gliomas are the most commonly associated malignancies with POT1 mutations, as our case demonstrates, presentations can be heterogeneous, and the spectrum of malignancies associated with POT1 may be more expansive than previously thought.
For our patient, the current surveillance plan is fullbody skin examinations every 3 months. Given no prior family history of malignancies, presumably our patient’s case was a spontaneous mutation. Interestingly, despite his many primary cancer diagnoses and metastases, our patient has responded well to all treatments without recurrence. It is unclear if these characteristics and treatment successes are features of POT1associated cancers. Further research is needed to refine recommendations for screening and management of patients with identified POT1 mutations.
Conclusion
This case report highlights a rare occurrence of MAC in a patient with a POT1 mutation. Given the limited research conducted on investigating POT1 mutations and skin cancer, it is important to consider various forms of skin cancer, in addition to melanoma, when treating patients with a POT1 mutation.
- Accardo ML, Osborne J, Else T. POT1 tumor predisposition. GeneReviews®. October 29, 2020. Updated December 4, 2025. University of Washington.
- Chaichamnan K, Satayasoontorn K, Puttanupaab S, et al. Malignant proliferating trichilemmal tumors with CD34 expression. J Med Assoc Thai. 2010;93(suppl 6):S28-S34.
- Kavand S, Cassarino DS. “Squamoid eccrine ductal carcinoma”: an unusual low-grade case with follicular differentiation. are these tumors squamoid variants of microcystic adnexal carcinoma? Am J Dermatopathol. 2009;31:849-852.
- Kaseb H, Babiker HM. Eccrine carcinoma. StatPearls [Internet]. Updated June 26, 2023. Accessed May 11, 2026. https://www.ncbi.nlm.nih.gov/books/NBK541042
- Ye JZ, Hockemeyer D, Krutchinsky AN, et al. POT1-interacting protein PIP1: a telomere length regulator that recruits POT1 to the TIN2/TRF1 complex. Genes Dev. 2004;18:1649-1654. doi:10.1101/gad.1215404
- Shi J, Yang XR, Ballew B, et al. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet. 2014;46:482-486. doi:10.1038/ng.2941
- Wilson TL, Hattangady N, Lerario AM, et al. A new POT1 germline mutation-expanding the spectrum of POT1-associated cancers. Fam Cancer. 2017;16:561-566. doi:10.1007/s10689-017-9984-y
- Müller C, Krunic M, Wendt J, et al. Germline variants in the POT1- gene in high-risk melanoma patients in Austria. G3 (Bethesda). 2018;8:1475-1480. doi:10.1534/g3.117.300394
- Robles-Espinoza CD, Harland M, Ramsay AJ, et al. POT1 loss-offunction variants predispose to familial melanoma. Nat Genet. 2014;46:478-481. doi:10.1038/ng.2947
- Wong K, Robles-Espinoza CD, Rodriguez D, et al. Association of the POT1 germline missense variant p.I78T with familial melanoma. JAMA Dermatol. 2019;155:604-609. doi:10.1001/jamadermatol.2018.3662
- Simonin-Wilmer I, Ossio R, Leddin EM, et al. Population-based analysis of POT1 variants in a cutaneous melanoma case-control cohort. J Med Genet. 2023;60:692-696. doi:10.1136/jmg-2022-108776
- Potjer TP, Bollen S, Grimbergen AJEM, et al; Dutch Working Group for Clinical Oncogenetics. Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families. Int J Cancer. 2019;144:2453- 2464. doi:10.1002/ijc.31984
- Pellegrini C, Raimondi S, Di Nardo L, et al; Italian Melanoma Intergroup (IMI). Melanoma in children and adolescents: analysis of susceptibility genes in 123 Italian patients. J Eur Acad Dermatol Venereol. 2022;36:213-221. doi:10.1111/jdv.17735
- Sargen MR, Calista D, Elder DE, et al. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain. J Am Acad Dermatol. 2020;83:860-869. doi:10.1016/j.jaad.2020.03.100
- Shen E, Xiu J, Lopez GY, et al. POT1 mutation spectrum in tumour types commonly diagnosed among POT1-associated hereditary cancer syndrome families. J Med Genet. 2020;57:664-670. doi:10.1136 /jmedgenet-2019-106657
- Nan H, Qureshi AA, Prescott J, et al. Genetic variants in telomere-maintaining genes and skin cancer risk. Hum Genet. 2011;129:247-253. doi:10.1007/s00439-010-0921-5
- Zhang L, Huang X, Zhu X, et al. Differential senescence capacities in meibomian gland carcinoma and basal cell carcinoma. Int J Cancer. 2016;138:1442-1452. doi:10.1002/ijc.29882
- Pastorino L, Andreotti V, Dalmasso B, et al. Insights into genetic susceptibility to melanoma by gene panel testing: potential pathogenic variants in ACD, ATM, BAP1, and POT1. Cancers (Basel). 2020;12:1007. doi:10.3390/cancers12041007
- Potrony M, Puig-Butille JA, Ribera-Sola M, et al. POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families. Br J Dermatol. 2019;181:105-113. doi:10.1111/bjd.17443
- Kim WT, Hennick K, Johnson J, et al. Cancer-associated POT1 mutations lead to telomere elongation without induction of a DNA damage response. EMBO J. 2021;40:e107346.
- Ventura A, Pellegrini C, Cardelli L, et al. Telomeres and telomerase in cutaneous squamous cell carcinoma. Int J Mol Sci. 2019;20:1333. doi:10.3390/ijms20061333
- Helgadottir H, Höiom V, Jönsson G, et al. High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J Med Genet. 2014;51:545-552. doi:10.1136/jmedgenet-2014-102320
- Tagliabue E, Fargnoli MC, Gandini S, et al; M-SKIP Study Group. MC1R gene variants and non-melanoma skin cancer: a pooledanalysis from the M-SKIP project. Br J Cancer. 2015;113:354-363. doi:10.1038/bjc.2015.231
- Accardo ML, Osborne J, Else T. POT1 tumor predisposition. GeneReviews®. October 29, 2020. Updated December 4, 2025. University of Washington.
- Chaichamnan K, Satayasoontorn K, Puttanupaab S, et al. Malignant proliferating trichilemmal tumors with CD34 expression. J Med Assoc Thai. 2010;93(suppl 6):S28-S34.
- Kavand S, Cassarino DS. “Squamoid eccrine ductal carcinoma”: an unusual low-grade case with follicular differentiation. are these tumors squamoid variants of microcystic adnexal carcinoma? Am J Dermatopathol. 2009;31:849-852.
- Kaseb H, Babiker HM. Eccrine carcinoma. StatPearls [Internet]. Updated June 26, 2023. Accessed May 11, 2026. https://www.ncbi.nlm.nih.gov/books/NBK541042
- Ye JZ, Hockemeyer D, Krutchinsky AN, et al. POT1-interacting protein PIP1: a telomere length regulator that recruits POT1 to the TIN2/TRF1 complex. Genes Dev. 2004;18:1649-1654. doi:10.1101/gad.1215404
- Shi J, Yang XR, Ballew B, et al. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet. 2014;46:482-486. doi:10.1038/ng.2941
- Wilson TL, Hattangady N, Lerario AM, et al. A new POT1 germline mutation-expanding the spectrum of POT1-associated cancers. Fam Cancer. 2017;16:561-566. doi:10.1007/s10689-017-9984-y
- Müller C, Krunic M, Wendt J, et al. Germline variants in the POT1- gene in high-risk melanoma patients in Austria. G3 (Bethesda). 2018;8:1475-1480. doi:10.1534/g3.117.300394
- Robles-Espinoza CD, Harland M, Ramsay AJ, et al. POT1 loss-offunction variants predispose to familial melanoma. Nat Genet. 2014;46:478-481. doi:10.1038/ng.2947
- Wong K, Robles-Espinoza CD, Rodriguez D, et al. Association of the POT1 germline missense variant p.I78T with familial melanoma. JAMA Dermatol. 2019;155:604-609. doi:10.1001/jamadermatol.2018.3662
- Simonin-Wilmer I, Ossio R, Leddin EM, et al. Population-based analysis of POT1 variants in a cutaneous melanoma case-control cohort. J Med Genet. 2023;60:692-696. doi:10.1136/jmg-2022-108776
- Potjer TP, Bollen S, Grimbergen AJEM, et al; Dutch Working Group for Clinical Oncogenetics. Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families. Int J Cancer. 2019;144:2453- 2464. doi:10.1002/ijc.31984
- Pellegrini C, Raimondi S, Di Nardo L, et al; Italian Melanoma Intergroup (IMI). Melanoma in children and adolescents: analysis of susceptibility genes in 123 Italian patients. J Eur Acad Dermatol Venereol. 2022;36:213-221. doi:10.1111/jdv.17735
- Sargen MR, Calista D, Elder DE, et al. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain. J Am Acad Dermatol. 2020;83:860-869. doi:10.1016/j.jaad.2020.03.100
- Shen E, Xiu J, Lopez GY, et al. POT1 mutation spectrum in tumour types commonly diagnosed among POT1-associated hereditary cancer syndrome families. J Med Genet. 2020;57:664-670. doi:10.1136 /jmedgenet-2019-106657
- Nan H, Qureshi AA, Prescott J, et al. Genetic variants in telomere-maintaining genes and skin cancer risk. Hum Genet. 2011;129:247-253. doi:10.1007/s00439-010-0921-5
- Zhang L, Huang X, Zhu X, et al. Differential senescence capacities in meibomian gland carcinoma and basal cell carcinoma. Int J Cancer. 2016;138:1442-1452. doi:10.1002/ijc.29882
- Pastorino L, Andreotti V, Dalmasso B, et al. Insights into genetic susceptibility to melanoma by gene panel testing: potential pathogenic variants in ACD, ATM, BAP1, and POT1. Cancers (Basel). 2020;12:1007. doi:10.3390/cancers12041007
- Potrony M, Puig-Butille JA, Ribera-Sola M, et al. POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families. Br J Dermatol. 2019;181:105-113. doi:10.1111/bjd.17443
- Kim WT, Hennick K, Johnson J, et al. Cancer-associated POT1 mutations lead to telomere elongation without induction of a DNA damage response. EMBO J. 2021;40:e107346.
- Ventura A, Pellegrini C, Cardelli L, et al. Telomeres and telomerase in cutaneous squamous cell carcinoma. Int J Mol Sci. 2019;20:1333. doi:10.3390/ijms20061333
- Helgadottir H, Höiom V, Jönsson G, et al. High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J Med Genet. 2014;51:545-552. doi:10.1136/jmedgenet-2014-102320
- Tagliabue E, Fargnoli MC, Gandini S, et al; M-SKIP Study Group. MC1R gene variants and non-melanoma skin cancer: a pooledanalysis from the M-SKIP project. Br J Cancer. 2015;113:354-363. doi:10.1038/bjc.2015.231
Microcystic Adnexal Carcinoma– like Neoplasm in a Patient With POT1 Mutation
Microcystic Adnexal Carcinoma– like Neoplasm in a Patient With POT1 Mutation
PRACTICE POINTS
- Dermatologists should consider referring patients with both a history of skin cancer and a strong family history of internal malignancy for genetic testing for POT1 (protection of telomeres 1) mutations.
- Although melanoma, chronic lymphocytic leukemia, angiosarcoma, and gliomas are most commonly associated with POT1 mutations, this case suggests a broader and more heterogeneous malignancy spectrum than previously recognized.
Ulcerated Lesions on the Right Leg
Ulcerated Lesions on the Right Leg
THE DIAGNOSIS: Mycobacteria infection
Despite the initial biopsy for tissue culture showing no growth, a subsequent biopsy performed 1 month later yielded a positive result. Mycobacterium marinum was identified through organism genome sequencing. The patient was further treated by infectious disease with clarithromycin and ethambutol, with complete resolution of the lesions.
Although initial staining with acid-fast bacilli and tissue culture were negative, we suspected a diagnosis of mycobacterial infection with sporotrichoid spread of multiple nodular and ulcerated lesions that was unresponsive to antibiotics. Performing a tissue culture is crucial for diagnosing mycobacterial skin and soft-tissue infections, as an acid-fast bacilli stain alone cannot distinguish between different mycobacterial species. Lowenstein-Jensen agar is a selective medium specifically used for the culture and isolation of Mycobacterium species. The strict temperature requirement of 30 °C to 32 °C (86-89.6 °F) for the growth of this organism suggests that the infection predominantly affects the limbs, which tend to have a slightly lower temperature compared to the core of the body.1 In our case, the histologic findings and clinical history suggested granulomatous involvement due to fungi or mycobacteria.
Cutaneous leishmaniasis is characterized by ulcers with possible accompanying nodular lymphangitis; however, the patient did not have relevant travel history. Leishmaniasis results from a parasite transmitted by a sandfly, with most cases occurring in Afghanistan, Algeria, Brazil, Iran, Pakistan, Peru, Saudi Arabia, and Syria.2
Ecthyma gangrenosum is characterized by tender necrotic plaques seen predominantly in immunocompromised patients and is associated with Pseudomonas aeruginosa bacteremia.3 Our patient had lesions present for a duration of 5 months, which is inconsistent with the more rapidly progressing course of ecthyma gangrenosum.
Leukocytoclastic vasculitis may manifest with palpable purpura of the lower extremities. An infectious trigger, such as Mycobacterium, may lead to a leukocytoclastic vasculitis. The histopathologic findings classically demonstrate neutrophil deposition in vessel walls, deposition of fibrin in the vessel lumen, and nuclear debris.4
Despite the presence of granulomatous changes in our patient, the presentation of ulcerated nodules in a sporotrichoid pattern on one extremity suggests a diagnosis of infectious etiology rather than sarcoidosis.
- Gonçalves IC, Furtado I, Gonçalves MJ, et al. Mycobacterium marinum cutaneous infection: a series of three cases and literature review. Cureus. 2022;14:E31787. doi:10.7759/cureus.31787
- de Vries HJC, Schallig HD. Cutaneous leishmaniasis: a 2022 updated narrative review into diagnosis and management developments. Am J Clin Dermatol. 2022;23:823-840. doi:10.1007 /s40257-022-00726-8
- Vaiman M, Lazarovitch T, Heller L, et al. Ecthyma gangrenosum and ecthyma-like lesions: review article. Eur J Clin Microbiol Infect Dis. 2015;34:633-639.
- Baigrie D, Goyal A, Crane JS. Leukocytoclastic vasculitis. StatPearls [Internet]. Updated August 8, 2023. Accessed May 11, 2026. https://www.ncbi.nlm.nih.gov/books/NBK482159/
THE DIAGNOSIS: Mycobacteria infection
Despite the initial biopsy for tissue culture showing no growth, a subsequent biopsy performed 1 month later yielded a positive result. Mycobacterium marinum was identified through organism genome sequencing. The patient was further treated by infectious disease with clarithromycin and ethambutol, with complete resolution of the lesions.
Although initial staining with acid-fast bacilli and tissue culture were negative, we suspected a diagnosis of mycobacterial infection with sporotrichoid spread of multiple nodular and ulcerated lesions that was unresponsive to antibiotics. Performing a tissue culture is crucial for diagnosing mycobacterial skin and soft-tissue infections, as an acid-fast bacilli stain alone cannot distinguish between different mycobacterial species. Lowenstein-Jensen agar is a selective medium specifically used for the culture and isolation of Mycobacterium species. The strict temperature requirement of 30 °C to 32 °C (86-89.6 °F) for the growth of this organism suggests that the infection predominantly affects the limbs, which tend to have a slightly lower temperature compared to the core of the body.1 In our case, the histologic findings and clinical history suggested granulomatous involvement due to fungi or mycobacteria.
Cutaneous leishmaniasis is characterized by ulcers with possible accompanying nodular lymphangitis; however, the patient did not have relevant travel history. Leishmaniasis results from a parasite transmitted by a sandfly, with most cases occurring in Afghanistan, Algeria, Brazil, Iran, Pakistan, Peru, Saudi Arabia, and Syria.2
Ecthyma gangrenosum is characterized by tender necrotic plaques seen predominantly in immunocompromised patients and is associated with Pseudomonas aeruginosa bacteremia.3 Our patient had lesions present for a duration of 5 months, which is inconsistent with the more rapidly progressing course of ecthyma gangrenosum.
Leukocytoclastic vasculitis may manifest with palpable purpura of the lower extremities. An infectious trigger, such as Mycobacterium, may lead to a leukocytoclastic vasculitis. The histopathologic findings classically demonstrate neutrophil deposition in vessel walls, deposition of fibrin in the vessel lumen, and nuclear debris.4
Despite the presence of granulomatous changes in our patient, the presentation of ulcerated nodules in a sporotrichoid pattern on one extremity suggests a diagnosis of infectious etiology rather than sarcoidosis.
THE DIAGNOSIS: Mycobacteria infection
Despite the initial biopsy for tissue culture showing no growth, a subsequent biopsy performed 1 month later yielded a positive result. Mycobacterium marinum was identified through organism genome sequencing. The patient was further treated by infectious disease with clarithromycin and ethambutol, with complete resolution of the lesions.
Although initial staining with acid-fast bacilli and tissue culture were negative, we suspected a diagnosis of mycobacterial infection with sporotrichoid spread of multiple nodular and ulcerated lesions that was unresponsive to antibiotics. Performing a tissue culture is crucial for diagnosing mycobacterial skin and soft-tissue infections, as an acid-fast bacilli stain alone cannot distinguish between different mycobacterial species. Lowenstein-Jensen agar is a selective medium specifically used for the culture and isolation of Mycobacterium species. The strict temperature requirement of 30 °C to 32 °C (86-89.6 °F) for the growth of this organism suggests that the infection predominantly affects the limbs, which tend to have a slightly lower temperature compared to the core of the body.1 In our case, the histologic findings and clinical history suggested granulomatous involvement due to fungi or mycobacteria.
Cutaneous leishmaniasis is characterized by ulcers with possible accompanying nodular lymphangitis; however, the patient did not have relevant travel history. Leishmaniasis results from a parasite transmitted by a sandfly, with most cases occurring in Afghanistan, Algeria, Brazil, Iran, Pakistan, Peru, Saudi Arabia, and Syria.2
Ecthyma gangrenosum is characterized by tender necrotic plaques seen predominantly in immunocompromised patients and is associated with Pseudomonas aeruginosa bacteremia.3 Our patient had lesions present for a duration of 5 months, which is inconsistent with the more rapidly progressing course of ecthyma gangrenosum.
Leukocytoclastic vasculitis may manifest with palpable purpura of the lower extremities. An infectious trigger, such as Mycobacterium, may lead to a leukocytoclastic vasculitis. The histopathologic findings classically demonstrate neutrophil deposition in vessel walls, deposition of fibrin in the vessel lumen, and nuclear debris.4
Despite the presence of granulomatous changes in our patient, the presentation of ulcerated nodules in a sporotrichoid pattern on one extremity suggests a diagnosis of infectious etiology rather than sarcoidosis.
- Gonçalves IC, Furtado I, Gonçalves MJ, et al. Mycobacterium marinum cutaneous infection: a series of three cases and literature review. Cureus. 2022;14:E31787. doi:10.7759/cureus.31787
- de Vries HJC, Schallig HD. Cutaneous leishmaniasis: a 2022 updated narrative review into diagnosis and management developments. Am J Clin Dermatol. 2022;23:823-840. doi:10.1007 /s40257-022-00726-8
- Vaiman M, Lazarovitch T, Heller L, et al. Ecthyma gangrenosum and ecthyma-like lesions: review article. Eur J Clin Microbiol Infect Dis. 2015;34:633-639.
- Baigrie D, Goyal A, Crane JS. Leukocytoclastic vasculitis. StatPearls [Internet]. Updated August 8, 2023. Accessed May 11, 2026. https://www.ncbi.nlm.nih.gov/books/NBK482159/
- Gonçalves IC, Furtado I, Gonçalves MJ, et al. Mycobacterium marinum cutaneous infection: a series of three cases and literature review. Cureus. 2022;14:E31787. doi:10.7759/cureus.31787
- de Vries HJC, Schallig HD. Cutaneous leishmaniasis: a 2022 updated narrative review into diagnosis and management developments. Am J Clin Dermatol. 2022;23:823-840. doi:10.1007 /s40257-022-00726-8
- Vaiman M, Lazarovitch T, Heller L, et al. Ecthyma gangrenosum and ecthyma-like lesions: review article. Eur J Clin Microbiol Infect Dis. 2015;34:633-639.
- Baigrie D, Goyal A, Crane JS. Leukocytoclastic vasculitis. StatPearls [Internet]. Updated August 8, 2023. Accessed May 11, 2026. https://www.ncbi.nlm.nih.gov/books/NBK482159/
Ulcerated Lesions on the Right Leg
Ulcerated Lesions on the Right Leg
A 78-year-old man was referred to our dermatology clinic for evaluation of nontender erythematous plaques and nodules with central ulceration on the right leg of 5 months’ duration. The patient’s medical history was remarkable for hyperlipidemia, gastroesophageal reflux disease, prostate cancer, and colon cancer status post resection. He denied any relevant travel history but noted that he was an avid hiker and suspected he may have obtained a puncture wound from a bush or a mosquito bite prior to the appearance of the lesions. Previous therapies prescribed by outside physicians and our practice included trimethoprim/sulfamethoxazole, ceftriaxone, levofloxacin, mupirocin, and topical corticosteroids, all with minimal benefit. Clinical examination on initial presentation revealed multiple ulcerations of the lower extremities present for more than 2 months. Punch biopsy of a sample lesion at the current presentation revealed granulomatous change, focal necrosis, and a mixed inflammatory cell infiltrate. Grocott-Gomori methenamine silver and periodic acid–Schiff stains were negative for fungal organisms. The initial acid-fast bacilli stain was negative for mycobacteria, and tissue culture showed no growth.

Multiple Grouped Erythematous to Violaceous Preauricular Papules
Multiple Grouped Erythematous to Violaceous Preauricular Papules
THE DIAGNOSIS: Angiolymphoid Hyperplasia With Eosinophilia
Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare, benign, inflammatory vascular proliferation with lymphocytic and eosinophilic infiltration. Bleeding and pruritus associated with ALHE can substantially affect a patient’s quality of life, necessitating correct diagnosis and effective treatment.1 The etiopathogenesis of ALHE is poorly understood, and it often is attributed to an underlying vascular malformation or local trauma. Vascular proliferation due to hyperestrogenemia could explain why pregnancy is considered a predisposing factor for ALHE.1,2
Angiolymphoid hyperplasia with eosinophilia typically manifests with solitary or multiple pink to red-brown, dome-shaped papules or nodules occurring most frequently on the head and neck. Lesions may be either asymptomatic or associated with pruritus, pain, and spontaneous bleeding.1 Dermoscopy is crucial to diagnosis. The most frequent dermoscopic findings include a polymorphic vascular pattern such as dotted and linear irregular vessels over a pink background, white lines, white dots, white structureless areas, and red-purple lacunae.2,3 Histopathology will demonstrate a vascular proliferation with plump epithelioid endothelial cells showing abundant eosinophilic cytoplasm, accompanied by a variable lymphocytic and eosinophilic inflammatory infiltrate (Figure 1).1
In our case, dermoscopic-histopathologic correlation suggested that the polymorphic vascular pattern and clods on a pink background corresponded to thin- and thick-walled vessels containing plump endothelial cells and intraluminal erythrocytes within the superficial and deep dermis. White structures could represent underlying fibrosis and altered dermal collagen due to vascular proliferation. The brown pigment network and peripheral brownish pigmentation were most likely secondary to increased melanin and accentuation of the pigment network in the setting of Fitzpatrick skin types IV to V, although pruritic trauma with postinflammatory hyperpigmentation may also have contributed, making dermoscopic-histopathologic correlation challenging.
Surgical excision is considered the primary treatment modality for ALHE, with the lowest recurrence rates.1 Alternative therapeutic options include intralesional steroids, cryotherapy, sclerotherapy, radiofrequency, pulsed dye laser, and carbon dioxide laser, with varying efficacy reported.1 Our patient was treated with a combination of a long-pulse Nd:YAG laser (pulse width of 30 ms) to target the vascular component, followed by a single session with an ablative Er:YAG laser. After 4 weeks, healing with good cosmetic results was observed (Figure 2). At 6-month follow-up, there was no recurrence of the lesions.
Kimura disease, often considered the closest differential diagnosis for ALHE, is a rare lymphoproliferative fibroinflammatory condition. Patients present with subcutaneous nodules on the head and neck, often associated with lymphadenopathy. Elevated serum IgE levels and peripheral blood eosinophilia are common.1 Another consideration in the differential diagnosis is cutaneous bacillary angiomatosis caused by Bartonella species, a vascular proliferative condition that mostly affects individuals with HIV, transplant recipients, and those taking immunosuppressive medications.4 Pyogenic granuloma, also known as lobular capillary haemangioma, is another benign vascular proliferation that resembles ALHE. Clinically, it manifests as a solitary, painless, flesh-colored to erythematous papulonodule; however, multiple grouped lesions also can occur. The lesions often are associated with bleeding and erosions.5 Epithelioid hemangioendothelioma is a rare vascular tumor most frequently manifesting in the liver, lungs, or bones, and very rarely is limited to skin. Cutaneous epithelioid hemangioendothelioma mimics ALHE and may manifest as a solitary erythematous mass, multiple dome-shaped masses, or dermal nodules.6
- Brahs A, Sledge B, Mullen H, et al. Angiolymphoid hyperplasia with eosinophilia: many syllables, many unanswered questions. J Clin Aesthet Dermatol. 2021;14:49-54.
- Kalantri M, Khopkar U. Spectrum of dermoscopic pattern in a patient with angiolymphoid hyperplasia with tissue eosinophilia. Indian J Dermatol. 2020;65:556-558.
- Chauhan P, Vinay K, Jindal R, et al. Dermoscopic characterisation of angiolymphoid hyperplasia in skin of colour: a case series of six patients with review of literature. Indian J Dermatol Venereol Leprol. 2024;90:848.
- Ramírez Ramírez CR, Saavedra S, Ramírez Ronda CH. Bacillary angiomatosis: microbiology, histopathology, clinical presentation, diagnosis and management. Bol Asoc Med PR. 1996;88:46-51.
- Leung AKC, Barankin B, Hon KL. Pyogenic granuloma. Clinics Mother Child Health. 2014;11:E106. doi:10.4172/2090-7214.1000e106
- Kumar V, Kachhawa D, Rekha S, et al. Cutaneous epithelioid hemangioendothelioma: a rare presentation. Indian J Dermatol Venereol Leprol. 2018;84:739-742.
THE DIAGNOSIS: Angiolymphoid Hyperplasia With Eosinophilia
Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare, benign, inflammatory vascular proliferation with lymphocytic and eosinophilic infiltration. Bleeding and pruritus associated with ALHE can substantially affect a patient’s quality of life, necessitating correct diagnosis and effective treatment.1 The etiopathogenesis of ALHE is poorly understood, and it often is attributed to an underlying vascular malformation or local trauma. Vascular proliferation due to hyperestrogenemia could explain why pregnancy is considered a predisposing factor for ALHE.1,2
Angiolymphoid hyperplasia with eosinophilia typically manifests with solitary or multiple pink to red-brown, dome-shaped papules or nodules occurring most frequently on the head and neck. Lesions may be either asymptomatic or associated with pruritus, pain, and spontaneous bleeding.1 Dermoscopy is crucial to diagnosis. The most frequent dermoscopic findings include a polymorphic vascular pattern such as dotted and linear irregular vessels over a pink background, white lines, white dots, white structureless areas, and red-purple lacunae.2,3 Histopathology will demonstrate a vascular proliferation with plump epithelioid endothelial cells showing abundant eosinophilic cytoplasm, accompanied by a variable lymphocytic and eosinophilic inflammatory infiltrate (Figure 1).1
In our case, dermoscopic-histopathologic correlation suggested that the polymorphic vascular pattern and clods on a pink background corresponded to thin- and thick-walled vessels containing plump endothelial cells and intraluminal erythrocytes within the superficial and deep dermis. White structures could represent underlying fibrosis and altered dermal collagen due to vascular proliferation. The brown pigment network and peripheral brownish pigmentation were most likely secondary to increased melanin and accentuation of the pigment network in the setting of Fitzpatrick skin types IV to V, although pruritic trauma with postinflammatory hyperpigmentation may also have contributed, making dermoscopic-histopathologic correlation challenging.
Surgical excision is considered the primary treatment modality for ALHE, with the lowest recurrence rates.1 Alternative therapeutic options include intralesional steroids, cryotherapy, sclerotherapy, radiofrequency, pulsed dye laser, and carbon dioxide laser, with varying efficacy reported.1 Our patient was treated with a combination of a long-pulse Nd:YAG laser (pulse width of 30 ms) to target the vascular component, followed by a single session with an ablative Er:YAG laser. After 4 weeks, healing with good cosmetic results was observed (Figure 2). At 6-month follow-up, there was no recurrence of the lesions.
Kimura disease, often considered the closest differential diagnosis for ALHE, is a rare lymphoproliferative fibroinflammatory condition. Patients present with subcutaneous nodules on the head and neck, often associated with lymphadenopathy. Elevated serum IgE levels and peripheral blood eosinophilia are common.1 Another consideration in the differential diagnosis is cutaneous bacillary angiomatosis caused by Bartonella species, a vascular proliferative condition that mostly affects individuals with HIV, transplant recipients, and those taking immunosuppressive medications.4 Pyogenic granuloma, also known as lobular capillary haemangioma, is another benign vascular proliferation that resembles ALHE. Clinically, it manifests as a solitary, painless, flesh-colored to erythematous papulonodule; however, multiple grouped lesions also can occur. The lesions often are associated with bleeding and erosions.5 Epithelioid hemangioendothelioma is a rare vascular tumor most frequently manifesting in the liver, lungs, or bones, and very rarely is limited to skin. Cutaneous epithelioid hemangioendothelioma mimics ALHE and may manifest as a solitary erythematous mass, multiple dome-shaped masses, or dermal nodules.6
THE DIAGNOSIS: Angiolymphoid Hyperplasia With Eosinophilia
Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare, benign, inflammatory vascular proliferation with lymphocytic and eosinophilic infiltration. Bleeding and pruritus associated with ALHE can substantially affect a patient’s quality of life, necessitating correct diagnosis and effective treatment.1 The etiopathogenesis of ALHE is poorly understood, and it often is attributed to an underlying vascular malformation or local trauma. Vascular proliferation due to hyperestrogenemia could explain why pregnancy is considered a predisposing factor for ALHE.1,2
Angiolymphoid hyperplasia with eosinophilia typically manifests with solitary or multiple pink to red-brown, dome-shaped papules or nodules occurring most frequently on the head and neck. Lesions may be either asymptomatic or associated with pruritus, pain, and spontaneous bleeding.1 Dermoscopy is crucial to diagnosis. The most frequent dermoscopic findings include a polymorphic vascular pattern such as dotted and linear irregular vessels over a pink background, white lines, white dots, white structureless areas, and red-purple lacunae.2,3 Histopathology will demonstrate a vascular proliferation with plump epithelioid endothelial cells showing abundant eosinophilic cytoplasm, accompanied by a variable lymphocytic and eosinophilic inflammatory infiltrate (Figure 1).1
In our case, dermoscopic-histopathologic correlation suggested that the polymorphic vascular pattern and clods on a pink background corresponded to thin- and thick-walled vessels containing plump endothelial cells and intraluminal erythrocytes within the superficial and deep dermis. White structures could represent underlying fibrosis and altered dermal collagen due to vascular proliferation. The brown pigment network and peripheral brownish pigmentation were most likely secondary to increased melanin and accentuation of the pigment network in the setting of Fitzpatrick skin types IV to V, although pruritic trauma with postinflammatory hyperpigmentation may also have contributed, making dermoscopic-histopathologic correlation challenging.
Surgical excision is considered the primary treatment modality for ALHE, with the lowest recurrence rates.1 Alternative therapeutic options include intralesional steroids, cryotherapy, sclerotherapy, radiofrequency, pulsed dye laser, and carbon dioxide laser, with varying efficacy reported.1 Our patient was treated with a combination of a long-pulse Nd:YAG laser (pulse width of 30 ms) to target the vascular component, followed by a single session with an ablative Er:YAG laser. After 4 weeks, healing with good cosmetic results was observed (Figure 2). At 6-month follow-up, there was no recurrence of the lesions.
Kimura disease, often considered the closest differential diagnosis for ALHE, is a rare lymphoproliferative fibroinflammatory condition. Patients present with subcutaneous nodules on the head and neck, often associated with lymphadenopathy. Elevated serum IgE levels and peripheral blood eosinophilia are common.1 Another consideration in the differential diagnosis is cutaneous bacillary angiomatosis caused by Bartonella species, a vascular proliferative condition that mostly affects individuals with HIV, transplant recipients, and those taking immunosuppressive medications.4 Pyogenic granuloma, also known as lobular capillary haemangioma, is another benign vascular proliferation that resembles ALHE. Clinically, it manifests as a solitary, painless, flesh-colored to erythematous papulonodule; however, multiple grouped lesions also can occur. The lesions often are associated with bleeding and erosions.5 Epithelioid hemangioendothelioma is a rare vascular tumor most frequently manifesting in the liver, lungs, or bones, and very rarely is limited to skin. Cutaneous epithelioid hemangioendothelioma mimics ALHE and may manifest as a solitary erythematous mass, multiple dome-shaped masses, or dermal nodules.6
- Brahs A, Sledge B, Mullen H, et al. Angiolymphoid hyperplasia with eosinophilia: many syllables, many unanswered questions. J Clin Aesthet Dermatol. 2021;14:49-54.
- Kalantri M, Khopkar U. Spectrum of dermoscopic pattern in a patient with angiolymphoid hyperplasia with tissue eosinophilia. Indian J Dermatol. 2020;65:556-558.
- Chauhan P, Vinay K, Jindal R, et al. Dermoscopic characterisation of angiolymphoid hyperplasia in skin of colour: a case series of six patients with review of literature. Indian J Dermatol Venereol Leprol. 2024;90:848.
- Ramírez Ramírez CR, Saavedra S, Ramírez Ronda CH. Bacillary angiomatosis: microbiology, histopathology, clinical presentation, diagnosis and management. Bol Asoc Med PR. 1996;88:46-51.
- Leung AKC, Barankin B, Hon KL. Pyogenic granuloma. Clinics Mother Child Health. 2014;11:E106. doi:10.4172/2090-7214.1000e106
- Kumar V, Kachhawa D, Rekha S, et al. Cutaneous epithelioid hemangioendothelioma: a rare presentation. Indian J Dermatol Venereol Leprol. 2018;84:739-742.
- Brahs A, Sledge B, Mullen H, et al. Angiolymphoid hyperplasia with eosinophilia: many syllables, many unanswered questions. J Clin Aesthet Dermatol. 2021;14:49-54.
- Kalantri M, Khopkar U. Spectrum of dermoscopic pattern in a patient with angiolymphoid hyperplasia with tissue eosinophilia. Indian J Dermatol. 2020;65:556-558.
- Chauhan P, Vinay K, Jindal R, et al. Dermoscopic characterisation of angiolymphoid hyperplasia in skin of colour: a case series of six patients with review of literature. Indian J Dermatol Venereol Leprol. 2024;90:848.
- Ramírez Ramírez CR, Saavedra S, Ramírez Ronda CH. Bacillary angiomatosis: microbiology, histopathology, clinical presentation, diagnosis and management. Bol Asoc Med PR. 1996;88:46-51.
- Leung AKC, Barankin B, Hon KL. Pyogenic granuloma. Clinics Mother Child Health. 2014;11:E106. doi:10.4172/2090-7214.1000e106
- Kumar V, Kachhawa D, Rekha S, et al. Cutaneous epithelioid hemangioendothelioma: a rare presentation. Indian J Dermatol Venereol Leprol. 2018;84:739-742.
Multiple Grouped Erythematous to Violaceous Preauricular Papules
Multiple Grouped Erythematous to Violaceous Preauricular Papules
A 35-year-old woman presented with an insidious onset of multiple grouped erythematous to violaceous papules over the left preauricular area of 3 months’ duration (top quiz image). The lesions were soft, itchy, nontender, and friable and were associated with bleeding on excoriation and preauricular lymphadenopathy. Serology for HIV was nonreactive, and Gram staining revealed no bacilli. Laboratory assessment including a complete blood count, urinalysis, and liver and renal function tests was normal.
On dermoscopy (middle quiz image), multiple linear and dotted vessels (circle), reddish lacunae (clods), hemorrhagic crusting (blue arrow), white scaling (black arrow), a brown pigment network (square), white structureless areas (yellow arrow), and white lines were seen over a pale-pink background (green arrow). Scaling and crusting over some lesions, along with a peripheral rim of scaling and brownish pigmentation, also was appreciated. Histopathology revealed a proliferation of vascular channels admixed with lymphocytes, plasma cells, and eosinophils along with a proliferation of thin- and thick-walled blood vessels in the superficial as well as deep dermis (bottom quiz image).
Horse Flies: Identification, Bite Reactions, and Clinical Management
Horse Flies: Identification, Bite Reactions, and Clinical Management
Horse flies (Tabanidae) are hematophagous dipteran insects that feed on the blood of their hosts, including humans.1 Their bites can cause minor cutaneous reactions (eg, urticaria) or, rarely, severe reactions such as anaphylaxis. They also are vectors of tularemia, which may manifest with cutaneous ulcers and systemic illness. In this article, we discuss identifying features of horse flies as well as clinical manifestations from bite reactions, symptomatic and emergency management, and strategies for prevention and control.
Morphology and Geographic Distribution
Horse flies, which can grow as large as 30 mm, can be identified by their brown or black bodies and characteristic large heads and proboscises, wing venation, large calypters, pulvilliform empodium between large pulvilli, and lack of bristles on the body.2 Occasionally, their bodies may be gray, yellow, green, or blue, but this is less likely than in the other species of the Tabanidae family. Short hairs are present on the head and thorax. The eyes are large and often patterned, multicolored, and bright, though they also can exhibit shades of dark brown, gray, or black. There is variation in the appearance of male vs female horse flies: females have eyes that are widely spaced apart, while males have eyes that are closer together.2 It is important to note the difference between male and female horseflies, as hematophagy is exhibited only by females.1
Horse flies are found worldwide, with the exception of Hawaii, Greenland, and Iceland.3,4 They are especially prevalent in warm and moist regions, as these conditions are optimal for breeding.3-5 They tend to be active during the day and inactive at night due to a preference for sunlight and warmth.6 Due to this preference, horse flies’ seasonal activity depends on the climate; for many regions, activity persists from summer to early autumn.7
Clinical Manifestations and Treatment
Female horse flies use their mouthparts to pierce the host’s skin, inject saliva, and suck blood. The saliva contains anticoagulant properties. The bites are painful for the host, and various reactions can occur, including large urticarial wheals or papules at the site of the bite. Treatment for these minor cutaneous reactions is largely symptomatic. The bite site should be washed with soap and water; ice can be applied to help reduce inflammation.8 Oral antihistamines may be administered to reduce pruritus and treat urticaria. Topical steroids also can be prescribed for symptomatic relief. Acetaminophen and nonsteroidal anti-inflammatory drugs can be administered for pain control.8
While most cases of horse fly bites are minor, there have been reports of anaphylaxis.9 Horse fly bite–induced anaphylaxis can manifest as generalized itching, urticaria, and angioedema within minutes of being bitten. This may be followed by pharyngeal constriction, shortness of breath, nausea, vomiting, shivers, perspiration, and loss of consciousness.9 Anaphylaxis symptoms should be treated with immediate administration of intramuscular epinephrine.10
Pathogen Transmission, Prevention, and Control
Although horse flies have been found to carry numerous viruses, bacteria, and protozoa that affect other mammals, there is not enough evidence to suggest that they are vectors of transmission for humans for most diseases.11,12 In particular, West Nile virus and Borrelia burgdorferi both have been found in horse flies, but there are no reports of transmission of these diseases to humans through their bites.12
Horse flies, their close cousins deer flies (specifically Chrysops discalis), and ticks are known vectors of Francisella tularensis.13 These bacteria cause tularemia, which can manifest with symptoms such as fever, headache, and malaise. Ulceroglandular tularemia is the most common manifestation, in which the patient develops a cutaneous ulceration at the site of the horse fly bite and exhibits associated tender regional lymphadenopathy.14 Exudative conjunctivitis, exudative pharyngitis, abdominal pain, diarrhea, vomiting, and severe bilateral pneumonia also are common symptoms. The most severe form of tularemia is systemic or typhoidal tularemia, which can manifest with fever, septic shock, and hepatosplenomegaly.14 The current treatment of choice for all forms of tularemia is intravenous gentamicin, with a recommended dosage of 5 mg/kg/d for 7 to 14 days; streptomycin is an acceptable alternative.14-16 Ciprofloxacin is used less commonly and is reserved for milder disease. Incision and drainage of the affected lymph nodes also may be necessary.14 It is important to promptly identify and treat tularemia, as the mortality rate can be as high as 50% for untreated disease, especially in patients with systemic symptoms. Even after treatment, many patients exhibit residual scarring at the site of the ulcer, as well as lung, kidney, and muscle damage.14
It is advised to avoid contact with horse flies due to the range of symptom severity caused by their bites, but avoidance and control can be difficult. Malaise traps, consisting of a tent and polyester netting, can be used to capture the insects.17 Octenol has been shown to be effective for attracting horse flies and can be applied to the trap in order to increase its effectiveness.18 A Manitoba horse fly trap is a modified version of the Malaise trap that contains a suspended dark sphere to further attract horse flies.19 Patients also should be instructed to wear long-sleeved shirts and pants when outdoors in areas with horse flies to avoid contact, and application of DEET (N,N-diethylmeta-toluamide), picaridin, citronella, or geraniol-based repellents also can be effective in reducing exposure.20
Final Thoughts
Horse flies are large, blood‑feeding dipteran insects whose bites usually produce painful local reactions. Although most bites are benign, they rarely can cause anaphylaxis, and certain Tabanidae insects can transmit Francisella tularensis; therefore, clinicians should consider the risk for tularemia infection in patients presenting with horse fly bites and start appropriate antibiotic therapy when indicated. Due to the risks, prevention of bites and reduction of contact with horse flies via protective clothing, repellents, and trapping methods is recommended. Patients should be advised on bite care and to seek urgent care for systemic symptoms or rapidly progressive local signs.
- Lucas M, Krolow TK, Riet-Correa F, et al. Diversity and seasonality of horse flies (Diptera: Tabanidae) in Uruguay. Sci Rep. 2020;10:401.
- Chainey JE. Horse‑flies, deer‑flies and clegs (Tabanidae). In: Lane RP, Crosskey RW, eds. Medical Insects and Arachnids. Springer; 1993:310‑332.
- Downes JA. The post‑glacial colonization of the North Atlantic islands. Memoirs of the Entomological Society of Canada. 1988;120(S144):55‑92.
- Squitier JM. Deer flies, yellow flies and horse flies. Featured Creatures. University of Florida; April 1, 2014. Accessed September 15, 2023.
- Middlekauff WW, Lane RS. Adult and immature Tabanidae (Diptera) of California. University of California Press. 1980:1‑2.
- Horse flies and deer flies. University of Kentucky. Accessed September 15, 2023. https://entomology.mgcafe.uky.edu/ef511
- Hoover J. Horse flies. LSU College of Agriculture. May 28, 2020. Accessed May 20, 2026. https://www.lsuagcenter.com/profiles/jhoover/articles/page1590683239678
- Powers J, Syed HA, McDowell RH. Insect bites. StatPearls [Internet]. Updated February 15, 2026. Accessed May 12, 2026. https://www.ncbi.nlm.nih.gov/books/NBK537235/
- Hemmer W, Focke M, Vieluf D, et al. Anaphylaxis induced by horsefly bites: identification of a 69 kd IgE-binding salivary gland protein from Chrysops spp. (Diptera, Tabanidae) by Western blot analysis. J Allergy Clin Immunol. 1998;101:134-136.
- McLendon K, Sternard BT. Anaphylaxis. StatPearls [Internet]. Updated January 26, 2023. Accessed May 12, 2026. https://www.ncbi.nlm.nih.gov/books/NBK482124/
- Cheng TC. General Parasitology. Elsevier Science; 2012:660.
- Purdue Medical Entomology. Horse and deer flies. Purdue University. Accessed April 28, 2026. https://extension.entm.purdue.edu/publichealth/diseases/tabanid.html
- US Geological Survey. Tularemia. USGS Publications Warehouse. Accessed April 28, 2026. https://pubs.usgs.gov/circ/1297/report.pdf
- Snowden J, Simonsen KA. Tularemia. StatPearls [Internet]. Updated July 17, 2023. Accessed May 12, 2026. https://www.ncbi.nlm.nih.gov/books/NBK430905/
- Enderlin G, Morales L, Jacobs RF, et al. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis. 1994;19:42-47.
- Balestra A, Bytyci H, Guillod C, et al. A case of ulceroglandular tularemia presenting with lymphadenopathy and an ulcer on a linear morphoea lesion surrounded by erysipelas. Int Med Case Rep J. 2018;11:313-318.
- Malaise R. A new insect‑trap. Entomologisk Tidskrift. 1937;58:148‑160.
- French F, Kline D. l-Octen-3-ol, an effective attractant for Tabanidae (Diptera). J Med Entomol. 1989;26:459-461
- Axtell RC, Edwards TD, Dukes JC. Rigid canopy trap for Tabanidae (Diptera). J Georgia Entomol Soc. 1975;10: 64-67.
- Squitier JM. Deer flies, yellow flies and horse flies. Featured Creatures. University of Florida. April 1, 2014. Accessed May 12, 2026. https://ask.ifas.ufl.edu/publication/IN155
Horse flies (Tabanidae) are hematophagous dipteran insects that feed on the blood of their hosts, including humans.1 Their bites can cause minor cutaneous reactions (eg, urticaria) or, rarely, severe reactions such as anaphylaxis. They also are vectors of tularemia, which may manifest with cutaneous ulcers and systemic illness. In this article, we discuss identifying features of horse flies as well as clinical manifestations from bite reactions, symptomatic and emergency management, and strategies for prevention and control.
Morphology and Geographic Distribution
Horse flies, which can grow as large as 30 mm, can be identified by their brown or black bodies and characteristic large heads and proboscises, wing venation, large calypters, pulvilliform empodium between large pulvilli, and lack of bristles on the body.2 Occasionally, their bodies may be gray, yellow, green, or blue, but this is less likely than in the other species of the Tabanidae family. Short hairs are present on the head and thorax. The eyes are large and often patterned, multicolored, and bright, though they also can exhibit shades of dark brown, gray, or black. There is variation in the appearance of male vs female horse flies: females have eyes that are widely spaced apart, while males have eyes that are closer together.2 It is important to note the difference between male and female horseflies, as hematophagy is exhibited only by females.1
Horse flies are found worldwide, with the exception of Hawaii, Greenland, and Iceland.3,4 They are especially prevalent in warm and moist regions, as these conditions are optimal for breeding.3-5 They tend to be active during the day and inactive at night due to a preference for sunlight and warmth.6 Due to this preference, horse flies’ seasonal activity depends on the climate; for many regions, activity persists from summer to early autumn.7
Clinical Manifestations and Treatment
Female horse flies use their mouthparts to pierce the host’s skin, inject saliva, and suck blood. The saliva contains anticoagulant properties. The bites are painful for the host, and various reactions can occur, including large urticarial wheals or papules at the site of the bite. Treatment for these minor cutaneous reactions is largely symptomatic. The bite site should be washed with soap and water; ice can be applied to help reduce inflammation.8 Oral antihistamines may be administered to reduce pruritus and treat urticaria. Topical steroids also can be prescribed for symptomatic relief. Acetaminophen and nonsteroidal anti-inflammatory drugs can be administered for pain control.8
While most cases of horse fly bites are minor, there have been reports of anaphylaxis.9 Horse fly bite–induced anaphylaxis can manifest as generalized itching, urticaria, and angioedema within minutes of being bitten. This may be followed by pharyngeal constriction, shortness of breath, nausea, vomiting, shivers, perspiration, and loss of consciousness.9 Anaphylaxis symptoms should be treated with immediate administration of intramuscular epinephrine.10
Pathogen Transmission, Prevention, and Control
Although horse flies have been found to carry numerous viruses, bacteria, and protozoa that affect other mammals, there is not enough evidence to suggest that they are vectors of transmission for humans for most diseases.11,12 In particular, West Nile virus and Borrelia burgdorferi both have been found in horse flies, but there are no reports of transmission of these diseases to humans through their bites.12
Horse flies, their close cousins deer flies (specifically Chrysops discalis), and ticks are known vectors of Francisella tularensis.13 These bacteria cause tularemia, which can manifest with symptoms such as fever, headache, and malaise. Ulceroglandular tularemia is the most common manifestation, in which the patient develops a cutaneous ulceration at the site of the horse fly bite and exhibits associated tender regional lymphadenopathy.14 Exudative conjunctivitis, exudative pharyngitis, abdominal pain, diarrhea, vomiting, and severe bilateral pneumonia also are common symptoms. The most severe form of tularemia is systemic or typhoidal tularemia, which can manifest with fever, septic shock, and hepatosplenomegaly.14 The current treatment of choice for all forms of tularemia is intravenous gentamicin, with a recommended dosage of 5 mg/kg/d for 7 to 14 days; streptomycin is an acceptable alternative.14-16 Ciprofloxacin is used less commonly and is reserved for milder disease. Incision and drainage of the affected lymph nodes also may be necessary.14 It is important to promptly identify and treat tularemia, as the mortality rate can be as high as 50% for untreated disease, especially in patients with systemic symptoms. Even after treatment, many patients exhibit residual scarring at the site of the ulcer, as well as lung, kidney, and muscle damage.14
It is advised to avoid contact with horse flies due to the range of symptom severity caused by their bites, but avoidance and control can be difficult. Malaise traps, consisting of a tent and polyester netting, can be used to capture the insects.17 Octenol has been shown to be effective for attracting horse flies and can be applied to the trap in order to increase its effectiveness.18 A Manitoba horse fly trap is a modified version of the Malaise trap that contains a suspended dark sphere to further attract horse flies.19 Patients also should be instructed to wear long-sleeved shirts and pants when outdoors in areas with horse flies to avoid contact, and application of DEET (N,N-diethylmeta-toluamide), picaridin, citronella, or geraniol-based repellents also can be effective in reducing exposure.20
Final Thoughts
Horse flies are large, blood‑feeding dipteran insects whose bites usually produce painful local reactions. Although most bites are benign, they rarely can cause anaphylaxis, and certain Tabanidae insects can transmit Francisella tularensis; therefore, clinicians should consider the risk for tularemia infection in patients presenting with horse fly bites and start appropriate antibiotic therapy when indicated. Due to the risks, prevention of bites and reduction of contact with horse flies via protective clothing, repellents, and trapping methods is recommended. Patients should be advised on bite care and to seek urgent care for systemic symptoms or rapidly progressive local signs.
Horse flies (Tabanidae) are hematophagous dipteran insects that feed on the blood of their hosts, including humans.1 Their bites can cause minor cutaneous reactions (eg, urticaria) or, rarely, severe reactions such as anaphylaxis. They also are vectors of tularemia, which may manifest with cutaneous ulcers and systemic illness. In this article, we discuss identifying features of horse flies as well as clinical manifestations from bite reactions, symptomatic and emergency management, and strategies for prevention and control.
Morphology and Geographic Distribution
Horse flies, which can grow as large as 30 mm, can be identified by their brown or black bodies and characteristic large heads and proboscises, wing venation, large calypters, pulvilliform empodium between large pulvilli, and lack of bristles on the body.2 Occasionally, their bodies may be gray, yellow, green, or blue, but this is less likely than in the other species of the Tabanidae family. Short hairs are present on the head and thorax. The eyes are large and often patterned, multicolored, and bright, though they also can exhibit shades of dark brown, gray, or black. There is variation in the appearance of male vs female horse flies: females have eyes that are widely spaced apart, while males have eyes that are closer together.2 It is important to note the difference between male and female horseflies, as hematophagy is exhibited only by females.1
Horse flies are found worldwide, with the exception of Hawaii, Greenland, and Iceland.3,4 They are especially prevalent in warm and moist regions, as these conditions are optimal for breeding.3-5 They tend to be active during the day and inactive at night due to a preference for sunlight and warmth.6 Due to this preference, horse flies’ seasonal activity depends on the climate; for many regions, activity persists from summer to early autumn.7
Clinical Manifestations and Treatment
Female horse flies use their mouthparts to pierce the host’s skin, inject saliva, and suck blood. The saliva contains anticoagulant properties. The bites are painful for the host, and various reactions can occur, including large urticarial wheals or papules at the site of the bite. Treatment for these minor cutaneous reactions is largely symptomatic. The bite site should be washed with soap and water; ice can be applied to help reduce inflammation.8 Oral antihistamines may be administered to reduce pruritus and treat urticaria. Topical steroids also can be prescribed for symptomatic relief. Acetaminophen and nonsteroidal anti-inflammatory drugs can be administered for pain control.8
While most cases of horse fly bites are minor, there have been reports of anaphylaxis.9 Horse fly bite–induced anaphylaxis can manifest as generalized itching, urticaria, and angioedema within minutes of being bitten. This may be followed by pharyngeal constriction, shortness of breath, nausea, vomiting, shivers, perspiration, and loss of consciousness.9 Anaphylaxis symptoms should be treated with immediate administration of intramuscular epinephrine.10
Pathogen Transmission, Prevention, and Control
Although horse flies have been found to carry numerous viruses, bacteria, and protozoa that affect other mammals, there is not enough evidence to suggest that they are vectors of transmission for humans for most diseases.11,12 In particular, West Nile virus and Borrelia burgdorferi both have been found in horse flies, but there are no reports of transmission of these diseases to humans through their bites.12
Horse flies, their close cousins deer flies (specifically Chrysops discalis), and ticks are known vectors of Francisella tularensis.13 These bacteria cause tularemia, which can manifest with symptoms such as fever, headache, and malaise. Ulceroglandular tularemia is the most common manifestation, in which the patient develops a cutaneous ulceration at the site of the horse fly bite and exhibits associated tender regional lymphadenopathy.14 Exudative conjunctivitis, exudative pharyngitis, abdominal pain, diarrhea, vomiting, and severe bilateral pneumonia also are common symptoms. The most severe form of tularemia is systemic or typhoidal tularemia, which can manifest with fever, septic shock, and hepatosplenomegaly.14 The current treatment of choice for all forms of tularemia is intravenous gentamicin, with a recommended dosage of 5 mg/kg/d for 7 to 14 days; streptomycin is an acceptable alternative.14-16 Ciprofloxacin is used less commonly and is reserved for milder disease. Incision and drainage of the affected lymph nodes also may be necessary.14 It is important to promptly identify and treat tularemia, as the mortality rate can be as high as 50% for untreated disease, especially in patients with systemic symptoms. Even after treatment, many patients exhibit residual scarring at the site of the ulcer, as well as lung, kidney, and muscle damage.14
It is advised to avoid contact with horse flies due to the range of symptom severity caused by their bites, but avoidance and control can be difficult. Malaise traps, consisting of a tent and polyester netting, can be used to capture the insects.17 Octenol has been shown to be effective for attracting horse flies and can be applied to the trap in order to increase its effectiveness.18 A Manitoba horse fly trap is a modified version of the Malaise trap that contains a suspended dark sphere to further attract horse flies.19 Patients also should be instructed to wear long-sleeved shirts and pants when outdoors in areas with horse flies to avoid contact, and application of DEET (N,N-diethylmeta-toluamide), picaridin, citronella, or geraniol-based repellents also can be effective in reducing exposure.20
Final Thoughts
Horse flies are large, blood‑feeding dipteran insects whose bites usually produce painful local reactions. Although most bites are benign, they rarely can cause anaphylaxis, and certain Tabanidae insects can transmit Francisella tularensis; therefore, clinicians should consider the risk for tularemia infection in patients presenting with horse fly bites and start appropriate antibiotic therapy when indicated. Due to the risks, prevention of bites and reduction of contact with horse flies via protective clothing, repellents, and trapping methods is recommended. Patients should be advised on bite care and to seek urgent care for systemic symptoms or rapidly progressive local signs.
- Lucas M, Krolow TK, Riet-Correa F, et al. Diversity and seasonality of horse flies (Diptera: Tabanidae) in Uruguay. Sci Rep. 2020;10:401.
- Chainey JE. Horse‑flies, deer‑flies and clegs (Tabanidae). In: Lane RP, Crosskey RW, eds. Medical Insects and Arachnids. Springer; 1993:310‑332.
- Downes JA. The post‑glacial colonization of the North Atlantic islands. Memoirs of the Entomological Society of Canada. 1988;120(S144):55‑92.
- Squitier JM. Deer flies, yellow flies and horse flies. Featured Creatures. University of Florida; April 1, 2014. Accessed September 15, 2023.
- Middlekauff WW, Lane RS. Adult and immature Tabanidae (Diptera) of California. University of California Press. 1980:1‑2.
- Horse flies and deer flies. University of Kentucky. Accessed September 15, 2023. https://entomology.mgcafe.uky.edu/ef511
- Hoover J. Horse flies. LSU College of Agriculture. May 28, 2020. Accessed May 20, 2026. https://www.lsuagcenter.com/profiles/jhoover/articles/page1590683239678
- Powers J, Syed HA, McDowell RH. Insect bites. StatPearls [Internet]. Updated February 15, 2026. Accessed May 12, 2026. https://www.ncbi.nlm.nih.gov/books/NBK537235/
- Hemmer W, Focke M, Vieluf D, et al. Anaphylaxis induced by horsefly bites: identification of a 69 kd IgE-binding salivary gland protein from Chrysops spp. (Diptera, Tabanidae) by Western blot analysis. J Allergy Clin Immunol. 1998;101:134-136.
- McLendon K, Sternard BT. Anaphylaxis. StatPearls [Internet]. Updated January 26, 2023. Accessed May 12, 2026. https://www.ncbi.nlm.nih.gov/books/NBK482124/
- Cheng TC. General Parasitology. Elsevier Science; 2012:660.
- Purdue Medical Entomology. Horse and deer flies. Purdue University. Accessed April 28, 2026. https://extension.entm.purdue.edu/publichealth/diseases/tabanid.html
- US Geological Survey. Tularemia. USGS Publications Warehouse. Accessed April 28, 2026. https://pubs.usgs.gov/circ/1297/report.pdf
- Snowden J, Simonsen KA. Tularemia. StatPearls [Internet]. Updated July 17, 2023. Accessed May 12, 2026. https://www.ncbi.nlm.nih.gov/books/NBK430905/
- Enderlin G, Morales L, Jacobs RF, et al. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis. 1994;19:42-47.
- Balestra A, Bytyci H, Guillod C, et al. A case of ulceroglandular tularemia presenting with lymphadenopathy and an ulcer on a linear morphoea lesion surrounded by erysipelas. Int Med Case Rep J. 2018;11:313-318.
- Malaise R. A new insect‑trap. Entomologisk Tidskrift. 1937;58:148‑160.
- French F, Kline D. l-Octen-3-ol, an effective attractant for Tabanidae (Diptera). J Med Entomol. 1989;26:459-461
- Axtell RC, Edwards TD, Dukes JC. Rigid canopy trap for Tabanidae (Diptera). J Georgia Entomol Soc. 1975;10: 64-67.
- Squitier JM. Deer flies, yellow flies and horse flies. Featured Creatures. University of Florida. April 1, 2014. Accessed May 12, 2026. https://ask.ifas.ufl.edu/publication/IN155
- Lucas M, Krolow TK, Riet-Correa F, et al. Diversity and seasonality of horse flies (Diptera: Tabanidae) in Uruguay. Sci Rep. 2020;10:401.
- Chainey JE. Horse‑flies, deer‑flies and clegs (Tabanidae). In: Lane RP, Crosskey RW, eds. Medical Insects and Arachnids. Springer; 1993:310‑332.
- Downes JA. The post‑glacial colonization of the North Atlantic islands. Memoirs of the Entomological Society of Canada. 1988;120(S144):55‑92.
- Squitier JM. Deer flies, yellow flies and horse flies. Featured Creatures. University of Florida; April 1, 2014. Accessed September 15, 2023.
- Middlekauff WW, Lane RS. Adult and immature Tabanidae (Diptera) of California. University of California Press. 1980:1‑2.
- Horse flies and deer flies. University of Kentucky. Accessed September 15, 2023. https://entomology.mgcafe.uky.edu/ef511
- Hoover J. Horse flies. LSU College of Agriculture. May 28, 2020. Accessed May 20, 2026. https://www.lsuagcenter.com/profiles/jhoover/articles/page1590683239678
- Powers J, Syed HA, McDowell RH. Insect bites. StatPearls [Internet]. Updated February 15, 2026. Accessed May 12, 2026. https://www.ncbi.nlm.nih.gov/books/NBK537235/
- Hemmer W, Focke M, Vieluf D, et al. Anaphylaxis induced by horsefly bites: identification of a 69 kd IgE-binding salivary gland protein from Chrysops spp. (Diptera, Tabanidae) by Western blot analysis. J Allergy Clin Immunol. 1998;101:134-136.
- McLendon K, Sternard BT. Anaphylaxis. StatPearls [Internet]. Updated January 26, 2023. Accessed May 12, 2026. https://www.ncbi.nlm.nih.gov/books/NBK482124/
- Cheng TC. General Parasitology. Elsevier Science; 2012:660.
- Purdue Medical Entomology. Horse and deer flies. Purdue University. Accessed April 28, 2026. https://extension.entm.purdue.edu/publichealth/diseases/tabanid.html
- US Geological Survey. Tularemia. USGS Publications Warehouse. Accessed April 28, 2026. https://pubs.usgs.gov/circ/1297/report.pdf
- Snowden J, Simonsen KA. Tularemia. StatPearls [Internet]. Updated July 17, 2023. Accessed May 12, 2026. https://www.ncbi.nlm.nih.gov/books/NBK430905/
- Enderlin G, Morales L, Jacobs RF, et al. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis. 1994;19:42-47.
- Balestra A, Bytyci H, Guillod C, et al. A case of ulceroglandular tularemia presenting with lymphadenopathy and an ulcer on a linear morphoea lesion surrounded by erysipelas. Int Med Case Rep J. 2018;11:313-318.
- Malaise R. A new insect‑trap. Entomologisk Tidskrift. 1937;58:148‑160.
- French F, Kline D. l-Octen-3-ol, an effective attractant for Tabanidae (Diptera). J Med Entomol. 1989;26:459-461
- Axtell RC, Edwards TD, Dukes JC. Rigid canopy trap for Tabanidae (Diptera). J Georgia Entomol Soc. 1975;10: 64-67.
- Squitier JM. Deer flies, yellow flies and horse flies. Featured Creatures. University of Florida. April 1, 2014. Accessed May 12, 2026. https://ask.ifas.ufl.edu/publication/IN155
Horse Flies: Identification, Bite Reactions, and Clinical Management
Horse Flies: Identification, Bite Reactions, and Clinical Management
PRACTICE POINTS
- Horse flies (Tabanidae) are hematophagous insects that can cause minor cutaneous reactions (eg, urticaria) or, rarely, severe reactions such as anaphylaxis. They also are vectors of tularemia, which may manifest with cutaneous ulcers or systemic illness.
- Mild reactions are managed symptomatically; anaphylaxis requires epinephrine, and tularemia requires systemic antibiotics such as gentamicin.
- Patients should be counseled on avoidance strategies, including wearing protective clothing and using topical repellents and environmental traps.
Getting a Grip on Occupational Hand Dermatitis: Key Considerations for Evaluation and Management
Getting a Grip on Occupational Hand Dermatitis: Key Considerations for Evaluation and Management
Hand dermatitis (HD) is a common dermatologic concern that can impair quality of life, work productivity, and daily functioning.1 Occupational HD is defined as hand eczema caused or worsened by workplace exposures. When caused by work, HD may lead to reduced productivity and even job loss. Subtypes of HD include irritant contact dermatitis (ICD), allergic contact dermatitis (ACD), protein contact dermatitis (PCD), atopic dermatitis (AD), hyperkeratotic HD, and dyshidrotic eczema.2,3
Often caused by wet work, ICD is the most common subtype, whereas PCD—which is caused by immediate hypersensitivity to protein—is less common and usually seen in food service workers.3,4 When HD does not improve with standard treatment, particularly in occupational cases, patch testing is prudent to evaluate for contact allergens. In this article, we review practical considerations for evaluation and management of occupational irritant and allergic HD, highlighting relevant exposures and pearls on workup and management.
Epidemiology of Hand Dermatitis
A 2021 systematic review and meta-analysis of European studies reported a 1-year HD prevalence of 9.1% and a lifetime prevalence of 14.5%.5 Hand dermatitis is most common in women; individuals aged 30 to 39 years; and those who are employed, underscoring the role of workplace exposure.6 High-risk occupations are those involving substantial wet work, such as hairdressers, beauticians, cleaners, and health care and construction workers.7 Individuals with a history of AD also are at high risk for HD.8
Hand Dermatitis Subtypes
Irritant Contact Dermatitis—Irritant contact dermatitis, the most common form of occupational HD, is caused by repeated exposure to irritants (eg, water, detergents, cleansers, and soaps) that disrupt the skin barrier.9 Occupations that involve wet work are a major risk factor, associated with a 56% higher likelihood of ICD.8 Wet work involves frequent handwashing, prolonged contact with liquids, or occlusive glove use.9 As a ubiquitous skin irritant, water can penetrate the stratum corneum, impair the skin barrier, and increase sensitization risk. The dorsal hands usually are affected by ICD due to the thinner stratum corneum in this area.9
Allergic Contact Dermatitis—Allergic contact dermatitis should be considered in cases of chronic, recurrent, or treatment-resistant disease. Clinical clues include dermatitis beyond irritant contact sites, recurrent pruritic and vesicular HD, and flares with occupational exposures or materials; however, it can be difficult to distinguish ACD from ICD on clinical presentation alone, as they have many overlapping features. When ACD is suspected, patch testing remains the gold standard for identifying allergens and guiding avoidance strategies, product alternatives, and workplace modifications.
Unique Occupational Considerations
Hairdressers—Hairdressers have an increased risk for HD due to wet work and exposure to sensitizers, with a pooled lifetime prevalence of 38.2% (including ICD, ACD, and occupational cases).10 Notably, frequent shampooing, rinsing, cutting wet hair, handwashing, and glove use increase the risk for ICD. Hairdressers also are exposed to allergens in hair products, including p-phenylenediamine, toluene-2,5-diamine, persulfate salts, glyceryl thioglycolate, preservatives, and fragrances. Occupational exposure to the preservative methylisothiazolinone is high among hairdressers, with a sensitization rate of 10.5% in HD cases.11
It has been reported that hyperkeratotic fissured eczema of the dorsal hands caused by wet work often indicates ICD, whereas pruritic dyshidrotic eczema involving the lateral fingers or palms suggests ACD; however, these conditions can share overlapping features.7 If ACD is suspected, broad patch testing with baseline and hairdresser series, along with specific chemicals that may be encountered in the workplace, is necessary. Management includes allergen avoidance, reduced wet work tasks, use of nitrile gloves with glove changes to mitigate occlusive effects, and skin barrier protection with emollients.
Health Care Workers—Health care workers are vulnerable to HD due to intensive hand hygiene, prolonged glove use, and allergen exposures, with a lifetime prevalence of self-reported HD of 33.4%.12 Common allergens among health care workers include rubber accelerators, most often from rubber gloves.13 Frequent handwashing and glove use can further impair the skin barrier, increasing irritant and sensitization risks.14 In contrast, alcohol-based hand sanitizers containing emollients are less irritating, with prior analyses showing no significant association with HD risk.15,16 Conversely, handwashing 8 to 10 times daily increased HD risk, with a relative risk of 1.51.15
Surgeons and proceduralists face unique risks for HD from preoperative scrubbing with products that can contain potential allergens such as chlorhexidine gluconate, chloroxylenol, povidone-iodine, fragrance, cocamide diethanolamine, lanolin, alkyl glucosides, sodium benzoate, sorbic acid, tocopherol, and propylene glycol.17,18 Subsequent occlusion under glove layers drives ICD and ACD risks, highlighting the importance of patch testing in affected individuals. While patch testing, exposure avoidance, and limited glove use can mitigate HD risk, frequent handwashing can contribute to refractory HD.
Food Service Workers—Food service workers have an increased risk for HD from allergens and irritants. In a retrospective study of patients with occupational food-related HD (N=372), 57% were diagnosed with ICD, 22% with PCD, and 1.8% with ACD.19 Skin barrier disruption from wet work, occlusion from glove use, and contact with food proteins increase HD risk, especially in bakers exposed to flours and grains, which can cause IgE–mediated PCD manifesting with contact urticaria. Protein contact dermatitis is confirmed by prick testing with suspected foods.20 Additionally, exposure to garlic can cause ICD and ACD due to sulfur-containing compounds, particularly allicin and diallyl disulfide.21,22 Pineapple also can trigger ICD associated with bromelain, a proteolytic enzyme that can break down the skin.23 Nickel exposure is another concern, as steel utensils and cookware can release nickel onto the skin of sensitized individuals.24 Rubber accelerator exposure from gloves also contributes to contact allergy and HD among food service workers; vinyl gloves usually are a good alternative in this setting.25 Management of food-related HD involves exposure avoidance, which may affect occupational viability
Construction Workers—Construction workers are at risk for occupational HD due to contact with irritants and sensitizers such as paints, adhesives, asphalt, cement, solvents, and gloves.26 A retrospective analysis of North American Contact Dermatitis Group data identified HD in 37.2% (253/681) of patch-tested construction workers. The most common occupational allergens include potassium dichromate, which can be present in cement and leather items; bisphenol A epoxy resin; cobalt chloride hexahydrate; and the rubber accelerators carba mix and thiuram mix.26 A thorough occupational history should assess materials handled, and patch testing should include common construction-related allergens to inform avoidance strategies. Workplace task modification can reduce exposure, as certain managerial roles in construction work may involve less contact with irritants and sensitizers.26
Nail Technicians—Nail technicians are at risk for HD, especially ACD from acrylate monomers used in nail gels, dips, and acrylics. In a 10-year analysis, around 87.5% (14/16) of nail technicians with contact allergy to methacrylate demonstrated hand involvement.27 Common acrylate monomers include 2-hydroxyethyl methacrylate, 2-hydroxypropyl methacrylate, and ethyl cyanoacrylate. 28 Evaluation requires a detailed occupational history, assessing HD onset relative to exposure, services performed, glove-use practices, and whether symptoms improve away from work. While gloves may appear to reduce exposure, a glove-penetration study showed that acrylate-containing nail products can penetrate commonly used disposable gloves from within seconds to approximately 20 minutes, depending on glove and product type.29 Among available options, nitrile gloves may provide dexterity and allergen avoidance when acrylate exposure is brief, with glove changes required every 15 to 30 minutes.30 Patch testing with 2-hydroxyethyl methacrylate and ethyl cyanoacrylate can identify nail acrylate allergy; however, avoidance can be challenging for nail technicians, as these products often are ubiquitous in their work.
Florists—Florists can develop HD from plant allergens and irritants, particularly tulipalin A and calcium oxalate, with a lifetime prevalence of 19.6%.31 Tulipalin A is a well-documented sensitizer causing ACD among florists exposed to tulip bulbs and other Alstroemeria flowers.32 The term tulip fingers actually was coined to describe ACD caused by tulip bulbs in the European tulip industry.33 Patch testing involves testing for tulipalin A, which may be commercially limited, or tulip plant materials; however, fresh tulips require open testing with small amounts due to higher allergen concentration.32 Additionally, the term daffodil itch describes a type of ICD caused by calcium oxalate crystals in daffodil bulbs and tulip sap.32,34 Diagnosis of plant-related HD requires an occupational history and targeted patch testing, while glove protection and exposure avoidance are essential for improvement.
Evaluation and Management
The workup for HD involves physical examination and medical history, including disease onset, course, and history of AD, along with occupational and exposure history to identify allergens and irritants. Understanding the patient’s tasks and responsibilities and workplace practices along with the materials they handle allows the dermatologist to anticipate relevant allergens for patch testing.
Patch testing should be comprehensive, as baseline screening series alone may miss between 26.3% and 50% of occupationally relevant allergens.35,36 Comprehensive patch testing also should include specialty series and supplemental allergens based on the patient’s clinical history and exposures. Specialty series may include hairdressing, bakery, cosmetics, dental, machinists, and adhesives.37 Gloves also warrant attention, as they may be overlooked as a sensitizer following repeated contact and occlusion. In persistent HD associated with glove use, patch testing should include a rubber accelerator series with relevant allergens, such as thiurams, carbamates, mercaptobenzothiazole, diphenylguanidine, and the patient’s own gloves.38 Latex allergy also should be considered, particularly in immediate-type reactions, and can be evaluated with latex-specific IgE testing.39
Management of HD relies on accurate diagnosis and allergen avoidance, which can be challenging in occupational settings. Structured tools, such as the American Contact Dermatitis Society’s Contact Allergen Management Program (https://www.contactderm.org/ resources/acds-camp), can help identify safe alternatives.
In occupational HD, risk assessment should identify occupational exposures and determine appropriate personal protective equipment while minimizing the risk for HD associated with such equipment. Protective gloves are advised to prevent contact with allergens and irritants. When glove use lasts more than 10 minutes, cotton glove liners may be worn to avoid occlusion and moisture retention.40 For wet work, vinyl gloves are recommended, with regular emollient use to support skin-barrier repair. Overall, gloves should be used when possible, changed regularly, and worn for limited periods of time to prevent ICD.
Work modification may be required to reduce exposure and flares, including task reassignment or substitution of materials containing allergens and irritants. Occupational HD may necessitate workplace accommodations, disability evaluation, medical leave, or even permanent job change. Dermatologists play a crucial role in the medical determination of work relatedness and functional impairment, guiding patients through occupational health, disability, and workers’ compensation when warranted.
Treatments for Occupational HD
Treatment of occupational HD depends on disease severity, chronicity, and avoidance of allergens and irritants in ACD, ICD, and PCD. Foundational management includes regular emollient use, which can even serve as monotherapy in mild occupational HD.40 Corticosteroids are the cornerstone of topical therapy, while calcineurin inhibitors can be used as a steroid-sparing option in milder disease.41 Off-label topical calcipotriol and AD-approved therapies crisaborole and ruxolitinib may be effective. For refractory disease after topical treatments, phototherapy can be considered.40 Biologic and targeted therapies also have emerged as potential treatments. Dupilumab is effective for atopic chronic HD and has demonstrated promise for nonatopic chronic HD.42 Recently, delgocitinib, a topical pan–Janus kinase inhibitor cream, showed clinical efficacy for chronic hand eczema and was approved by the US Food and Drug Administration.43 Off-label use of alternative systemic therapies, including acitretin, cyclosporine, methotrexate, and azathioprine, and other biologics and systemic Janus kinase inhibitors also may treat HD, but larger studies are lacking.40
Our Final Interpretation
Occupational HD is a common skin condition with multiple etiologies. It is important for clinicians to gather a thorough occupational and exposure history to narrow the differential diagnosis, inform patch testing, and guide effective management. In practice, successful treatment depends on screening for and diagnosis of workplace exposures driving disease.
- Agner T, Andersen KE, Brandao FM, et al. Hand eczema severity and quality of life: a cross-sectional, multicentre study of hand eczema patients. Contact Dermatitis. 2008;59:43-47. doi:10.1111 /j.1600-0536.2008.01362.x
- Agner T, Aalto-Korte K, Andersen KE, et al. Classification of hand eczema. J Eur Acad Dermatol Venereol. 2015;29:2417-2422. doi:10.1111 /jdv.13308
- Bissonnette R, Agner T, Molin S, et al. Hand eczema—part 1: epidemiology, pathogenesis, diagnosis, and work-up. J Am Acad Dermatol. 2025;93:1201-1210. doi:10.1016/j.jaad.2024.09.048
- Barbaud A. Mechanism and diagnosis of protein contact dermatitis. Curr Opin Allergy Clin Immunol. 2020;20:117-121. doi:10.1097/ACI.0000000000000621
- Quaade AS, Simonsen AB, Halling AS, et al. Prevalence, incidence, and severity of hand eczema in the general population - a systematic review and meta-analysis. Contact Dermatitis. 2021;84:361-374. doi:10.1111/cod.13804
- Apfelbacher C, Bewley A, Molin S, et al. Prevalence of chronic hand eczema in adults: a cross-sectional survey of over 60 000 respondents from the general population of Canada, France, Germany, Italy, Spain and the UK. Br J Dermatol. 2025;192:1047-1054. doi:10.1093 /bjd/ljaf020
- Weidinger S, Novak N. Hand eczema. Lancet. 2024;404:2476-2486. doi:10.1016/S0140-6736(24)01810-5
- Schütte MG, Tamminga SJ, de Groene GJ, et al. Work-related and personal risk factors for occupational contact dermatitis: a systematic review of the literature with meta-analysis. Contact Dermatitis. 2023;88:171-187. doi:10.1111/cod.14253
- Behroozy A, Keegel TG. Wet-work exposure: a main risk factor for occupational hand dermatitis. Saf Health Work. 2014;5:175-180. doi:10.1016/j.shaw.2014.08.001
- Havmose MS, Kezic S, Uter W, et al. Prevalence and incidence of hand eczema in hairdressers-a systematic review and meta-analysis of the published literature from 2000-2021. Contact Dermatitis. 2022;86:254-265. doi:10.1111/cod.14048
- Uter W, Hallmann S, Gefeller O, et al. Contact allergy to ingredients of hair cosmetics in female hairdressers and female consumers—an update based on IVDK data 2013–2020. Contact Dermatitis. 2023;89:161-170. doi:10.1111/cod.14363
- Yüksel YT, Symanzik C, Christensen MO, et al. Prevalence and incidence of hand eczema in healthcare workers: a systematic review and meta-analysis. Contact Dermatitis. 2024;90:331-342. doi:10.1111 /cod.14489
- Warshaw EM, Schram SE, Maibach HI, et al. Occupation-related contact dermatitis in North American health care workers referred for patch testing: cross-sectional data, 1998 to 2004. Dermatitis. 2008;19:261-274. doi:10.2310/6620.2008.07059
- Hamnerius N, Svedman C, Bergendorff O, et al. Wet work exposure and hand eczema among healthcare workers: a cross-sectional study. Br J Dermatol. 2018;178:452-461. doi:10.1111 /bjd.15813
- Loh EDW, Yew YW. Hand hygiene and hand eczema: a systematic review and meta-analysis. Contact Dermatitis. 2022;87:303-314. doi:10.1111/cod.14133
- Lotfinejad N, Peters A, Tartari E, et al. Hand hygiene in health care: 20 years of ongoing advances and perspectives. Lancet Infect Dis. 2021;21:e209-e221. doi:10.1016/S1473-3099(21)00383-2
- Schlarbaum JP, Hylwa SA. Allergic contact dermatitis to operating room scrubs and disinfectants. Dermat Contact Atopic Occup Drug. 2019;30:363-370. doi:10.1097/DER.0000000000000525
- Rodriguez-Homs LG, Atwater AR. Allergens in medical hand skin cleansers. Dermat Contact Atopic Occup Drug. 2019;30:336-341. doi:10.1097/DER.0000000000000504
- Vester L, Thyssen JP, Menné T, et al. Occupational food-related hand dermatoses seen over a 10-year period. Contact Dermatitis. 2012;66:264-270. doi:10.1111/j.1600-0536.2011.02048.x
- Pesonen M, Koskela K, Aalto-Korte K. Contact urticaria and protein contact dermatitis in the Finnish Register of Occupational Diseases in a period of 12 years. Contact Dermatitis. 2020;83:1-7. doi:10.1111/cod.13547
- McFadden JP, White JML, Basketter DA, et al. Reduced allergy rates in atopic eczema to contact allergens used in both skin products and foods: atopy and the “hapten-atopy hypothesis.” Contact Dermatitis. 2008;58:156-158. doi:10.1111/j.1600-0536.2007.01291.x
- Kao SH, Hsu CH, Su SN, et al. Identification and immunologic characterization of an allergen, alliin lyase, from garlic (Allium sativum). J Allergy Clin Immunol. 2004;113:161-168. doi:10.1016/j.jaci.2003.10.040
- Reddy VB, Lerner EA. Plant cysteine proteases that evoke itch activate protease-activated receptors. Br J Dermatol. 2010;163:532-535. doi:10.1111/j.1365-2133.2010.09862.x
- Silverberg NB, Pelletier JL, Jacob SE, et al; Section on Dermatology, Section on Allergy and Immunology. Nickel allergic contact dermatitis: identification, treatment, and prevention. Pediatrics. 2020;145:e20200628. doi:10.1542/peds.2020-0628
- Clément A, Ferrier le Bouëdec MC, Crépy MN, et al. Hand eczema in glove-wearing patients. Contact Dermatitis. 2023;89:143-152. doi:10.1111/cod.14357
- Reeder MJ, Idrogo-Lam A, Aravamuthan SR, et al. Occupational contact dermatitis in construction workers: a retrospective analysis of the North American Contact Dermatitis Group Data, 2001-2020. Dermat Contact Atopic Occup Drug. 2024;35:467-475. doi:10.1089/derm.2024.0018
- Fisch A, Hamnerius N, Isaksson M. Dermatitis and occupational (meth)acrylate contact allergy in nail technicians-a 10-year study. Contact Dermatitis. 2019;81:58-60. doi:10.1111/cod.13216
- Atwater AR, Reeder M. Trends in nail services may cause dermatitis: not your mother’s nail polish. Cutis. 2019;103:315-317.
- Suuronen K, Ylinen K, Heikkilä J, et al. Acrylates in artificial nails— results of product analyses and glove penetration studies. Contact Dermatitis. 2024;90:266-272. doi:10.1111/cod.14474
- Morgado F, Batista M, Gonçalo M. Short exposures and glove protection against (meth)acrylates in nail beauticians-thoughts on a rising concern. Contact Dermatitis. 2019;81:62-63. doi:10.1111 /cod.13222
- Paulsen E, Søgaard J, Andersen KE. Occupational dermatitis in Danish gardeners and greenhouse workers (I). prevalence and possible risk factors. Contact Dermatitis. 1997;37:263-270. doi:10.1111/j.1600-0536.1997.tb02462.x
- Fonacier L, Bernstein DI, Pacheco K, et al. Contact dermatitis: a practice parameter–update 2015. J Allergy Clin Immunol Pract. 2015; 3(3 suppl):S1-S39. doi:10.1016/j.jaip.2015.02.009
- Gette MT, Marks JE. Tulip fingers. Arch Dermatol. 1990;126:203-205.
- Bruynzeel DP. Bulb dermatitis. Dermatological problems in the flower bulb industries. Contact Dermatitis. 1997;37:70-77. doi:10.1111/j.1600-0536.1997.tb00042.x
- Nettis E, Marcandrea M, Colanardi MC, et al. Results of standard series patch testing in patients with occupational allergic contact dermatitis. Allergy. 2003;58:1304-1307. doi:10.1046/j.1398-9995.2003.00346.x
- Saripalli YV, Achen F, Belsito DV. The detection of clinically relevant contact allergens using a standard screening tray of twenty-three allergens. J Am Acad Dermatol. 2003;49:65-69. doi:10.1067/mjd.2003.489
- Warshaw EM, Buonomo M, DeKoven JG, et al. Importance of supplemental patch testing beyond a screening series for patients with dermatitis: the North American Contact Dermatitis Group experience. JAMA Dermatol. 2021;157:1456-1465. doi:10.1001/jamadermatol.2021.4314
- Geier J, Lessmann H, Mahler V, et al. Occupational contact allergy caused by rubber gloves--nothing has changed. Contact Dermatitis. 2012;67:149-156. doi:10.1111/j.1600-0536.2012.02139.x
- Toraason M, Sussman G, Biagini R, et al. Latex allergy in the workplace. Toxicol Sci Off J Soc Toxicol. 2000;58:5-14. doi:10.1093/toxsci/58.1.5
- Bissonnette R, Agner T, Taylor JS, et al. Hand eczema-part 2: prevention, management, and treatment. J Am Acad Dermatol. 2025;93:1213-1224. doi:10.1016/j.jaad.2024.09.049
- Schliemann S, Kelterer D, Bauer A, et al. Tacrolimus ointment in the treatment of occupationally induced chronic hand dermatitis. Contact Dermatitis. 2008;58:299-306. doi:10.1111/j.1600-0536.2007.01314.x
- Voorberg AN, Kamphuis E, Christoffers WA, et al. Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study. Br J Dermatol. 2023;189:400-409. doi:10.1093/bjd/ljad156
- Gooderham M, Molin S, Bissonnette R, et al. Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials. J Am Acad Dermatol. 2025;93:95-103. doi:10.1016/j.jaad.2025.03.008
Hand dermatitis (HD) is a common dermatologic concern that can impair quality of life, work productivity, and daily functioning.1 Occupational HD is defined as hand eczema caused or worsened by workplace exposures. When caused by work, HD may lead to reduced productivity and even job loss. Subtypes of HD include irritant contact dermatitis (ICD), allergic contact dermatitis (ACD), protein contact dermatitis (PCD), atopic dermatitis (AD), hyperkeratotic HD, and dyshidrotic eczema.2,3
Often caused by wet work, ICD is the most common subtype, whereas PCD—which is caused by immediate hypersensitivity to protein—is less common and usually seen in food service workers.3,4 When HD does not improve with standard treatment, particularly in occupational cases, patch testing is prudent to evaluate for contact allergens. In this article, we review practical considerations for evaluation and management of occupational irritant and allergic HD, highlighting relevant exposures and pearls on workup and management.
Epidemiology of Hand Dermatitis
A 2021 systematic review and meta-analysis of European studies reported a 1-year HD prevalence of 9.1% and a lifetime prevalence of 14.5%.5 Hand dermatitis is most common in women; individuals aged 30 to 39 years; and those who are employed, underscoring the role of workplace exposure.6 High-risk occupations are those involving substantial wet work, such as hairdressers, beauticians, cleaners, and health care and construction workers.7 Individuals with a history of AD also are at high risk for HD.8
Hand Dermatitis Subtypes
Irritant Contact Dermatitis—Irritant contact dermatitis, the most common form of occupational HD, is caused by repeated exposure to irritants (eg, water, detergents, cleansers, and soaps) that disrupt the skin barrier.9 Occupations that involve wet work are a major risk factor, associated with a 56% higher likelihood of ICD.8 Wet work involves frequent handwashing, prolonged contact with liquids, or occlusive glove use.9 As a ubiquitous skin irritant, water can penetrate the stratum corneum, impair the skin barrier, and increase sensitization risk. The dorsal hands usually are affected by ICD due to the thinner stratum corneum in this area.9
Allergic Contact Dermatitis—Allergic contact dermatitis should be considered in cases of chronic, recurrent, or treatment-resistant disease. Clinical clues include dermatitis beyond irritant contact sites, recurrent pruritic and vesicular HD, and flares with occupational exposures or materials; however, it can be difficult to distinguish ACD from ICD on clinical presentation alone, as they have many overlapping features. When ACD is suspected, patch testing remains the gold standard for identifying allergens and guiding avoidance strategies, product alternatives, and workplace modifications.
Unique Occupational Considerations
Hairdressers—Hairdressers have an increased risk for HD due to wet work and exposure to sensitizers, with a pooled lifetime prevalence of 38.2% (including ICD, ACD, and occupational cases).10 Notably, frequent shampooing, rinsing, cutting wet hair, handwashing, and glove use increase the risk for ICD. Hairdressers also are exposed to allergens in hair products, including p-phenylenediamine, toluene-2,5-diamine, persulfate salts, glyceryl thioglycolate, preservatives, and fragrances. Occupational exposure to the preservative methylisothiazolinone is high among hairdressers, with a sensitization rate of 10.5% in HD cases.11
It has been reported that hyperkeratotic fissured eczema of the dorsal hands caused by wet work often indicates ICD, whereas pruritic dyshidrotic eczema involving the lateral fingers or palms suggests ACD; however, these conditions can share overlapping features.7 If ACD is suspected, broad patch testing with baseline and hairdresser series, along with specific chemicals that may be encountered in the workplace, is necessary. Management includes allergen avoidance, reduced wet work tasks, use of nitrile gloves with glove changes to mitigate occlusive effects, and skin barrier protection with emollients.
Health Care Workers—Health care workers are vulnerable to HD due to intensive hand hygiene, prolonged glove use, and allergen exposures, with a lifetime prevalence of self-reported HD of 33.4%.12 Common allergens among health care workers include rubber accelerators, most often from rubber gloves.13 Frequent handwashing and glove use can further impair the skin barrier, increasing irritant and sensitization risks.14 In contrast, alcohol-based hand sanitizers containing emollients are less irritating, with prior analyses showing no significant association with HD risk.15,16 Conversely, handwashing 8 to 10 times daily increased HD risk, with a relative risk of 1.51.15
Surgeons and proceduralists face unique risks for HD from preoperative scrubbing with products that can contain potential allergens such as chlorhexidine gluconate, chloroxylenol, povidone-iodine, fragrance, cocamide diethanolamine, lanolin, alkyl glucosides, sodium benzoate, sorbic acid, tocopherol, and propylene glycol.17,18 Subsequent occlusion under glove layers drives ICD and ACD risks, highlighting the importance of patch testing in affected individuals. While patch testing, exposure avoidance, and limited glove use can mitigate HD risk, frequent handwashing can contribute to refractory HD.
Food Service Workers—Food service workers have an increased risk for HD from allergens and irritants. In a retrospective study of patients with occupational food-related HD (N=372), 57% were diagnosed with ICD, 22% with PCD, and 1.8% with ACD.19 Skin barrier disruption from wet work, occlusion from glove use, and contact with food proteins increase HD risk, especially in bakers exposed to flours and grains, which can cause IgE–mediated PCD manifesting with contact urticaria. Protein contact dermatitis is confirmed by prick testing with suspected foods.20 Additionally, exposure to garlic can cause ICD and ACD due to sulfur-containing compounds, particularly allicin and diallyl disulfide.21,22 Pineapple also can trigger ICD associated with bromelain, a proteolytic enzyme that can break down the skin.23 Nickel exposure is another concern, as steel utensils and cookware can release nickel onto the skin of sensitized individuals.24 Rubber accelerator exposure from gloves also contributes to contact allergy and HD among food service workers; vinyl gloves usually are a good alternative in this setting.25 Management of food-related HD involves exposure avoidance, which may affect occupational viability
Construction Workers—Construction workers are at risk for occupational HD due to contact with irritants and sensitizers such as paints, adhesives, asphalt, cement, solvents, and gloves.26 A retrospective analysis of North American Contact Dermatitis Group data identified HD in 37.2% (253/681) of patch-tested construction workers. The most common occupational allergens include potassium dichromate, which can be present in cement and leather items; bisphenol A epoxy resin; cobalt chloride hexahydrate; and the rubber accelerators carba mix and thiuram mix.26 A thorough occupational history should assess materials handled, and patch testing should include common construction-related allergens to inform avoidance strategies. Workplace task modification can reduce exposure, as certain managerial roles in construction work may involve less contact with irritants and sensitizers.26
Nail Technicians—Nail technicians are at risk for HD, especially ACD from acrylate monomers used in nail gels, dips, and acrylics. In a 10-year analysis, around 87.5% (14/16) of nail technicians with contact allergy to methacrylate demonstrated hand involvement.27 Common acrylate monomers include 2-hydroxyethyl methacrylate, 2-hydroxypropyl methacrylate, and ethyl cyanoacrylate. 28 Evaluation requires a detailed occupational history, assessing HD onset relative to exposure, services performed, glove-use practices, and whether symptoms improve away from work. While gloves may appear to reduce exposure, a glove-penetration study showed that acrylate-containing nail products can penetrate commonly used disposable gloves from within seconds to approximately 20 minutes, depending on glove and product type.29 Among available options, nitrile gloves may provide dexterity and allergen avoidance when acrylate exposure is brief, with glove changes required every 15 to 30 minutes.30 Patch testing with 2-hydroxyethyl methacrylate and ethyl cyanoacrylate can identify nail acrylate allergy; however, avoidance can be challenging for nail technicians, as these products often are ubiquitous in their work.
Florists—Florists can develop HD from plant allergens and irritants, particularly tulipalin A and calcium oxalate, with a lifetime prevalence of 19.6%.31 Tulipalin A is a well-documented sensitizer causing ACD among florists exposed to tulip bulbs and other Alstroemeria flowers.32 The term tulip fingers actually was coined to describe ACD caused by tulip bulbs in the European tulip industry.33 Patch testing involves testing for tulipalin A, which may be commercially limited, or tulip plant materials; however, fresh tulips require open testing with small amounts due to higher allergen concentration.32 Additionally, the term daffodil itch describes a type of ICD caused by calcium oxalate crystals in daffodil bulbs and tulip sap.32,34 Diagnosis of plant-related HD requires an occupational history and targeted patch testing, while glove protection and exposure avoidance are essential for improvement.
Evaluation and Management
The workup for HD involves physical examination and medical history, including disease onset, course, and history of AD, along with occupational and exposure history to identify allergens and irritants. Understanding the patient’s tasks and responsibilities and workplace practices along with the materials they handle allows the dermatologist to anticipate relevant allergens for patch testing.
Patch testing should be comprehensive, as baseline screening series alone may miss between 26.3% and 50% of occupationally relevant allergens.35,36 Comprehensive patch testing also should include specialty series and supplemental allergens based on the patient’s clinical history and exposures. Specialty series may include hairdressing, bakery, cosmetics, dental, machinists, and adhesives.37 Gloves also warrant attention, as they may be overlooked as a sensitizer following repeated contact and occlusion. In persistent HD associated with glove use, patch testing should include a rubber accelerator series with relevant allergens, such as thiurams, carbamates, mercaptobenzothiazole, diphenylguanidine, and the patient’s own gloves.38 Latex allergy also should be considered, particularly in immediate-type reactions, and can be evaluated with latex-specific IgE testing.39
Management of HD relies on accurate diagnosis and allergen avoidance, which can be challenging in occupational settings. Structured tools, such as the American Contact Dermatitis Society’s Contact Allergen Management Program (https://www.contactderm.org/ resources/acds-camp), can help identify safe alternatives.
In occupational HD, risk assessment should identify occupational exposures and determine appropriate personal protective equipment while minimizing the risk for HD associated with such equipment. Protective gloves are advised to prevent contact with allergens and irritants. When glove use lasts more than 10 minutes, cotton glove liners may be worn to avoid occlusion and moisture retention.40 For wet work, vinyl gloves are recommended, with regular emollient use to support skin-barrier repair. Overall, gloves should be used when possible, changed regularly, and worn for limited periods of time to prevent ICD.
Work modification may be required to reduce exposure and flares, including task reassignment or substitution of materials containing allergens and irritants. Occupational HD may necessitate workplace accommodations, disability evaluation, medical leave, or even permanent job change. Dermatologists play a crucial role in the medical determination of work relatedness and functional impairment, guiding patients through occupational health, disability, and workers’ compensation when warranted.
Treatments for Occupational HD
Treatment of occupational HD depends on disease severity, chronicity, and avoidance of allergens and irritants in ACD, ICD, and PCD. Foundational management includes regular emollient use, which can even serve as monotherapy in mild occupational HD.40 Corticosteroids are the cornerstone of topical therapy, while calcineurin inhibitors can be used as a steroid-sparing option in milder disease.41 Off-label topical calcipotriol and AD-approved therapies crisaborole and ruxolitinib may be effective. For refractory disease after topical treatments, phototherapy can be considered.40 Biologic and targeted therapies also have emerged as potential treatments. Dupilumab is effective for atopic chronic HD and has demonstrated promise for nonatopic chronic HD.42 Recently, delgocitinib, a topical pan–Janus kinase inhibitor cream, showed clinical efficacy for chronic hand eczema and was approved by the US Food and Drug Administration.43 Off-label use of alternative systemic therapies, including acitretin, cyclosporine, methotrexate, and azathioprine, and other biologics and systemic Janus kinase inhibitors also may treat HD, but larger studies are lacking.40
Our Final Interpretation
Occupational HD is a common skin condition with multiple etiologies. It is important for clinicians to gather a thorough occupational and exposure history to narrow the differential diagnosis, inform patch testing, and guide effective management. In practice, successful treatment depends on screening for and diagnosis of workplace exposures driving disease.
Hand dermatitis (HD) is a common dermatologic concern that can impair quality of life, work productivity, and daily functioning.1 Occupational HD is defined as hand eczema caused or worsened by workplace exposures. When caused by work, HD may lead to reduced productivity and even job loss. Subtypes of HD include irritant contact dermatitis (ICD), allergic contact dermatitis (ACD), protein contact dermatitis (PCD), atopic dermatitis (AD), hyperkeratotic HD, and dyshidrotic eczema.2,3
Often caused by wet work, ICD is the most common subtype, whereas PCD—which is caused by immediate hypersensitivity to protein—is less common and usually seen in food service workers.3,4 When HD does not improve with standard treatment, particularly in occupational cases, patch testing is prudent to evaluate for contact allergens. In this article, we review practical considerations for evaluation and management of occupational irritant and allergic HD, highlighting relevant exposures and pearls on workup and management.
Epidemiology of Hand Dermatitis
A 2021 systematic review and meta-analysis of European studies reported a 1-year HD prevalence of 9.1% and a lifetime prevalence of 14.5%.5 Hand dermatitis is most common in women; individuals aged 30 to 39 years; and those who are employed, underscoring the role of workplace exposure.6 High-risk occupations are those involving substantial wet work, such as hairdressers, beauticians, cleaners, and health care and construction workers.7 Individuals with a history of AD also are at high risk for HD.8
Hand Dermatitis Subtypes
Irritant Contact Dermatitis—Irritant contact dermatitis, the most common form of occupational HD, is caused by repeated exposure to irritants (eg, water, detergents, cleansers, and soaps) that disrupt the skin barrier.9 Occupations that involve wet work are a major risk factor, associated with a 56% higher likelihood of ICD.8 Wet work involves frequent handwashing, prolonged contact with liquids, or occlusive glove use.9 As a ubiquitous skin irritant, water can penetrate the stratum corneum, impair the skin barrier, and increase sensitization risk. The dorsal hands usually are affected by ICD due to the thinner stratum corneum in this area.9
Allergic Contact Dermatitis—Allergic contact dermatitis should be considered in cases of chronic, recurrent, or treatment-resistant disease. Clinical clues include dermatitis beyond irritant contact sites, recurrent pruritic and vesicular HD, and flares with occupational exposures or materials; however, it can be difficult to distinguish ACD from ICD on clinical presentation alone, as they have many overlapping features. When ACD is suspected, patch testing remains the gold standard for identifying allergens and guiding avoidance strategies, product alternatives, and workplace modifications.
Unique Occupational Considerations
Hairdressers—Hairdressers have an increased risk for HD due to wet work and exposure to sensitizers, with a pooled lifetime prevalence of 38.2% (including ICD, ACD, and occupational cases).10 Notably, frequent shampooing, rinsing, cutting wet hair, handwashing, and glove use increase the risk for ICD. Hairdressers also are exposed to allergens in hair products, including p-phenylenediamine, toluene-2,5-diamine, persulfate salts, glyceryl thioglycolate, preservatives, and fragrances. Occupational exposure to the preservative methylisothiazolinone is high among hairdressers, with a sensitization rate of 10.5% in HD cases.11
It has been reported that hyperkeratotic fissured eczema of the dorsal hands caused by wet work often indicates ICD, whereas pruritic dyshidrotic eczema involving the lateral fingers or palms suggests ACD; however, these conditions can share overlapping features.7 If ACD is suspected, broad patch testing with baseline and hairdresser series, along with specific chemicals that may be encountered in the workplace, is necessary. Management includes allergen avoidance, reduced wet work tasks, use of nitrile gloves with glove changes to mitigate occlusive effects, and skin barrier protection with emollients.
Health Care Workers—Health care workers are vulnerable to HD due to intensive hand hygiene, prolonged glove use, and allergen exposures, with a lifetime prevalence of self-reported HD of 33.4%.12 Common allergens among health care workers include rubber accelerators, most often from rubber gloves.13 Frequent handwashing and glove use can further impair the skin barrier, increasing irritant and sensitization risks.14 In contrast, alcohol-based hand sanitizers containing emollients are less irritating, with prior analyses showing no significant association with HD risk.15,16 Conversely, handwashing 8 to 10 times daily increased HD risk, with a relative risk of 1.51.15
Surgeons and proceduralists face unique risks for HD from preoperative scrubbing with products that can contain potential allergens such as chlorhexidine gluconate, chloroxylenol, povidone-iodine, fragrance, cocamide diethanolamine, lanolin, alkyl glucosides, sodium benzoate, sorbic acid, tocopherol, and propylene glycol.17,18 Subsequent occlusion under glove layers drives ICD and ACD risks, highlighting the importance of patch testing in affected individuals. While patch testing, exposure avoidance, and limited glove use can mitigate HD risk, frequent handwashing can contribute to refractory HD.
Food Service Workers—Food service workers have an increased risk for HD from allergens and irritants. In a retrospective study of patients with occupational food-related HD (N=372), 57% were diagnosed with ICD, 22% with PCD, and 1.8% with ACD.19 Skin barrier disruption from wet work, occlusion from glove use, and contact with food proteins increase HD risk, especially in bakers exposed to flours and grains, which can cause IgE–mediated PCD manifesting with contact urticaria. Protein contact dermatitis is confirmed by prick testing with suspected foods.20 Additionally, exposure to garlic can cause ICD and ACD due to sulfur-containing compounds, particularly allicin and diallyl disulfide.21,22 Pineapple also can trigger ICD associated with bromelain, a proteolytic enzyme that can break down the skin.23 Nickel exposure is another concern, as steel utensils and cookware can release nickel onto the skin of sensitized individuals.24 Rubber accelerator exposure from gloves also contributes to contact allergy and HD among food service workers; vinyl gloves usually are a good alternative in this setting.25 Management of food-related HD involves exposure avoidance, which may affect occupational viability
Construction Workers—Construction workers are at risk for occupational HD due to contact with irritants and sensitizers such as paints, adhesives, asphalt, cement, solvents, and gloves.26 A retrospective analysis of North American Contact Dermatitis Group data identified HD in 37.2% (253/681) of patch-tested construction workers. The most common occupational allergens include potassium dichromate, which can be present in cement and leather items; bisphenol A epoxy resin; cobalt chloride hexahydrate; and the rubber accelerators carba mix and thiuram mix.26 A thorough occupational history should assess materials handled, and patch testing should include common construction-related allergens to inform avoidance strategies. Workplace task modification can reduce exposure, as certain managerial roles in construction work may involve less contact with irritants and sensitizers.26
Nail Technicians—Nail technicians are at risk for HD, especially ACD from acrylate monomers used in nail gels, dips, and acrylics. In a 10-year analysis, around 87.5% (14/16) of nail technicians with contact allergy to methacrylate demonstrated hand involvement.27 Common acrylate monomers include 2-hydroxyethyl methacrylate, 2-hydroxypropyl methacrylate, and ethyl cyanoacrylate. 28 Evaluation requires a detailed occupational history, assessing HD onset relative to exposure, services performed, glove-use practices, and whether symptoms improve away from work. While gloves may appear to reduce exposure, a glove-penetration study showed that acrylate-containing nail products can penetrate commonly used disposable gloves from within seconds to approximately 20 minutes, depending on glove and product type.29 Among available options, nitrile gloves may provide dexterity and allergen avoidance when acrylate exposure is brief, with glove changes required every 15 to 30 minutes.30 Patch testing with 2-hydroxyethyl methacrylate and ethyl cyanoacrylate can identify nail acrylate allergy; however, avoidance can be challenging for nail technicians, as these products often are ubiquitous in their work.
Florists—Florists can develop HD from plant allergens and irritants, particularly tulipalin A and calcium oxalate, with a lifetime prevalence of 19.6%.31 Tulipalin A is a well-documented sensitizer causing ACD among florists exposed to tulip bulbs and other Alstroemeria flowers.32 The term tulip fingers actually was coined to describe ACD caused by tulip bulbs in the European tulip industry.33 Patch testing involves testing for tulipalin A, which may be commercially limited, or tulip plant materials; however, fresh tulips require open testing with small amounts due to higher allergen concentration.32 Additionally, the term daffodil itch describes a type of ICD caused by calcium oxalate crystals in daffodil bulbs and tulip sap.32,34 Diagnosis of plant-related HD requires an occupational history and targeted patch testing, while glove protection and exposure avoidance are essential for improvement.
Evaluation and Management
The workup for HD involves physical examination and medical history, including disease onset, course, and history of AD, along with occupational and exposure history to identify allergens and irritants. Understanding the patient’s tasks and responsibilities and workplace practices along with the materials they handle allows the dermatologist to anticipate relevant allergens for patch testing.
Patch testing should be comprehensive, as baseline screening series alone may miss between 26.3% and 50% of occupationally relevant allergens.35,36 Comprehensive patch testing also should include specialty series and supplemental allergens based on the patient’s clinical history and exposures. Specialty series may include hairdressing, bakery, cosmetics, dental, machinists, and adhesives.37 Gloves also warrant attention, as they may be overlooked as a sensitizer following repeated contact and occlusion. In persistent HD associated with glove use, patch testing should include a rubber accelerator series with relevant allergens, such as thiurams, carbamates, mercaptobenzothiazole, diphenylguanidine, and the patient’s own gloves.38 Latex allergy also should be considered, particularly in immediate-type reactions, and can be evaluated with latex-specific IgE testing.39
Management of HD relies on accurate diagnosis and allergen avoidance, which can be challenging in occupational settings. Structured tools, such as the American Contact Dermatitis Society’s Contact Allergen Management Program (https://www.contactderm.org/ resources/acds-camp), can help identify safe alternatives.
In occupational HD, risk assessment should identify occupational exposures and determine appropriate personal protective equipment while minimizing the risk for HD associated with such equipment. Protective gloves are advised to prevent contact with allergens and irritants. When glove use lasts more than 10 minutes, cotton glove liners may be worn to avoid occlusion and moisture retention.40 For wet work, vinyl gloves are recommended, with regular emollient use to support skin-barrier repair. Overall, gloves should be used when possible, changed regularly, and worn for limited periods of time to prevent ICD.
Work modification may be required to reduce exposure and flares, including task reassignment or substitution of materials containing allergens and irritants. Occupational HD may necessitate workplace accommodations, disability evaluation, medical leave, or even permanent job change. Dermatologists play a crucial role in the medical determination of work relatedness and functional impairment, guiding patients through occupational health, disability, and workers’ compensation when warranted.
Treatments for Occupational HD
Treatment of occupational HD depends on disease severity, chronicity, and avoidance of allergens and irritants in ACD, ICD, and PCD. Foundational management includes regular emollient use, which can even serve as monotherapy in mild occupational HD.40 Corticosteroids are the cornerstone of topical therapy, while calcineurin inhibitors can be used as a steroid-sparing option in milder disease.41 Off-label topical calcipotriol and AD-approved therapies crisaborole and ruxolitinib may be effective. For refractory disease after topical treatments, phototherapy can be considered.40 Biologic and targeted therapies also have emerged as potential treatments. Dupilumab is effective for atopic chronic HD and has demonstrated promise for nonatopic chronic HD.42 Recently, delgocitinib, a topical pan–Janus kinase inhibitor cream, showed clinical efficacy for chronic hand eczema and was approved by the US Food and Drug Administration.43 Off-label use of alternative systemic therapies, including acitretin, cyclosporine, methotrexate, and azathioprine, and other biologics and systemic Janus kinase inhibitors also may treat HD, but larger studies are lacking.40
Our Final Interpretation
Occupational HD is a common skin condition with multiple etiologies. It is important for clinicians to gather a thorough occupational and exposure history to narrow the differential diagnosis, inform patch testing, and guide effective management. In practice, successful treatment depends on screening for and diagnosis of workplace exposures driving disease.
- Agner T, Andersen KE, Brandao FM, et al. Hand eczema severity and quality of life: a cross-sectional, multicentre study of hand eczema patients. Contact Dermatitis. 2008;59:43-47. doi:10.1111 /j.1600-0536.2008.01362.x
- Agner T, Aalto-Korte K, Andersen KE, et al. Classification of hand eczema. J Eur Acad Dermatol Venereol. 2015;29:2417-2422. doi:10.1111 /jdv.13308
- Bissonnette R, Agner T, Molin S, et al. Hand eczema—part 1: epidemiology, pathogenesis, diagnosis, and work-up. J Am Acad Dermatol. 2025;93:1201-1210. doi:10.1016/j.jaad.2024.09.048
- Barbaud A. Mechanism and diagnosis of protein contact dermatitis. Curr Opin Allergy Clin Immunol. 2020;20:117-121. doi:10.1097/ACI.0000000000000621
- Quaade AS, Simonsen AB, Halling AS, et al. Prevalence, incidence, and severity of hand eczema in the general population - a systematic review and meta-analysis. Contact Dermatitis. 2021;84:361-374. doi:10.1111/cod.13804
- Apfelbacher C, Bewley A, Molin S, et al. Prevalence of chronic hand eczema in adults: a cross-sectional survey of over 60 000 respondents from the general population of Canada, France, Germany, Italy, Spain and the UK. Br J Dermatol. 2025;192:1047-1054. doi:10.1093 /bjd/ljaf020
- Weidinger S, Novak N. Hand eczema. Lancet. 2024;404:2476-2486. doi:10.1016/S0140-6736(24)01810-5
- Schütte MG, Tamminga SJ, de Groene GJ, et al. Work-related and personal risk factors for occupational contact dermatitis: a systematic review of the literature with meta-analysis. Contact Dermatitis. 2023;88:171-187. doi:10.1111/cod.14253
- Behroozy A, Keegel TG. Wet-work exposure: a main risk factor for occupational hand dermatitis. Saf Health Work. 2014;5:175-180. doi:10.1016/j.shaw.2014.08.001
- Havmose MS, Kezic S, Uter W, et al. Prevalence and incidence of hand eczema in hairdressers-a systematic review and meta-analysis of the published literature from 2000-2021. Contact Dermatitis. 2022;86:254-265. doi:10.1111/cod.14048
- Uter W, Hallmann S, Gefeller O, et al. Contact allergy to ingredients of hair cosmetics in female hairdressers and female consumers—an update based on IVDK data 2013–2020. Contact Dermatitis. 2023;89:161-170. doi:10.1111/cod.14363
- Yüksel YT, Symanzik C, Christensen MO, et al. Prevalence and incidence of hand eczema in healthcare workers: a systematic review and meta-analysis. Contact Dermatitis. 2024;90:331-342. doi:10.1111 /cod.14489
- Warshaw EM, Schram SE, Maibach HI, et al. Occupation-related contact dermatitis in North American health care workers referred for patch testing: cross-sectional data, 1998 to 2004. Dermatitis. 2008;19:261-274. doi:10.2310/6620.2008.07059
- Hamnerius N, Svedman C, Bergendorff O, et al. Wet work exposure and hand eczema among healthcare workers: a cross-sectional study. Br J Dermatol. 2018;178:452-461. doi:10.1111 /bjd.15813
- Loh EDW, Yew YW. Hand hygiene and hand eczema: a systematic review and meta-analysis. Contact Dermatitis. 2022;87:303-314. doi:10.1111/cod.14133
- Lotfinejad N, Peters A, Tartari E, et al. Hand hygiene in health care: 20 years of ongoing advances and perspectives. Lancet Infect Dis. 2021;21:e209-e221. doi:10.1016/S1473-3099(21)00383-2
- Schlarbaum JP, Hylwa SA. Allergic contact dermatitis to operating room scrubs and disinfectants. Dermat Contact Atopic Occup Drug. 2019;30:363-370. doi:10.1097/DER.0000000000000525
- Rodriguez-Homs LG, Atwater AR. Allergens in medical hand skin cleansers. Dermat Contact Atopic Occup Drug. 2019;30:336-341. doi:10.1097/DER.0000000000000504
- Vester L, Thyssen JP, Menné T, et al. Occupational food-related hand dermatoses seen over a 10-year period. Contact Dermatitis. 2012;66:264-270. doi:10.1111/j.1600-0536.2011.02048.x
- Pesonen M, Koskela K, Aalto-Korte K. Contact urticaria and protein contact dermatitis in the Finnish Register of Occupational Diseases in a period of 12 years. Contact Dermatitis. 2020;83:1-7. doi:10.1111/cod.13547
- McFadden JP, White JML, Basketter DA, et al. Reduced allergy rates in atopic eczema to contact allergens used in both skin products and foods: atopy and the “hapten-atopy hypothesis.” Contact Dermatitis. 2008;58:156-158. doi:10.1111/j.1600-0536.2007.01291.x
- Kao SH, Hsu CH, Su SN, et al. Identification and immunologic characterization of an allergen, alliin lyase, from garlic (Allium sativum). J Allergy Clin Immunol. 2004;113:161-168. doi:10.1016/j.jaci.2003.10.040
- Reddy VB, Lerner EA. Plant cysteine proteases that evoke itch activate protease-activated receptors. Br J Dermatol. 2010;163:532-535. doi:10.1111/j.1365-2133.2010.09862.x
- Silverberg NB, Pelletier JL, Jacob SE, et al; Section on Dermatology, Section on Allergy and Immunology. Nickel allergic contact dermatitis: identification, treatment, and prevention. Pediatrics. 2020;145:e20200628. doi:10.1542/peds.2020-0628
- Clément A, Ferrier le Bouëdec MC, Crépy MN, et al. Hand eczema in glove-wearing patients. Contact Dermatitis. 2023;89:143-152. doi:10.1111/cod.14357
- Reeder MJ, Idrogo-Lam A, Aravamuthan SR, et al. Occupational contact dermatitis in construction workers: a retrospective analysis of the North American Contact Dermatitis Group Data, 2001-2020. Dermat Contact Atopic Occup Drug. 2024;35:467-475. doi:10.1089/derm.2024.0018
- Fisch A, Hamnerius N, Isaksson M. Dermatitis and occupational (meth)acrylate contact allergy in nail technicians-a 10-year study. Contact Dermatitis. 2019;81:58-60. doi:10.1111/cod.13216
- Atwater AR, Reeder M. Trends in nail services may cause dermatitis: not your mother’s nail polish. Cutis. 2019;103:315-317.
- Suuronen K, Ylinen K, Heikkilä J, et al. Acrylates in artificial nails— results of product analyses and glove penetration studies. Contact Dermatitis. 2024;90:266-272. doi:10.1111/cod.14474
- Morgado F, Batista M, Gonçalo M. Short exposures and glove protection against (meth)acrylates in nail beauticians-thoughts on a rising concern. Contact Dermatitis. 2019;81:62-63. doi:10.1111 /cod.13222
- Paulsen E, Søgaard J, Andersen KE. Occupational dermatitis in Danish gardeners and greenhouse workers (I). prevalence and possible risk factors. Contact Dermatitis. 1997;37:263-270. doi:10.1111/j.1600-0536.1997.tb02462.x
- Fonacier L, Bernstein DI, Pacheco K, et al. Contact dermatitis: a practice parameter–update 2015. J Allergy Clin Immunol Pract. 2015; 3(3 suppl):S1-S39. doi:10.1016/j.jaip.2015.02.009
- Gette MT, Marks JE. Tulip fingers. Arch Dermatol. 1990;126:203-205.
- Bruynzeel DP. Bulb dermatitis. Dermatological problems in the flower bulb industries. Contact Dermatitis. 1997;37:70-77. doi:10.1111/j.1600-0536.1997.tb00042.x
- Nettis E, Marcandrea M, Colanardi MC, et al. Results of standard series patch testing in patients with occupational allergic contact dermatitis. Allergy. 2003;58:1304-1307. doi:10.1046/j.1398-9995.2003.00346.x
- Saripalli YV, Achen F, Belsito DV. The detection of clinically relevant contact allergens using a standard screening tray of twenty-three allergens. J Am Acad Dermatol. 2003;49:65-69. doi:10.1067/mjd.2003.489
- Warshaw EM, Buonomo M, DeKoven JG, et al. Importance of supplemental patch testing beyond a screening series for patients with dermatitis: the North American Contact Dermatitis Group experience. JAMA Dermatol. 2021;157:1456-1465. doi:10.1001/jamadermatol.2021.4314
- Geier J, Lessmann H, Mahler V, et al. Occupational contact allergy caused by rubber gloves--nothing has changed. Contact Dermatitis. 2012;67:149-156. doi:10.1111/j.1600-0536.2012.02139.x
- Toraason M, Sussman G, Biagini R, et al. Latex allergy in the workplace. Toxicol Sci Off J Soc Toxicol. 2000;58:5-14. doi:10.1093/toxsci/58.1.5
- Bissonnette R, Agner T, Taylor JS, et al. Hand eczema-part 2: prevention, management, and treatment. J Am Acad Dermatol. 2025;93:1213-1224. doi:10.1016/j.jaad.2024.09.049
- Schliemann S, Kelterer D, Bauer A, et al. Tacrolimus ointment in the treatment of occupationally induced chronic hand dermatitis. Contact Dermatitis. 2008;58:299-306. doi:10.1111/j.1600-0536.2007.01314.x
- Voorberg AN, Kamphuis E, Christoffers WA, et al. Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study. Br J Dermatol. 2023;189:400-409. doi:10.1093/bjd/ljad156
- Gooderham M, Molin S, Bissonnette R, et al. Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials. J Am Acad Dermatol. 2025;93:95-103. doi:10.1016/j.jaad.2025.03.008
- Agner T, Andersen KE, Brandao FM, et al. Hand eczema severity and quality of life: a cross-sectional, multicentre study of hand eczema patients. Contact Dermatitis. 2008;59:43-47. doi:10.1111 /j.1600-0536.2008.01362.x
- Agner T, Aalto-Korte K, Andersen KE, et al. Classification of hand eczema. J Eur Acad Dermatol Venereol. 2015;29:2417-2422. doi:10.1111 /jdv.13308
- Bissonnette R, Agner T, Molin S, et al. Hand eczema—part 1: epidemiology, pathogenesis, diagnosis, and work-up. J Am Acad Dermatol. 2025;93:1201-1210. doi:10.1016/j.jaad.2024.09.048
- Barbaud A. Mechanism and diagnosis of protein contact dermatitis. Curr Opin Allergy Clin Immunol. 2020;20:117-121. doi:10.1097/ACI.0000000000000621
- Quaade AS, Simonsen AB, Halling AS, et al. Prevalence, incidence, and severity of hand eczema in the general population - a systematic review and meta-analysis. Contact Dermatitis. 2021;84:361-374. doi:10.1111/cod.13804
- Apfelbacher C, Bewley A, Molin S, et al. Prevalence of chronic hand eczema in adults: a cross-sectional survey of over 60 000 respondents from the general population of Canada, France, Germany, Italy, Spain and the UK. Br J Dermatol. 2025;192:1047-1054. doi:10.1093 /bjd/ljaf020
- Weidinger S, Novak N. Hand eczema. Lancet. 2024;404:2476-2486. doi:10.1016/S0140-6736(24)01810-5
- Schütte MG, Tamminga SJ, de Groene GJ, et al. Work-related and personal risk factors for occupational contact dermatitis: a systematic review of the literature with meta-analysis. Contact Dermatitis. 2023;88:171-187. doi:10.1111/cod.14253
- Behroozy A, Keegel TG. Wet-work exposure: a main risk factor for occupational hand dermatitis. Saf Health Work. 2014;5:175-180. doi:10.1016/j.shaw.2014.08.001
- Havmose MS, Kezic S, Uter W, et al. Prevalence and incidence of hand eczema in hairdressers-a systematic review and meta-analysis of the published literature from 2000-2021. Contact Dermatitis. 2022;86:254-265. doi:10.1111/cod.14048
- Uter W, Hallmann S, Gefeller O, et al. Contact allergy to ingredients of hair cosmetics in female hairdressers and female consumers—an update based on IVDK data 2013–2020. Contact Dermatitis. 2023;89:161-170. doi:10.1111/cod.14363
- Yüksel YT, Symanzik C, Christensen MO, et al. Prevalence and incidence of hand eczema in healthcare workers: a systematic review and meta-analysis. Contact Dermatitis. 2024;90:331-342. doi:10.1111 /cod.14489
- Warshaw EM, Schram SE, Maibach HI, et al. Occupation-related contact dermatitis in North American health care workers referred for patch testing: cross-sectional data, 1998 to 2004. Dermatitis. 2008;19:261-274. doi:10.2310/6620.2008.07059
- Hamnerius N, Svedman C, Bergendorff O, et al. Wet work exposure and hand eczema among healthcare workers: a cross-sectional study. Br J Dermatol. 2018;178:452-461. doi:10.1111 /bjd.15813
- Loh EDW, Yew YW. Hand hygiene and hand eczema: a systematic review and meta-analysis. Contact Dermatitis. 2022;87:303-314. doi:10.1111/cod.14133
- Lotfinejad N, Peters A, Tartari E, et al. Hand hygiene in health care: 20 years of ongoing advances and perspectives. Lancet Infect Dis. 2021;21:e209-e221. doi:10.1016/S1473-3099(21)00383-2
- Schlarbaum JP, Hylwa SA. Allergic contact dermatitis to operating room scrubs and disinfectants. Dermat Contact Atopic Occup Drug. 2019;30:363-370. doi:10.1097/DER.0000000000000525
- Rodriguez-Homs LG, Atwater AR. Allergens in medical hand skin cleansers. Dermat Contact Atopic Occup Drug. 2019;30:336-341. doi:10.1097/DER.0000000000000504
- Vester L, Thyssen JP, Menné T, et al. Occupational food-related hand dermatoses seen over a 10-year period. Contact Dermatitis. 2012;66:264-270. doi:10.1111/j.1600-0536.2011.02048.x
- Pesonen M, Koskela K, Aalto-Korte K. Contact urticaria and protein contact dermatitis in the Finnish Register of Occupational Diseases in a period of 12 years. Contact Dermatitis. 2020;83:1-7. doi:10.1111/cod.13547
- McFadden JP, White JML, Basketter DA, et al. Reduced allergy rates in atopic eczema to contact allergens used in both skin products and foods: atopy and the “hapten-atopy hypothesis.” Contact Dermatitis. 2008;58:156-158. doi:10.1111/j.1600-0536.2007.01291.x
- Kao SH, Hsu CH, Su SN, et al. Identification and immunologic characterization of an allergen, alliin lyase, from garlic (Allium sativum). J Allergy Clin Immunol. 2004;113:161-168. doi:10.1016/j.jaci.2003.10.040
- Reddy VB, Lerner EA. Plant cysteine proteases that evoke itch activate protease-activated receptors. Br J Dermatol. 2010;163:532-535. doi:10.1111/j.1365-2133.2010.09862.x
- Silverberg NB, Pelletier JL, Jacob SE, et al; Section on Dermatology, Section on Allergy and Immunology. Nickel allergic contact dermatitis: identification, treatment, and prevention. Pediatrics. 2020;145:e20200628. doi:10.1542/peds.2020-0628
- Clément A, Ferrier le Bouëdec MC, Crépy MN, et al. Hand eczema in glove-wearing patients. Contact Dermatitis. 2023;89:143-152. doi:10.1111/cod.14357
- Reeder MJ, Idrogo-Lam A, Aravamuthan SR, et al. Occupational contact dermatitis in construction workers: a retrospective analysis of the North American Contact Dermatitis Group Data, 2001-2020. Dermat Contact Atopic Occup Drug. 2024;35:467-475. doi:10.1089/derm.2024.0018
- Fisch A, Hamnerius N, Isaksson M. Dermatitis and occupational (meth)acrylate contact allergy in nail technicians-a 10-year study. Contact Dermatitis. 2019;81:58-60. doi:10.1111/cod.13216
- Atwater AR, Reeder M. Trends in nail services may cause dermatitis: not your mother’s nail polish. Cutis. 2019;103:315-317.
- Suuronen K, Ylinen K, Heikkilä J, et al. Acrylates in artificial nails— results of product analyses and glove penetration studies. Contact Dermatitis. 2024;90:266-272. doi:10.1111/cod.14474
- Morgado F, Batista M, Gonçalo M. Short exposures and glove protection against (meth)acrylates in nail beauticians-thoughts on a rising concern. Contact Dermatitis. 2019;81:62-63. doi:10.1111 /cod.13222
- Paulsen E, Søgaard J, Andersen KE. Occupational dermatitis in Danish gardeners and greenhouse workers (I). prevalence and possible risk factors. Contact Dermatitis. 1997;37:263-270. doi:10.1111/j.1600-0536.1997.tb02462.x
- Fonacier L, Bernstein DI, Pacheco K, et al. Contact dermatitis: a practice parameter–update 2015. J Allergy Clin Immunol Pract. 2015; 3(3 suppl):S1-S39. doi:10.1016/j.jaip.2015.02.009
- Gette MT, Marks JE. Tulip fingers. Arch Dermatol. 1990;126:203-205.
- Bruynzeel DP. Bulb dermatitis. Dermatological problems in the flower bulb industries. Contact Dermatitis. 1997;37:70-77. doi:10.1111/j.1600-0536.1997.tb00042.x
- Nettis E, Marcandrea M, Colanardi MC, et al. Results of standard series patch testing in patients with occupational allergic contact dermatitis. Allergy. 2003;58:1304-1307. doi:10.1046/j.1398-9995.2003.00346.x
- Saripalli YV, Achen F, Belsito DV. The detection of clinically relevant contact allergens using a standard screening tray of twenty-three allergens. J Am Acad Dermatol. 2003;49:65-69. doi:10.1067/mjd.2003.489
- Warshaw EM, Buonomo M, DeKoven JG, et al. Importance of supplemental patch testing beyond a screening series for patients with dermatitis: the North American Contact Dermatitis Group experience. JAMA Dermatol. 2021;157:1456-1465. doi:10.1001/jamadermatol.2021.4314
- Geier J, Lessmann H, Mahler V, et al. Occupational contact allergy caused by rubber gloves--nothing has changed. Contact Dermatitis. 2012;67:149-156. doi:10.1111/j.1600-0536.2012.02139.x
- Toraason M, Sussman G, Biagini R, et al. Latex allergy in the workplace. Toxicol Sci Off J Soc Toxicol. 2000;58:5-14. doi:10.1093/toxsci/58.1.5
- Bissonnette R, Agner T, Taylor JS, et al. Hand eczema-part 2: prevention, management, and treatment. J Am Acad Dermatol. 2025;93:1213-1224. doi:10.1016/j.jaad.2024.09.049
- Schliemann S, Kelterer D, Bauer A, et al. Tacrolimus ointment in the treatment of occupationally induced chronic hand dermatitis. Contact Dermatitis. 2008;58:299-306. doi:10.1111/j.1600-0536.2007.01314.x
- Voorberg AN, Kamphuis E, Christoffers WA, et al. Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study. Br J Dermatol. 2023;189:400-409. doi:10.1093/bjd/ljad156
- Gooderham M, Molin S, Bissonnette R, et al. Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials. J Am Acad Dermatol. 2025;93:95-103. doi:10.1016/j.jaad.2025.03.008
Getting a Grip on Occupational Hand Dermatitis: Key Considerations for Evaluation and Management
Getting a Grip on Occupational Hand Dermatitis: Key Considerations for Evaluation and Management
PRACTICE POINTS
- Occupational hand dermatitis (HD) is a common multifactorial disease with a major impact on quality of life, worker safety, and productivity.
- High-risk occupations include those involving wet work, such as hairdressers, beauticians, cleaners, and health care and construction workers.
- A detailed occupational and exposure history is essential for managing occupational HD.